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ABSTRACT 
Dermatitis herpetiformis (DH) is an extraintestinal manifestation of coeliac disease 
presenting with an intensely itchy and blistering rash mainly on the elbows, knees, 
and buttocks. Diagnosis is based on the demonstration of granular IgA deposits in 
the papillary dermis by examination with direct immunofluorescence (IF). The 
disease is caused by gluten, a protein found in wheat, rye and barley, which initiates 
an autoimmune response in genetically predisposed individuals. This leads to small 
bowel mucosal damage typical of coeliac disease and, in some individuals, to a 
blistering rash typical of DH. At present, 13 % of adults with coeliac disease have 
DH in Finland. The incidence of DH is decreasing, whereas the reverse is true for 
coeliac disease. The mainstay of treatment for DH and coeliac disease is a life-long 
gluten-free diet (GFD), which in DH also heals the rash.  
In the research presented in the present dissertation, a cohort of patients with 
DH diagnosed between 1970 and 2014 at Tampere University Hospital, Finland 
were investigated. The first aim was to evaluate diagnostic delay in DH. The second 
aim was to study whether small bowel histological findings have changed over the 
45-year period and to determine how mucosal damage correlates to serum 
transglutaminase 2 (TG2) antibody levels. The third aim was to examine if the 
presence or absence of small bowel villous atrophy at diagnosis affects the long-term 
prognosis of DH patients on a GFD. The fourth aim was to examine, by gluten 
challenge, whether DH patients on a long-term GFD treatment could have 
developed gluten tolerance, as suggested by a few earlier studies. 
The dissertation consists of four separate studies. In Study I, the duration of the 
rash before diagnosis was examined from hospital records in 446 DH patients. The 
diagnosis was considered delayed when the duration of the rash before diagnosis was 
two years or longer. Factors associated with the delayed diagnosis were analysed in 
more detail using follow-up questionnaires obtained from 217 patients. Over the 
study period, the median duration of the rash before diagnosis decreased and the 
number of patients with delayed diagnosis decreased. Female gender and the 
presence of villous atrophy correlated with the delayed diagnosis, whereas age at 
diagnosis and the activity of the rash did not. According to the follow-up 
questionnaire, bone fractures or malignancies were shown not to occur more often 
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in those patients with a delayed diagnosis compared to those with a non-delayed 
diagnosis. 
In Study II, the severity of small bowel villous atrophy was examined in 393 DH 
patients over the 45-year study period. The prevalence of severe (subtotal/total) 
villous atrophy (SVA) was shown to decrease over time. At the same time, an 
increase was seen in both partial villous atrophy (PVA) and normal villous 
architecture. Patients with villous atrophy had higher TG2 antibody levels than those 
with normal villous architecture. However, several patients with villous atrophy had 
normal TG2 antibody levels, indicating that a negative test result does not always 
exclude villous damage in DH. 
In Study III, long-term prognoses were compared between DH patients with and 
without small bowel villous atrophy at diagnosis (n=352) and 128 coeliac disease 
controls. Initial data was gathered from the patient records and follow-up data was 
collected via questionnaires from 181 DH patients on a GFD. At the DH diagnosis, 
98 (28%) patients had normal villous architecture and 254 (72%) had villous atrophy. 
Clinical recovery did not differ significantly between the DH groups, nor did the 
presence of long-term illnesses, coeliac disease-related complications or quality of 
life (QoL). By contrast, the coeliac disease controls had osteopenia/osteoporosis, 
thyroid diseases and malignancies more often compared to the DH patients.  
In Study IV, 19 asymptomatic DH patients who had adhered to a GFD for a 
mean of 23 years were challenged with gluten for up to 12 months. Before the 
challenge skin biopsies showed negative IgA and transglutaminase 3 (TG3) deposits 
in 84% of the patients and normal villous mucosa in all of them. The gluten challenge 
caused a relapse of the rash and/or villous atrophy in 18 (95%) DH patients; 15 
(79%) patients showed a rash within a mean of 5.6 months and three (16%) had only 
small bowel villous atrophy.  
The results of the present dissertation show that diagnostic delay in DH has 
decreased over time. Further, the prevalence of SVA decreased during the 45 years 
study period and high serum TG2 antibody levels reveals rather well whether the 
patients have villous atrophy. However, the presence of villous atrophy at the time 
of diagnosis was shown not to effect GFD treatment response or long-term 
morbidity and QoL and hence has no effect on the prognosis of DH. Importantly, 
the gluten challenge showed that a life-long GFD treatment remains justified in all 
DH patients.  
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TIIVISTELMÄ  
Ihokeliakia on keliakian suoliston ulkopuolinen manifestaatio, joka aiheuttaa 
kutisevan ja pienirakkulaisen ihottuman. Ihottumaa esiintyy tyypillisesti kyynärpäissä, 
polvissa ja pakara-alueella. Ihokeliakian diagnoosi perustuu terveeltä iholta 
otettavaan koepalaan ja siitä tehtävään immunofluoresenssitutkimukseen, jossa 
havaitaan rakeiset IgA kertymät verinahassa. Sairauden aiheuttaa gluteeni eli vehnän, 
rukiin tai ohran proteiini, joka käynnistää immuunireaktion geneettisesti alttiilla 
henkilöllä. Immuunivälitteisen reaktion seurauksena suolistoon tulee keliakialle 
tyypillinen nukkavaurio tai tulehdus ja osalla ihmisistä iholle kehittyy lisäksi 
ihokeliakialle tyypillisiä rakkuloita. Nykyisin Suomessa 13%:lla aikuisista 
keliakiapotilaista on ihokeliakia. Ihokeliakian ilmaantuvuus on laskussa, kun taas 
keliakian ilmaantuvuus päinvastoin lisääntyy. Ihokeliakian ja keliakian hoitona on 
elinikäinen gluteeniton ruokavalio, joka parantaa suoliston vaurion sekä 
ihokeliakiassa myös ihottuman.  
Tämän väitöskirjatyön tutkimuskohorttina olivat vuosina 1970-2014 Tampereen 
Yliopistollisessa sairaalassa diagnosoidut ihokeliakiapotilaat. Ensimmäisenä 
tavoitteena oli tutkia ihokeliakian diagnostista viivettä. Toisena tavoitteena oli 
selvittää ihokeliakiapotilaiden suolivaurion vaikeusasteessa tapahtuneita muutoksia ja 
sitä, kuinka seerumin transglutaminaasi (TG) 2 vasta-aineet liittyvät 
suolivaurioasteeseen. Kolmantena tavoitteena oli selvittää, vaikuttaako 
diagnoosivaiheen suolivaurion olemassaolo hoidettujen ihokeliakiapotilaiden 
pitkäaikaisennusteeseen. Neljäntenä osatyönä oli gluteenialtistus, jossa tutkittiin, 
pitkään gluteenittomalla ruokavaliohoidolla olleiden ihokeliakiapotilaiden gluteenin 
sietokyvyn palautumisen mahdollisuutta, kuten muutamissa aiemmissa tutkimuksissa 
oli esitetty. 
Väitöskirja koostuu neljästä erillisestä osatyöstä. Osatyössä I tutkittiin 446 
ihokeliakiapotilaalla diagnostista viivettä eli iho-oireiden alkamisesta diagnoosiin 
kestänyttä aikaa sairaskertomuksista kerätyllä aineistolla. Diagnoosia pidettiin 
viivästyneenä, jos oireiden alkamisesta diagnoosiin kesti kaksi vuotta tai enemmän. 
Viivästyneeseen diagnoosiin liittyviä tietoja täydennettiin kyselytutkimustiedolla 
(n=217). Diagnostisen viiveen mediaaniaika lyhentyi sekä viivästynyt diagnoosi 
muuttui harvinaisemmaksi seurantajakson aikana. Viivästyneeseen diagnoosiin 
 xii
yhdistyi naissukupuoli sekä vaikeampiasteinen suolen nukkavaurio, mutta ei 
diagnoosi-ikä tai iho-oireiden vaikeusaste. Potilailla joiden diagnoosi oli viivästynyt, 
ei kuitenkaan todettu useammin luunmurtumia tai lisääntynyttä syöpäriskiä 
verrattuna potilaisiin, joilla diagnoosiin päästiin nopeammin. 
Osatyössä II tutkittiin suolen nukkavaurion olemassaoloa 393 
ihokeliakiapotilaalla 45 vuoden tarkastelujakson aikana. Vaikea suolivaurio 
harvinaistui tarkastelujakson aikana, kun taas lievempi suolivaurio ja normaali 
suolirakenne yleistyivät. Seerumista tutkittavat TG2 vasta-aineet olivat useammin 
koholla silloin, kun suolistossa todettiin vaurio, verrattuna tilanteeseen, jossa 
nukkavauriota ei todettu. Osalla tutkittavista vasta-aineet olivat kuitenkin negatiiviset 
ohutsuolen nukkavauriosta huolimatta. Vasta-aineita tutkimalla ei täten löydetä 
kaikkia ihokeliakiapotilaita, joilla on suolivaurio. 
Osatyössä III tutkittiin, vaikuttaako suolivaurion olemassaolo ihokeliakiapotilaan 
pitkäaikaisennusteeseen. Sairaskertomustieto kerättiin 352 ihokeliakiapotilaalta, 
joista diagnoosivaiheessa 98:lla (28%) oli todettu normaali suolirakenne ja 254 (72%) 
potilasta, joilla oli todettu suolivaurio sekä kontrollina olleilta 128 keliakiapotilaalta. 
Tietoja täydennettiin kyselytutkimuksen avulla 181 ihokeliakiapotilaalta. 
Ihokeliakiapotilaiden välillä ei havaittu eroa iho-oireiden keston, keliakiaan 
yhdistettyjen komplikaatioiden, pitkäaikaissairauksien tai elämänlaadun välillä. 
Keliakiakontrolleilla todettiin kuitenkin useammin osteopeniaa tai osteoporoosia, 
kilpirauhassairauksia ja syöpiä verrattuna ihokeliakiapotilaisiin. 
Osatyössä IV toteutettiin 12 kuukauden gluteenialtistus oireettomille, 
keskimäärin 23 vuotta gluteenittomalla dieetillä olleille, ihokeliakiapotilaille. Ennen 
altistusta potilailla ei todettu nukkavauriota suolistossa ja 84%:lla ei todettu 
ihokoepalassa IgA/TG3 kertymiä. Altistus johti 18 (95%) potilaalla iho-oireiden 
ja/tai suolivaurion uusiutumiseen eli relapsiin. Iho-oireita tuli keskimäärin 5.6 
kuukauden kuluttua 15 (79%) potilaalle ja kolmella (16%) todettiin vain suolivaurio 
relapsin yhteydessä.  
Väitöskirjatyön tulokset osoittavat, että ihokeliakian diagnostinen viive on 
lyhentynyt. Ohutsuolivaurioaste on ihokeliakiassa lieventynyt 45 vuoden aikana, ja 
seerumin korkeat TG2 vasta-aineet liittyvät usein ohutsuolivaurion olemassaoloon. 
Diagnoosivaiheen suolivaurion olemassaolo ei kuitenkaan vaikuta gluteenittoman 
ruokavaliohoidon vasteeseen eikä sairastumisriskiin tai elämänlaatuun ihokeliakiassa. 
Gluteenialtistus tuki aiempaa tietoa siitä, että tiukka gluteeniton ruokavalio on 
edelleen välttämätön kaikilla ihokeliakiapotilailla.  
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INTRODUCTION 
Dermatitis herpetiformis (DH) is an autoimmune disease characterized by a highly 
itchy and symmetrical rash typically on elbows, knees, and buttocks (Bolotin and 
Petronic-Rosic, 2011a). The majority of DH patients have small bowel villous 
atrophy, but only a minority have overt gastrointestinal symptoms (Gawkrodger et 
al., 1984, Reunala et al., 1984). In 2011, the prevalence of DH in Finland was 75 per 
100, 000, which is the highest reported rate to date (Salmi et al., 2011). 
Similarly to coeliac disease, DH patients have immunoglobulin A (IgA) 
autoantibodies in the serum and small bowel mucosa against the transglutaminase 2 
(TG2) enzyme, which occurs in the small intestine and other tissues (Dieterich et al., 
1998, Korponay-Szabó et al., 2004). Diagnosis of DH is based on the clinical picture 
and pathognomonic IgA deposits in the papillary dermis detected in an uninvolved 
skin biopsy with a direct immunofluorescence (IF) examination (Zone et al., 1996). 
The treatment for DH and coeliac disease is a life-long gluten-free diet (GFD). 
In DH, a GFD heals both the enteropathy and the rash. As alleviation of the rash is 
often slow, additional treatment with dapsone medication is frequently needed upon 
starting a GFD. The long-term prognosis of DH patients on a GFD seems to be 
good, but there is an increased risk of lymphoma during the first five years following 
diagnosis (Lewis et al., 1996). However, it is not known whether a delay in DH 
diagnosis and the presence or absence of small bowel villous atrophy affect the 
prognosis. Surprisingly, there have been studies suggesting that some DH patients 
adhering to a GFD or normal gluten-containing diet could re-develop gluten 
tolerance and go into remission (Bardella et al., 2003, Paek et al., 2011).  
The aim of the present study was to investigate diagnostic delay in a large DH 
cohort collected prospectively at the Tampere University Hospital, Finland. As small 
bowel biopsies have been taken routinely from this DH cohort, additional aims were 
to examine whether mucosal findings have changed over the past 45 years and 
whether the presence villous atrophy affects the prognosis. A further aim was to 
examine how TG2 antibodies associate with the villous atrophy in DH. Finally, a 
gluten challenge study was performed with long-term GFD-treated DH patients to 
investigate whether gluten tolerance had re-developed to some of the patients.  
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1 DERMATITIS HERPETIFORMIS  
1.1 History 
Dermatitis herpetiformis (DH)  was initially delineated and named by the American 
dermatologist Louis Duhring at the University of Pennsylvania in 1884 (Duhring, 
1884). In 1940, it was discovered that sulphones relieved the intensively itchy rash 
in DH and thereafter response to this medication was used as a diagnostic tool for 
DH (Costello, 1940). Histological skin biopsy findings for DH were documented in 
the early 1960s (Pierard and Whimster, 1961). A breakthrough in the diagnosis of 
DH was made in 1969, when granular immunoglobulin A (IgA) deposits were found 
at the dermal papillae of DH patients by direct IF examination (Van der Meer, 1969). 
Subsequently, this finding became the diagnostic hallmark of the disease (Seah and 
Fry, 1975, Zone et al., 1996). Moreover, it was demonstrated in the 1960s that the 
majority of DH patients have enteropathy, which was usually asymptomatic (Marks 
et al., 1966). Thereafter, it was documented that both enteropathy (Fry et al., 1969) 
and the rash responded to a strict gluten-free diet (GFD) (Fry et al., 1973, Reunala 
et al., 1977). Later, it was shown that a gluten challenge induced a relapse of the DH 
rash and small bowel villous atrophy, indicating that adherence to a GFD should be 
life-long in DH (Leonard et al., 1983a). The genetic association between DH and 
coeliac disease became evident when the same human leukocyte antigen (HLA) 
alleles were found to predispose to both conditions, and DH and coeliac disease 
were shown to occur even in the same families (Katz et al., 1972, Reunala et al., 
1976). Based on all of the observations above, it became obvious that DH is a 
specific cutaneous manifestation of coeliac disease, and not only an associated 
condition as was previously often thought (Reunala, 1998). 
1.2 Clinical features 
DH is characterized as a highly itchy and symmetrical rash with small papulovesicular 
eruption favouring the extensor surfaces of the elbows and knees (Bolotin and 
Petronic-Rosic, 2011a, Figure 1.). Additionally, the buttocks and scalp can be 
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affected, and more rarely also the upper back, abdomen, or face. Oral blisters are 
rare in DH (Patinen et al., 2002). In addition to representative herpetiform vesicles, 
the clinical spectrum can comprise erythematous macules and urticarial plaques and 
papules. Intense pruritus and easily excoriated vesicles often result in the 
presentation of crusted papules, erosions, and erythaema (Bolotin and Petronic-
Rosic, 2011a, Junkins-Hopkins, 2010). The severity of the DH rash can range from 
mild to severe in different individuals, and even in the same individual the rash can 
show a fluctuating course of disease activity. Palmar purpura is one – albeit more 
infrequent – presentation of DH, and it can be the sole presentation or occur 
coincidentally with the typical blistering DH rash (Karpati et al., 1986). 
Linear IgA disease resembles DH closely (Chanal et al., 2013), and pruritic skin 
diseases, such as scabies or atopic dermatitis can be difficult to differentiate from 
DH (Bolotin and Petronic-Rosic, 2011a). Regardless of the coexisting enteropathy, 
obvious gastrointestinal symptoms are rare at the DH diagnosis. The prevalence of 
gastrointestinal symptoms in DH has varied from 10% to 38% in previous Finnish 
studies, with the prevalence being highest in children with DH (Alakoski et al., 2012, 
Pasternack et al., 2017, Reunala et al., 1984). When present, the gastrointestinal 
symptoms are generally mild and typically include abdominal pain or loose stools 
(Collin et al., 2017, Kárpáti, 2004). 
Similarly to coeliac disease, DH has also been associated with other autoimmune 
diseases (Gaspari et al., 1990, Reijonen et al., 1991). Studies featuring patients with 
DH showed that 1–2 % have type 1 diabetes and the frequency of autoimmune 
thyroid disease is as high as 4% (Gaspari et al., 1990, Hervonen et al., 2004, Reijonen 
et al., 1991, Reunala and Collin, 1997). Sjögren syndrome, vitiligo, and alopecia areata 
are diseases which have associated at a low frequency with DH (Reunala and Collin, 
1997). Most of the associated autoimmune diseases seem to develop prior to the DH 
diagnosis (Reunala and Collin, 1997). However, a recent register study from Finland 
found that patients with previously diagnosed DH have a 22-fold risk for the later 
development of bullous pemphigoid (Varpuluoma et al. 2019).  
1.3 Diagnosis by skin biopsy 
DH diagnosis is based on the typical clinical picture and pathognomonic granular 
IgA deposits in the papillary dermis detected with direct IF (Zone et al., 1996, Figure 
2). IF test is known to be highly sensitive (95%) for DH (Bresler and Scott, 2015), 
but in order to avoid false-negative results, the skin biopsy should be obtained from 
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normal appearing skin near the rash, i.e. the perilesional area, since deposition is less 
intense in the inflamed and never involved skin areas (Zone et al., 1996).  
Granular IgA in DH skin is known to target the epidermal transglutaminase 
(TG3) enzyme (Sárdy et al., 2002). This is closely related, but not identical to tissue 
transglutaminase (TG2) (Lorand and Graham, 2003), which is a major autoantigen 
in coeliac disease (Dieterich et al., 1998). IgA and TG3 have been shown to disappear 
from the dermis of DH patients on a GFD at the same time (Hietikko et al., 2018a), 
but surprisingly, IgA deposits can persist in the skin for many years after the skin 
symptoms are controlled with a GFD (Garioch et al., 1994, Reunala et al., 2015b). 
Consequently, IgA deposits are probably present in the skin even if a patient has 
initiated GFD a few weeks or months before the IF examination. However, it is 
recommended that the skin biopsy is taken when the patient is still on a gluten-
containing diet. Only after the confirmed DH diagnosis, the patients should be 
advised to adhere to a strict GFD. 
Histopathological findings in a lesional skin biopsy are not required for a DH 
diagnosis (Bolotin and Petronic-Rosic, 2011b). If taken, ideal areas are an intact 
vesicle or erythematous skin, and the typical findings include non-specific 
subepidermal blister and papillary microabscesses together with neutrophil and a few 
eosinophil infiltrates (Pierard and Whimster, 1961).  
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Figure 1.  Symmetrical dermatitis herpetiformis rash with excoriated blisters and crusts on the 
elbows and knees. 
  
Figure 2.  Granular immunoglobulin A (IgA) deposits at the papillary dermis (arrows) of dermatitis 
herpetiformis patient detected with direct immunofluorescence examination.  
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1.4 Small bowel findings and serum antibodies 
At diagnosis, approximately 75% of DH patients have small bowel mucosal villous 
atrophy and crypt hyperplasia identical to coeliac disease (Fry et al., 1969, Marks et 
al., 1966, Reunala et al., 1977), and the remainder have normal villous architecture 
but coeliac-type inflammation with increased densities of intraepithelial lymphocytes 
(IELs). Similarly to coeliac disease, an increased density of γδ+ IELs studied from 
frozen small bowel mucosal samples is relatively representative finding in DH 
(Järvinen et al., 2003, Savilahti et al., 1997). Furthermore, it was shown already in 
1988 that the small bowel mucosa of children with DH contain deposited IgA 
(Kárpáti et al., 1988). In 2004, Korponay-Szabó and colleagues discovered that IgA 
deposits detected in frozen small bowel mucosal samples of both coeliac disease and 
DH patients target the TG2 enzyme (Korponay-Szabó et al., 2003). Thereafter, it 
has been shown that the majority of DH patients have gluten-dependent TG2-
specific IgA deposits in the small bowel mucosa, but the prevalence of these deposits 
seems to be lower than in coeliac disease (Koskinen et al., 2008, Salmi et al., 2014). 
At present, examinations of γδ+ IELs and TG2-specific IgA deposits from frozen 
small bowel mucosal samples are special investigations used only for study purposes 
in DH. 
At diagnosis, DH patients have a similar autoantibody response in the serum as 
coeliac disease patients, and these antibodies are described in detail in Chapter 2.2. 
In both DH and coeliac disease, the circulating IgA autoantibodies described first 
were against reticulin (ARA) (Seach et al., 1971, Vainio et al., 1986), then against 
endomysium (EmA), and finally against TG2, which is considered the autoantigen 
of coeliac disease (Dieterich et al., 1998, Dieterich et al., 1999). EmA and TG2-
antibody tests both measure antibodies directed against TG2 (Korponay-Szabó et 
al., 2003), but since the indirect IF EmA test is more laborious and subjective in the 
interpretation, the TG2 antibody ELISA test is now used as the first-line serological 
screening test in coeliac disease (Giersiepen et al., 2012). 
In DH studies, the IgA-class TG2 antibody and EmA test have shown a 
specificity of 98% but slightly lower sensitivity figures (89-93%) than for coeliac 
disease (Dieterich et al., 1997, Kumar et al., 2001, Reunala et al., 1987). There is 
preliminary evidence suggesting that the occurrence of TG2-targeted antibodies in 
the serum reflects the severity of small intestinal damage in DH (Dahlbom et al., 
2010, Hällström, 1989, Reunala et al., 1987). TG2-targeted coeliac autoantibody 
levels can be utilized in the follow-up of GFD treatment (Reunala et al., 2015a). 
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In addition to TG2 antibodies, circulating IgA-class autoantibodies against TG3 
exist in the majority of DH patients at diagnosis (Hull et al., 2008, Sárdyet al., 2002). 
Even though TG3 is considered the autoantigen of DH, circulating antibodies 
against TG3 are occasionally detected also in the serum of coeliac disease patients 
without DH (Hull et al., 2008, Reunala et al., 2015a, Sárdy et al., 2002). However, 
these antibodies are less prevalent, the titres are lower, and the antibodies express a 
lower affinity for TG3 in coeliac disease compared to DH (Reunala et al., 2015a, 
Salmi et al., 2016, Sárdy et al., 2002). In addition, gluten-dependency is not as evident 
as it is in DH (Salmi et al., 2016) where TG3 antibody levels have shown to decrease 
on GFD in parallel to the levels of TG2 antibodies (Reunala et al., 2015a). Currently 
serum TG3 antibody measurements are solely used in research setting as their 
specificity for DH and exact role is yet to be fully elucidated. 
Moreover, measurement of IgA-class antibodies against gliadin (AGA) are no 
longer used in DH diagnostics, and the clinical validity of deamidated gliadin peptide 
(DGP) antibodies is currently obscure (Jaskowski et al., 2010, Reunala et al., 1987). 
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2 COELIAC DISEASE 
2.1 Clinical features 
In the past, coeliac disease was considered a rare malabsorptive disease causing 
severe steatorrhoea, cachexia, and the failure to thrive mostly in children (Visakorpi 
and Immonen, 1967). However, presently coeliac disease is widely recognized as the 
most common food-related disorder, and it can be diagnosed at any age. 
Furthermore, the clinical spectrum of the disease is highly versatile. According to a 
recent classification, coeliac disease can be divided into classical, non-classical and 
asymptomatic coeliac disease (Ludvigsson et al., 2013).  
The classical presentation of coeliac disease includes gastrointestinal and 
malabsorptive symptoms such as diarrhoea, abdominal pain, weight loss, nutritional 
deficiencies, and growth retardation in children (Ludvigssonet al., 2013, Visakorpi 
and Mäki, 1994). These symptoms are not specific to coeliac disease, and further, it 
must be recognized that the symptoms can be mild or vague, for example moderate 
gastrointestinal discomfort, loose stools, or flatulence without malabsorption.  
Non-classical symptoms are nowadays increasingly common in coeliac disease 
(Fasano and Catassi, 2001, Green and Cellier, 2007) and symptoms can derive from 
various organs other than the gastrointestinal tract. Besides DH, the cutaneous 
manifestation of coeliac disease, the best described extraintestinal symptoms of 
coeliac disease include neurological conditions such as gluten ataxia, polyneuropathy, 
and epilepsy (Hadjivassiliou et al., 2006, Jericho et al., 2017), joint pain or arthritis 
(Nurminen et al., 2018, Savilahti et al., 2010) or gynaecological problems, such as 
delayed puberty, infertility, and recurrent miscarriages (Tersigni et al., 2014). Dental 
enamel defects found in adult patients’ permanent teeth are due to subclinical 
childhood coeliac disease, and they can also be present in DH (Aine et al., 1992, 
Ballinger et al., 1994, Collin and Reunala, 2003). Extraintestinal symptoms further 
include liver problems, and the severity can vary from mild reversible dysfunction 
and hypertransaminasemia to liver failure (Bardella et al., 1995, Kaukinen et al., 
2002).  
Coeliac disease can also be diagnosed in totally asymptomatic individuals, and 
these patients are typically diagnosed through screening (Fasano and Catassi, 2001). 
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Serological mass screening of the general population is not recommended at present; 
instead, active case findings with screenings among patients with an increased risk 
for coeliac disease is currently highly advised (Husby et al., 2012). The most 
important patient groups with an increased risk of coeliac disease – and thus also the 
target groups for coeliac disease screening – are listed in Table 1. The highest 
prevalence of coeliac disease is in first-degree relatives and especially in monozygotic 
twins and siblings with the same HLA risk alleles (Fasano et al., 2003, Greco et al., 
2002, Singh et al., 2015). Moreover, coeliac disease is more common in patients with 
autoimmune thyroid disorders (Reunala and Collin, 1997, Roy et al., 2016) as well as 
patients with multiple endocrine diseases (Collin et al., 2002). In addition, an 
increased risk for coeliac disease is found in patients with a selective IgA deficiency, 
and IgG class coeliac antibodies should be used for screening in these patients 
(Collin et al., 1992).  
Table 1. The most important patient and disease groups with an increased risk of coeliac disease. 
Risk groups for coeliac 
Disease 
Prevalence of 
coeliac 
disease (%) 
First degree relatives 8–10 % 
Type 1 diabetes 5–9 % 
Hyper- or hypothyreoiditis 2–6 % 
Sjögren’s syndrome 2–4% 
Addison disease 6–8% 
Selective IgA deficiency 7–10 % 
Down syndrome  4–14 % 
Data collected from Collin, 1992; Collin and Mäki, 1994; Gale et al., 1997; Bonamico et al., 1998; Collin et al., 2002; Biagi et al., 
2006; Fasano et al., 2003; Mårild et al., 2013a; Mårild et al., 2016; Singh et al., 2015; and Kurppa et al., 2018. 
2.2 Diagnosis by small bowel biopsy and autoantibodies 
The gold standard in the diagnosis of coeliac disease is the small bowel biopsy, 
obtained during gastroscopy, revealing villous atrophy and crypt hyperplasia. 
Biopsies should be taken while the patient is adhering to a normal gluten-containing 
diet, and multiple biopsy specimens should be taken to detect patchy villous atrophy 
(Lebwohl et al., 2011, Pais et al., 2008). Proper specimen orientation is essential as it 
reduces the risk of both false-negative and -positive results (Arguelles-Grande et al., 
2012, Taavela et al., 2013).  
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In coeliac disease, the small bowel mucosal damage progresses gradually from 
inflammatory changes to overt villous atrophy and crypt hyperplasia when the 
patient is consuming gluten. The Marsh classification has been used to describe the 
stepwise development of mucosal lesions (Marsh, 1992). To assess the mucosal 
damage in more detail, villous height/crypt depth ratios (Vh/CrD) should be 
measured from at least three different sites, and generally mean values of Vh/CrD 
≥2 are considered normal (Kuitunen et al., 1982, Taavela et al., 2013). However, in 
clinical practice, small bowel biopsy findings are often divided more roughly into 
three subgroups: normal villous architecture, partial villous atrophy and severe 
villous atrophy. 
An increase in small bowel mucosal IELs is typical for coeliac disease and 
considered the first detectable abnormal histological feature (Marsh, 1992). The 
lymphocytes in the lamina propria are mainly CD3+ IELs, and these cells express 
either T-cell receptor (TCR) αβ+ or γδ+. In untreated coeliac disease, the densities 
of αβ+ and γδ+ cells are elevated, and an especially increased density of γδ+ T-cells 
is considered relatively specific for coeliac disease (Holm et al., 1992; Järvinen et al., 
2003). Furthermore, densities of CD3+ and γδ+ IELs are typically increased already 
in early-stage coeliac disease, and the density of γδ+ IELs often remains elevated 
even when the patients adhere to a GFD (Järvinen et al., 2003). However, 
determination of γδ+ IELs requires frozen small bowel mucosal specimens, and 
therefore, it should be used only in problematic cases with diagnostic difficulties. 
Further, when frozen small bowel mucosal specimens are available, the presence of 
intestinal TG2-specific autoantibody deposits can also be examined. In coeliac 
disease, TG2-targeted autoantibodies are produced mainly by B-lymphocytes in the 
lamina propria (Marzari et al., 2001), and with direct IF examination intestinal TG2-
specific IgA deposits can be detected with high sensitivity and specificity in coeliac 
disease (Koskinen et al., 2010). Moreover, these deposits appear even before the 
development of villous atrophy and occur also in seronegative coeliac disease 
patients (Koskinen et al., 2008, Salmi et al., 2006).  
Serological tests were developed to screen patients suspected of suffering from 
coeliac disease. The first test developed was the ARA, which seemed reliable in 
experienced hands (Hällström, 1989) but showed highly variable sensitivity and 
specificity in different studies (Lock et al., 1999, Mäki et al., 1984, Sulkanen et al., 
1998). The IgA-class AGA test was also used contemporarily with the ARA until 
more accurate serological methods became available (Leffler and Schuppan, 2010, 
Savilahti et al., 1983). The EmA test started to replace these two tests in 1984 
(Chorzelski et al., 1984) and when TG2 was identified as the autoantigen in coeliac 
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disease, an enzyme-linked immunosorbent assay (ELISA) method for detecting IgA-
class TG2 antibodies was developed (Dieterich et al., 1997, Sulkanen et al., 1998). 
Subsequently, it was shown that TG2 is also the antigen of the ARA and EmA tests 
(Korponay-Szabóet al., 2003). The TG2 ELISA antibody test is cheaper and 
considered more sensitive but slightly less specific than the EmA test, which has a 
specificity of 97–100% (Rostom et al., 2005). In the EmA test, human umbilical cord 
is needed as the substrate, the indirect IF microscopic evaluation is subjective, and 
the test requires skilful laboratory personnel (Schyum and Rumessen, 2013). 
Therefore, the IgA-class TG2-antibody ELISA test should primarily be used when 
coeliac disease is screened. The measurement of DGP antibodies has shown 
relatively high specificity (90–98%) in coeliac disease but this test method is currently 
lacking extensive use in clinical practice (Adriaanse and Leffler, 2015). Moreover, 
circulating antibodies against transglutaminase 6 (TG6) have been proposed to be 
valuable in identifying patients with coeliac disease-related neurological symptoms 
like cerebellar ataxia (Hadjivassiliou et al., 2006).  
The European Society for Paediatric Gastroenterology, Hepatology and 
Nutrition (ESPGHAN) recommended the serology-based diagnosis of coeliac 
disease in children already in 2012. According to the criteria, diagnosis without small 
bowel biopsies can be made when the TG2 antibody level is more than ten times the 
upper limit of normal and the EmA test is positive in a different blood sample. In 
addition, the HLA DQ2 or DQ8 haplotype must be present (Husby et al., 2012). 
Recently, the National Guidelines for coeliac disease (Celiac Disease, Current Care 
Guidelines, 2018) in Finland recommended that coeliac disease in adults can also be 
diagnosed without small bowel biopsies when the TG2 antibody level is at least ten 
times the normal limit and the subsequent EmA test is also positive. It has been 
estimated that serology-based criteria could be sufficient to make the diagnosis in at 
least one third of adult patients with coeliac disease (Fuchs et al., 2019).  
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3 EPIDEMIOLOGY IN DERMATITIS 
HERPETIFORMIS AND COELIAC DISEASE  
DH is most common among individuals of northern European origin. In the early 
1970s, the prevalence was 10.4 per 100,000 in Finland (Reunala and Lokki, 1978). In 
the 1980s, similar or somewhat higher figures were found in Sweden, Scotland, and 
Ireland (Buckley et al., 1983, Gawkrodger et al., 1984, Mobacken et al., 1984). In 
2011, the prevalence of DH in Finland was 75,3 per 100,000 – the highest figure 
reported to date (Salmi et al., 2011). At the same time, the prevalence in the United 
Kingdom (UK) was lower, at 30.3 per 100,000 (West et al., 2014). Importantly, in 
both Finland and the UK, the prevalence of DH was eight times lower than the 
prevalence of coeliac disease (Salmi et al., 2011, West et al., 2014). 
A rather high prevalence of DH – 10.2 per 100,000 – has been reported in the 
United States (US) state of Utah (Smith et al., 1992, Westet al., 2014). DH is rare in 
African-Americans (Hall et al., 1990). A few small case series have been published 
on Asia populations but none have been published on Africa populations (Zhang et 
al., 2012). A study from Japan showed the occurrence of DH type disease with 
mostly fibrillar IgA deposits in the papillary dermis (Ohata et al., 2012). Despite the 
similarities, the disease is likely to differ from the classical DH occurring in the 
Caucasian population. Overall, the geographical differences in the prevalence of DH 
and coeliac disease are mainly explained by HLA genetics and wheat consumption 
habits (Kang et al., 2013). 
In the 1970s, the annual incidence of DH was 1.3 per 100,000 in Finland (Reunala 
and Lokki, 1978) and by the early 1980s, the incidence of DH and coeliac disease 
was almost the same (Collin et al., 2007). Later studies from Finland and the UK 
have shown that the incidence of DH has significantly decreased in recent decades, 
from 5.2 to 2.7 per 100,000 in the Finnish study and from 1.8 to 0.8 per 100,000 in 
the UK study (Salmi et al., 2011, West et al., 2014). At the same time the incidence 
of coeliac disease has increased fourfold in the UK and Finland (West et al., 2014, 
Virta et al. 2017). Seroepidemiological studies suggest that in addition to the better 
recognition of coeliac disease, there has also been a true increase in the incidence in 
recent decades (Lohi et al., 2007). Importantly, as only 0.7% of the Finnish adult 
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population has a coeliac disease diagnosis (Ilus et al., 2014), the disease is still greatly 
underdiagnosed in Finland, like in many other countries (Fasano et al., 2003). 
Age at onset and gender differ markedly between DH and coeliac disease. In 
contrast to coeliac disease, DH is rare in childhood in Finland, where approximately 
4% of the DH patients are diagnosed under the age of 16 (Hervonen et al., 2014, 
Kivelä et al., 2015) but seems more common among children in Hungary and Italy 
(Antiga et al., 2013, Dahlbom et al., 2010). The mean age at DH diagnosis has 
increased significantly from 35 to 51 years in men and from 36 to 46 years in women 
during the last 30 years. Currently, the mean age at DH diagnosis is 49 years in 
Finland (Salmi et al., 2011). In coeliac disease, there are two peak ages of onset: early 
childhood and the fourth or fifth decades of life (Tack et al., 2010). Similarly, to DH, 
the age at diagnosis seems to be increasing also in adults with coeliac disease in 
Finland (Collin et al., 2018). There is a slight or moderate male preponderance in 
DH studies (Salmi et al., 2011), whereas in adults with coeliac disease, females 
markedly outnumber males (Green and Cellier, 2007).  
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4 PATHOGENESIS OF DERMATITIS 
HERPETIFORMIS AND COELIAC DISEASE 
4.1 Genetic background and familial occurrence 
Practically all patients with DH and coeliac disease carry the HLA alleles DQ2 or 
DQ8 (Spurkland et al., 1997). It is important to note that 25–35% of the Caucasoid 
population carries the HLA DQ2 and DQ8 haplotypes, and only a minority of these 
will develop DH or coeliac disease (Monsuur et al., 2008). On the other hand, the 
absence of the HLA DQ2 or DQ8 in patients suspected for the disease excludes DH 
and coeliac disease with a negative predictive value of more than 99% (Caproni et 
al., 2009).  
Due to the common genetic background, the prevalence of DH and coeliac 
disease are increased in first-degree relatives (Fasano et al., 2003, Hervonen et al., 
2002, Rubio–Tapia et al., 2008). A recent meta-analysis showed that the prevalence 
of coeliac disease was 7.5% among first-degree relatives (Singh et al., 2015). In a 
Finnish family study, 18% of patients with DH and 19% of patients with coeliac 
disease had one or several affected first-degree relatives, most of whom had coeliac 
disease (Hervonen et al., 2002). Monozygotic twins are known to have a high 
concordance of coeliac disease (Nisticò et al., 2006). Interestingly, monozygotic 
twins can also be affected by different gluten-sensitive phenotypes; one twin pair can 
have DH and the other coeliac disease (Hervonen et al., 2000).  
4.2 Gluten and other environmental factors 
DH and coeliac disease have unique pathogenesis among autoimmune diseases. In 
genetically predisposed individuals, the exogenous factor responsible is dietary 
gluten. Gluten is the storage protein for alcohol-insoluble prolamine glycoproteins: 
gliadin in wheat, secalin in barley, and hordein in rye. The major amino acid 
constituents of gluten are proline, glutamine, and hydrophobic amino acids, which 
make gluten resistant to complete degradation by gastric, pancreatic, and brush-
border enzymes. When the partly digested gluten proteins and peptides reach the 
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small intestinal lumen in affected individuals, they start a cascade of adaptive and 
innate immunological reactions leading to gluten-sensitive enteropathy typical of 
coeliac disease and DH (Shan et al., 2002). 
Other environmental factors than gluten have been proposed for the complete 
explanation of the development of coeliac disease. Changes in infant feeding 
practices were considered to be important in the Swedish epidemic of coeliac disease 
in the 1980s (Ivarsson et al., 2000). However, a recent controlled study on breast-
feeding and early introduced gluten did not show any increased risk for coeliac 
disease development (Vriezinga et al., 2014). Gastrointestinal infections and 
especially the rotavirus in children have been proposed as additional risk factors 
(Stene et al., 2006). In addition, the augmented use of antibiotics can disturb normal 
gut microbiota, which may increase the risk for coeliac disease (Mårild et al., 2013b). 
4.3 Immunopathology in gluten-sensitive enteropathy  
The partly digested gluten peptides enter via transcellular or paracellular routes into 
the lamina propria of small intestinal mucosa (Shan et al., 2002). In affected 
individuals, an adaptive immune reaction occurs that is dependent on deamidation 
of gliadin peptides by the TG2-enzyme (Qiao et al., 2009). Deamidation increases 
the immunogenicity, facilitating binding to the HLA-DQ2 or -DQ8 molecules on 
antigen presenting cells (Molberg et al., 1998). These antigen-presenting cells interact 
with gliadin-specific CD4+T cells, which produce pro-inflammatory cytokines, such 
as interfreron γ (IFN-γ) and interleukin (IL) 21, which leads to tissue damage (Bodd 
et al., 2010, Lundin et al., 1993). These CD4+ cells are also able to bind to gluten-
specific B-cells which then differentiate into plasma cells releasing TG2 and gliadin 
antibodies to circulation (Rauhavirta et al. 2016). See Figure 3. 
The innate immune response to gliadin occurs in the epithelial component of the 
intestinal mucosa and involves the increased production of cytokines, in particular 
IL-15, by enterocytes and macrophages (Mention et al., 2003). The result is the 
differentiation of IELs into cytotoxic CD8+T cells. The cumulative resulting 
damage to the intestinal mucosa from this cascade of inflammatory mediators is the 
villous atrophy and crypt hyperplasia in coeliac disease and DH.  
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4.4 Rash and skin IgA deposits in dermatitis herpetiformis 
Granular IgA deposits within the papillary dermis are pathognomonic for DH (Zone 
et al., 1996). Biopsies taken routinely from perilesional skin and stained with the 
direct IF method show typical IgA deposits, which are also present in skin areas not 
affected by the DH rash (Zone et al., 1996). The autoantigen for deposited cutaneous 
IgA is TG3 (Sárdyet al., 2002), an enzyme normally present only in the epidermis. 
Thus, the TG3-bound IgA aggregates in the dermis are thought to derive from the 
blood vessels (Preisz et al., 2005, Taylor et al., 2015). Supporting this hypothesis, 
patients with DH have frequently circulating high-avidity IgA-class TG3 antibodies, 
and one study has also found TG3-IgA immune complexes in the blood (Collin et 
al., 2017, Görög et al., 2016, Sárdy et al., 2002). 
A valid hypothesis suggests that immune pathogenesis in DH begins in the small 
bowel from latent or manifest gluten-sensitive enteropathy, i.e. coeliac disease 
(Collin et al., 2017, Reunala et al., 1998). See Figure 3. The gluten-induced immune 
response in the small bowel releases circulating IgA-class TG2 autoantibodies in 
both coeliac disease and DH, whereas TG3 autoantibodies are found mainly in DH 
(Dieterich et al., 1998, Korponay-Szabó et al., 2004, Reunala et al., 2015a). 
Importantly, the TG3 protein has not been found in the small bowel like the TG2 
enzyme, and therefore epitope spreading could be a reason for the production of 
TG3 antibodies (Sárdy et al., 2002). In line with this, a recent study showed that 
patients with untreated DH secreted high levels of TG3 antibodies into the small 
bowel organ culture medium, and TG3-secreting plasma cells were also seen in the 
small bowel mucosa (Hietikko et al., 2018b).  
The initial events of blister formation in DH are still unclear. Recently, Taylor 
and colleagues (2015) showed that TG3 present in IgA aggregates in DH skin is 
enzymatically active and binds soluble fibrinogen. This fits well with earlier studies 
showing marked fibrin deposition and the upregulation of a urokinase-type 
plasminogen activator in evolving DH blisters (Airola et al., 1995, Reitamo et al., 
1981). An influx of neutrophils and macrophages into developing DH lesions is a 
rather late phenomenon, which may be initiated by the activation of fibrinogen to 
fibrin, resulting in fibrinolysis (Davalos and Akassoglou, 2012, Görög et al., 2016, 
Reitamo et al., 1981). A second open question is why the blistering DH lesions occur 
on the knees, elbows, and buttocks even though IgA-TG3 aggregates are also 
deposited at sites never involved in blister formation (Zone et al., 1996). The most 
likely explanation for this unique distribution involves the influence of local factors, 
such as pressure and stretching, which may directly activate TG3 in dermal 
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aggregates in the same way that mechanical force activates TG2 in blood vessel walls 
(Huelsz-Prince et al., 2013). 
 
Figure 3.  Proposed pathogenesis of dermatitis herpetiformis and coeliac disease adapted from 
Reunala et al. 2015b. 
Abbreviations: APC=antigen presenting cells, TG= transglutaminase, ab= antibodies, IFN= interferon, IL=interleukin.  
After dietary (gluten-containing) wheat, rye or barley is digested in the small bowel lumen, it is absorbed 
through the lamina propria. Gliadin is deamidated close to the lamina propria by TG2. Thereafter, CD4+ cells 
recognize the gliadin peptides presented by HLA DQ2/DQ8 antigen presenting cells (APC). This results in 
cytokine production leading to mucosal damage and the activation of gluten-specific B-cells. B-cell activation 
leads differentiated plasma cells to produce TG2 antibodies and cytokine production then leads to mucosal 
damage  
Epitope spreading is one explanation for the development of TG3 antibodies. TG2 and TG3 antibodies 
circulate in the blood vessels, and thereafter TG3 antibodies leave the circulation and enter the dermis. TG3 
antibodies make immunocomplex depositions with TG3 enzymes. IgA TG3 antibody +TG3 enzyme 
immunocomplexes are deposited near the papillary dermis and lead to neutrophilic abscesses and 
subepidermal blister production in the skin. 
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5 TREATMENT OF DERMATITIS HERPETIFORMIS 
AND COELIAC DISEASE  
5.1 Gluten-free diet 
The most important treatment for both DH and coeliac disease is a strict life-long 
GFD, which is initiated by patients after the diagnosis is confirmed. A GFD means 
the avoidance of wheat, rye, and barley and foods made from these cereals. Gluten-
free oats, i.e. oats not contaminated by gluten traces from other cereals, have been 
shown to be safe both in DH (Reunala et al., 1998) and coeliac disease (Janatuinen 
et al., 1995, Pinto-Sánchez et al., 2017). Even though the role of oats as a part of a 
GFD is somewhat controversial worldwide, gluten-free oats are available for coeliac 
disease and DH patients for example in Finland, Canada, the UK, and the US.  
In an ideal GFD diet, gluten intake would be zero, but this is almost impossible 
to achieve. There is no evidence of a single definitive threshold for a safe gluten 
intake in DH and coeliac disease. Tolerance to gluten traces also seems to vary 
between individuals (Lähdeaho et al., 2011). For most coeliac disease patients, a daily 
intake of 10 milligrams of gluten is unlikely to cause small bowel damage (Akobeng 
and Thomas, 2008). The European Commission has issued a regulation for foods 
that are labelled “gluten-free”. These foods can contain less than 20 parts per million 
(ppm) of gluten. This is equal to 20 mg/kg of food, which is also a widely accepted 
threshold for a GFD. Studies have shown that this amount of gluten is safe for 
patients with coeliac disease (See et al., 2015). In the Western diet, people eat on 
average 13 g of gluten per day, but individual variation is large (Antvorskov et al., 
2018, Köhler-Brands et al., 1997). 
In DH, GFD heals both the rash and the small bowel villous atrophy. Regardless 
of adhering strictly to the GFD, skin symptoms can take several months to a few 
years to clear (Fry et al., 1973, Reunala et al., 1977). In coeliac disease, the alleviation 
of gastrointestinal symptoms usually takes a few weeks after starting a GFD. Small 
bowel mucosal recovery seems to be slow in adult patients with coeliac disease, and 
normalization of the villous architecture may take even 2–5 years (Lanzini et al., 
2009, Rubio-Tapia et al., 2010, Wahab et al., 2002).  
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As a GFD can be personally and socially problematic (Zarkadas et al., 2013), all 
patients should receive dietary advice by dietitian when starting the diet (See et al., 
2015). While it is important to avoid gluten by replacing it with alternative products, 
it is equally essential to ensure an adequate amount of nutrients, vitamins, fibre, and 
calcium in the diet (Ciacci et al., 2015). A GFD is also more expensive when 
compared to a normal gluten-containing diet, and the availability of gluten-free 
products can be limited. Travelling and eating outside the home can be especially 
problematic (Whitaker et al., 2009; Zarkadas et al., 2013). Due to these discomforts, 
some coeliac disease patients may often have dietary lapses or even non-adherence 
to a GFD (See et al., 2015).  
A long-term follow-up study conducted in Finland showed that 98% of DH 
patients adhered to a GFD and 72% of them adhered strictly without any lapses 
(Hervonen et al., 2012). In another Finnish study, adherence to a strict GFD was 
88% among patients with coeliac disease, and dietary lapses were associated with a 
younger age at diagnosis, being a teenager, and existing symptoms (Kurppa et al., 
2012). However, dietary adherence rates have been shown to vary, and based on self-
reported questionnaires in several European countries, strict dietary adherence was 
only seen in 40–62% of patients with coeliac disease (See et al., 2015). 
The prevailing view is that GFD treatment should be life-long both in DH and 
coeliac disease. There are nevertheless a few reports suggesting that a small 
proportion of DH patients could go into remission and be able to re-introduce 
gluten to their diet without developing any symptoms or signs of DH (Garioch et 
al., 1994, Gawkrodger et al., 1984, Paek et al., 2011). Furthermore, in a recent Italian 
study (Bardella et al., 2003) in which DH patients were gluten-challenged, seven 
(18%) did not show clinical or small bowel histological relapse. There are studies 
also suggesting that patients with coeliac disease could re-develop gluten tolerance 
and enter clinical and histological remission (Hopman et al., 2008, Matysiak-Budnik 
et al., 2007). However, further studies are needed to verify what the possible 
mechanisms for gluten tolerance could be and how frequently this is achieved in 
patients with DH and coeliac disease adhering to a GFD treatment. 
5.2 Dapsone medication in dermatitis herpetiformis 
After a DH diagnosis, all patients are advised to start the GFD treatment. Even when 
adhering strictly to a GFD, the rash and intensive pruritus usually subsides within a 
few weeks to several months (Fry et al., 1973, Reunala et al., 1977). Patients with a 
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widespread rash and intense itch need additional treatment with dapsone, and in our 
cohort this drug was initiated in 65% of newly diagnosed DH patients (Hervonen et 
al., 2012). 
Dapsone has antibacterial and anti-inflammatory effects, and in the skin it inhibits 
neutrophil- and eosinophil-mediated tissue damage. Dapsone relieves the rash in a 
couple of days, but it has no effect on the small bowel enteropathy or IgA deposits 
in the skin (Bolotin and Petronic-Rosic, 2011b, Zone et al., 1996).  
For children, the starting dose of dapsone is usually 0.5 mg/kg/day. For adults, 
a dosage of 25–50 mg/day is usually enough to control the pruritus and the 
development of new skin lesions in most patients (Gawkrodger et al., 1984, Reunala 
et al., 1977). The dapsone dose is slowly reduced, and the drug treatment can be 
stopped after an average of two years on a strict GFD (Bolotin and Petronic-Rosic, 
2011b, Garioch et al., 1994). 
Dapsone treatment rarely causes agranulocytosis, but it can have a dose-
dependent risk for haematological adverse effects, such as haemolysis and 
methaemoglobinaemia (Bolotin and Petronic-Rosic, 2011b). Therefore, patients 
need to be followed-up until the dapsone medication has been discontinued 
(Garioch et al., 1994, Leonard and Fry, 1991). 
Topical treatment with 5% dapsone gel available in the US has been reported to 
have beneficial effects on the DH rash (Burbidge and Haber 2016). In contrast, even 
potent or superpotent topical steroids have shown only mild or no impact on 
pruritus when used as a monotherapy (Caproni et al., 2009, Bolotin and Petronic-
Rosic, 2011b).  
 40
6 PROGNOSIS OF DERMATITIS HERPETIFORMIS 
AND COELIAC DISEASE 
6.1 Long-term prognosis on a gluten-free diet 
In DH, the GFD treatment offers a good long-term prognosis in regard to mortality 
in addition to the healing of the rash and small bowel mucosa. In a recent Finnish 
DH study, the standardized mortality rate (0.70) was significantly lower than that for 
the general population (Hervonen et al., 2012). In contrast to DH, most studies on 
coeliac disease have shown an increased risk for all-cause mortality (Tio et al., 2012). 
See Table 2. The overall risk in 17 studies was 1.24, and the most common causes 
of death were lymphoproliferative and cardiovascular diseases (Tio et al., 2012). 
Compared to the DH mortality study (Hervonen et al., 2012), knowledge about 
adherence to a GFD has been scant in coeliac disease studies. A previous DH 
mortality study from UK reported normal (hazard ratio 0.93) all-cause mortality 
(Lewis et al., 2008).  
The results for bone mineral density (BMD) in DH patients are somewhat 
contradictory. In two studies, BMD was shown not to differ from that of the healthy 
controls (Abuzakouk et al., 2007, Lheure et al., 2017). However, in one study DH 
patients were found to have a lower BMD compared to non-coeliac controls, but a 
higher BMD compared to coeliac disease patients at diagnosis (Di Stefano et al., 
1999). Long-term studies suggest that DH patients on a GFD do not have lowered 
BMD, unlike patients with coeliac disease (Lorinczy et al., 2013). The risk for bone 
fractures in GFD-treated DH patients seems not to be increased according one study 
(Lewis et al., 2008, Pasternack et al., 2018). This is in contrast to the results of a meta-
analysis study performed for coeliac disease, where the risk of hip fractures, and 
fractures in general was increased (Heikkilä et al., 2015). 
The most serious complication of DH and coeliac disease is the development of 
a lymphoma or other malignancy.  The association of DH and lymphoma was first 
reported in the 1980s, when a very high, 100-fold relative risk was found (Leonard 
et al., 1983b). After that, the reported risk rates of lymphoma in DH have been 
markedly lower – 2–10-fold compared to general population (Collin et al., 1996, 
Sigurgeisson et al., 1994, Viljamaa et al., 2006). Importantly, the risk of lymphoma 
 41 
seems to be elevated only during the first five years after DH diagnosis, but not 
thereafter, whereas the risk persists with coeliac disease for over 15 years (Grainge 
et al., 2012, Lewis et al., 1996). Furthermore, DH patients developing a lymphoma 
have been reported not to follow a GFD or adhere to it strictly (Hervonen et al., 
2005). The risk for any cancer or gastrointestinal carcinoma is not increased in GFD-
treated DH patients (Collin et al., 1996, Hervonen et al., 2012, Lewis et al., 2008, 
Sigurgeisson et al., 1994, Swerdlow et al., 1993) which again is in contrast to coeliac 
disease (Askling et al., 2002, Green et al., 2003, West et al., 2004, Table 2).  
Table 2. Comparison of the long-term prognosis of gluten-free diet-treated patients with dermatitis 
herpetiformis and coeliac disease 
 
 Dermatitits Herpetiformis Coeliac disease 
Bone mineral density Normal  Lowered in most studies 
Risk of bone fractures Not increased Increased 
Risk of Non-Hodgkin’s lymphoma  Increased for the first five 
years after diagnosis  
Increased 
Risk of gastrointestinal 
malignancies 
Not increased Increased 
Mortality Reduced  Slightly increased  
Quality of life  Not decreased Decreased in most studies 
6.2 Refractory disease 
In DH, there are a few earlier reports describing patients, whose rash does not 
response to a strict GFD (Gariochet al., 1994, Hervonen et al., 2016, Leonard and 
Fry, 1991). One reason for the non-response is intentional or inadvertent ongoing 
gluten consumption. However, this seems not always to be the case. A recent Finnish 
study of 403 DH patients, found seven (1.7%) non-responsive patients, who had 
been on a strict GFD for a mean of 16 years (Hervonen et al., 2016). These patients 
still needed dapsone for the active rash, although their GFD was considered strict, 
the serum coeliac autoantibodies were negative, and the small bowel mucosa had 
healed. This condition, named as refractory DH, seems to be different from 
refractory coeliac disease since there were no signs of lymphoma or other 
complications for which refractory coeliac disease is known (Hervonen et al., 2016).  
In coeliac disease, there are patients whose symptoms and small bowel villous 
atrophy do not response to a strict GFD. In these cases, ongoing gluten ingestion 
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must always be ruled out. This condition has been termed refractory coeliac disease, 
and it has overt malabsorptive symptoms together with persistent villous atrophy for 
a minimum of 6–12 months despite a strict GFD (Rubio-Tapia and Murray, 2010). 
Refractory coeliac disease is classified as subtype I or II based on the detection of a 
normal or aberrant IEL T-cell population in small bowel biopsy specimens. In type 
I, there is a normal IEL immunophenotype, whereas in type II, the 
immunophenotype is abnormal. The prognosis in these subtypes is different; in type 
I nutritional support together with pharmacologic therapy usually improves the 
disease, whereas in type II, the prognosis is poor. In the latter subtype patients are 
at risk for severe complications, such as intestinal T-cell lymphoma and premature 
death (Rubio-Tapia and Murray, 2010). The prevalence of refractory coeliac disease 
is thought to be very rare. In Finland, refractory coeliac disease was diagnosed in 44 
(0.36%) of 12,243 coeliac disease patients (Ilus et al., 2014). Of these, 68% had type 
I, 23% had type II, and 9% remained uncharacterized. 
6.3 Quality of life 
Quality of life (QoL) has been described as psychological, physical, and social well-
being and the awareness of one’s position in life compared to others (Calman, 1984, 
Deepak et al., 2018). When QoL is monitored, it enables a more comprehensive 
evaluation of the disease and the benefits of the treatment.  
There is little data about QoL in DH. A recent study featuring 52 newly diagnosed 
DH patients showed that QoL was decreased and the burden of untreated DH was 
even greater among patients with gastrointestinal symptoms (Pasternack et al., 2017). 
After adherence to a GFD for one year, QoL was at the same level as that of the 
normal controls (Pasternack et al., 2017), a result found also earlier in long-term 
GFD-treated DH patients (Pasternack et al., 2015). 
More extensive QoL research has been performed for coeliac disease. At 
diagnosis, the patients with coeliac disease have shown to have reduced QoL when 
compared to healthy controls (Green et al., 2001, Ukkola et al., 2011). Moreover, 
diagnostic delay has been shown to associate with reduced QoL (Fuchs et al., 2018, 
Paarlahti et al., 2013). After one year on a GFD, the majority of coeliac disease 
patients reported an improvement in their health-related QoL (Greenet al., 2001, 
Mustalahti et al., 2002). However, 25 % of coeliac disease patients undergoing long-
term GFD-treatment reported having persistent gastrointestinal symptoms and 
reduced QoL (Hallert et al., 2002, Häuser et al., 2006, Paarlahti et al., 2013).  
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Gender seems to affect QoL in DH and coeliac disease. Compared to males, 
female DH patients have shown to have a lower QoL at diagnosis but not on GFD 
treatment (Pasternack et al., 2017). Furthermore, on GFD DH females have shown 
to suffer more commonly from abdominal symptoms compared to males 
(Pasternack et al., 2015). Similarly, females with coeliac disease have shown to have 
lower QoL both at diagnosis (Nordström et al. 2011) and on GFD when compared 
to male patients (Hallert et al., 2002, Pulido et al., 2013, Roos et al., 2006, Zarkadas 
et al., 2006).  
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7 AIMS OF THE PRESENT STUDY 
The main aims of the present DH study were to investigate the diagnostic delay and 
the severity and long-term prognosis of villous atrophy in DH utilizing a 
prospectively collected patient series at the Tampere University Hospital. The 
possibility of remission from DH after long-term GFD treatment was investigated 
with a 12-month gluten challenge. 
The specific aims were: 
1. To investigate the diagnostic delay in DH and factors associated with 
delayed diagnosis (I). 
2. To study whether small bowel histological findings at DH diagnosis have 
changed over the last 45 years, and to investigate the correlations of serum 
TG 2 antibodies and the degree of mucosal damage (II). 
3. To examine whether the presence or absence of villous atrophy at diagnosis 
affects the long-term prognosis of DH (III). 
4. To determine whether the development of gluten-tolerance is possible in 
long-term GFD-treated DH patients using a gluten challenge (IV). 
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8 DERMATITIS HERPETIFORMIS PATIENTS AND 
COELIAC DISEASE CONTROLS 
8.1 Dermatitis herpetiformis patients  
Table 3.  Patients with dermatitis herpetiformis (DH) and the coeliac disease controls. 
Study  Study design Number of 
DH 
patients 
Men (%)  
 
Mean age at 
DH diagnosis: 
years (range) 
Mean age at 
the time of the 
study: years 
(range) 
Control 
patients 
I. Diagnostic 
delay 
Retrospective cohort 
study  
 
Questionnaire 
446 
 
 
217 
229 (51)  
 
 
118 (54) 
43 (3–83) 
 
 
45 (5–78) 
- 
 
 
63 (18–96) 
- 
 
 
- 
II. Prevalence 
of small bowel 
villous atrophy 
Retrospective cohort 
study 
393 214 (54)  45 (18–84) - - 
III. Prognosis in 
patients with 
and without 
small bowel 
villous atrophy 
Retrospective cohort 
study 
352 177 (50) 42 (3–84) 63 (18–96) 248 
coeliac 
controls 
 Questionnaire 181 96 (53) 45 (5–78) 62 (18–96) 128 
coeliac 
controls 
IV. Gluten 
challenge 
Prospective study 19 13 (68) 35 (19–57) 58 (37–72) - 
The DH study cohorts in Studies I–IV (Table 3) derived from our prospectively 
collected series of DH patients at the Department of Dermatology, Tampere 
University Hospital. This single-centre DH cohort consists a total of 502 patients 
who had been diagnosed and treated at a special DH outpatient clinic between 1970 
and 2014. All patients suspected of having DH by general practitioners in health care 
centres and private dermatologists were referred to the Department of Dermatology, 
Tampere University Hospital for the confirmation of a DH diagnosis. This was 
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based on the typical clinical picture and the detection of granular IgA deposits in the 
papillary dermis by direct IF examination. All patients were asked to undergo 
gastroscopy to obtain small bowel biopsies at the Department of Gastroenterology 
and Alimentary Tract Surgery (or previously at the Department of Internal Medicine) 
at Tampere University Hospital. After the diagnosis, all patients were advised to 
adhere to a GFD routinely. About 65% of the patients received dapsone, from 12.5 
to 50mg/day, to control the skin symptoms (Hervonenet al., 2012). The patients on 
a GFD were followed up routinely by an experienced dermatologist in the outpatient 
clinic for at least 1–2 years or until the rash had cleared up and the need for dapsone 
medication stopped.  
Study I included 446 DH patients. Of the 502 patients, 56 were excluded from 
further analysis: 21 had died more than 20 years previously and adequate data was 
lacking, and 35 had a prior (≥2 years earlier) diagnosis of coeliac disease. In Studies 
II and III, 53 patients had to be excluded as a small bowel biopsy result was not 
available, and in Study III, and additional 41 patients were excluded due to 
inadequate follow-up data. Long-term follow-up data for Studies I and III was 
obtained by questionnaires (see Chapter 9.5) collected between December 2015 and 
May 2016. The questionnaires were mailed to all 420 DH patients living in the 
Pirkanmaa Hospital District, and the overall response rate was 62%. In Studies I and 
III, 217 and 181 patients had adequate data for further analysis, respectively (Table 
3). 
Gluten challenge Study IV was a prospective study that included 19 GFD-treated 
DH patients from the cohort described above who volunteered to participate. They 
had adhered to a GFD for a mean of 23 (range 5–40) years and were all in clinical 
remission, i.e. they did not use dapsone and had been rash-free for at least three 
years. 
8.2 Coeliac disease controls (III) 
The controls included 248 coeliac disease patients suffering from abdominal 
symptoms at the time of the diagnosis (Study III, Table 3). The diagnosis of all 
control patients was based on histological analysis of small bowel biopsy specimens 
at the Department of Gastroenterology and Alimentary Tract Surgery, Tampere 
University Hospital. 
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The follow-up data from coeliac disease controls were collected on May 2016 by 
specific questionnaires (see Chapter 9.5) mailed to the 222 adult coeliac disease 
patients who were still alive. A total of 128 (58%) responded. 
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9 METHODS 
9.1 Duration and activity of rash and skin immune deposit 
examinations 
In Studies I–IV, data on demographic characteristics, the duration and severity of 
the rash, and the results of coeliac autoantibodies and haemoglobin values at DH 
diagnosis were gathered from the patient records of Tampere University Hospital. 
In Study I, the duration of the rash before diagnosis was collected from all patients. 
Diagnosis was defined as delayed when the duration of the rash before the diagnosis 
was two years or longer. The severity of the rash at DH diagnosis was scored as mild, 
moderate, or severe according to presence of a few, several, or many blisters, macular 
eruptions, and erosions on the knees, elbows, buttocks, and scalp or elsewhere on 
the body based on descriptions in the medical records (Studies I, III, and IV). In 
Study IV, the severity of the rash was based on clinical examination.  
In Study IV, a punch biopsy was taken in the absence of skin symptoms from 
normal appearing forearm skin or from perilesional skin. The specimens were stored 
at -70C before the examinations. To investigate IgA deposits, sections cut from the 
specimens were stained with TRITC-conjugated goat antihuman IgA (1:50) 
(A18786, Life Technologies, Frederick, Maryland, USA) at the coeliac disease 
research laboratory. Skin IF-IgA intensity was graded negative, positive, or strong 
positive. TG3 deposits were stained with FITC-conjugated rabbit polyclonal TG3 
antibody (1:100) (A030, Zedira, Darmstadt, Germany). All sections were further 
double-stained for IgA and TG3 with TRITC goat antihuman IgA (1:50) (A18786, 
Thermo Fisher Scientific, Waltham, MA, USA) as previously described (Hietikko et 
al., 2018c). 
9.2 Small bowel biopsy examinations  
After the DH diagnosis, a gastroscopy and a small bowel biopsy was performed in 
about 75% of the patients. In the 1970s, biopsies were obtained with a Crosby 
capsule under x-ray control and thereafter upon upper gastrointestinal endoscopy. 
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Small bowel mucosal samples were scored morphologically as SVA, PVA, or normal 
villous architecture. Pathologists with a special knowledge of intestinal pathology 
made the interpretations. Small bowel biopsy results at DH diagnosis were collected 
from the medical records (Studies I–IV). 
In Study IV at pre- and post-challenge, 6–8 forceps biopsy specimens were taken 
from the distal part of the duodenum during gastroscopy. At least two specimens 
were stained with haematoxylin and eosin and investigated with light microscopy. At 
least three well-oriented villous crypt units were examined by measuring the villi 
lengths and crypt depths; the mean was calculated and a ratio >2.0 was considered 
normal (Kuitunenet al., 1982, Taavelaet al., 2013). The remaining specimens were 
freshly embedded in OCT (Tissue-Tec.), snap-frozen in liquid nitrogen, and stored 
at -70°C before examinations. Stainings of CD3+ and γδ+ IELs were carried out on 
5 µm-thick frozen sections, and the normal values were <37 cells/mm for CD3+ 
and <4.3 cells/mm for γδ+ IELs (Järvinenet al., 2003).  
Small bowel TG2-targeted IgA deposits (Study IV) were studied from unfixed, 
frozen, 5 μm-thick small bowel mucosal sections by direct IF. These were stained 
with mouse monoclonal anti-TG2 antibody (CUB7402; NeoMarkers, Fremont, 
California, USA), followed by detection with fluorescein isothiocyanate 
(FITC) -labelled rabbit anti-human IgA antibody (Dako A/S, Glostrup, Denmark; 
(Korponay-Szabóet al., 2004). Based on their presence along the basement 
membrane in the villous-crypt area, the deposits were graded as positive or negative 
as in our previous study (Salmi et al., 2014).  
9.3 Serum antibody measurements  
The investigated serum IgA-class TG2-targeted antibodies in Studies I–IV were 
ARA, EmA, and/or TG2 antibodies depending on the time of testing. Over time, 
EmA has replaced ARA in clinical practice, but in our laboratory these tests have 
proved to be highly identical (Mäki, 1995). In Study IV, TG3 antibodies were also 
analysed. 
In Study I, the serum of 250 patients with DH was investigated by IgA-class ARA 
and/or EmA. In Study II, 96 patients with DH were examined for IgA-class TG2 
antibody levels. In Study III, 163 DH patients and 148 controls were examined with 
ARA, EmA, or TG2 antibodies. In Study IV, the investigated IgA-class antibodies 
were TG2 antibodies, TG3 antibodies, and EmA. 
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Serum IgA-class ARA and EmA were measured with an indirect IF method. In 
ARA, a typical R1 pattern was required in rat kidney and liver sections (Hällström, 
1989), and in EmA, human umbilical cord was used as a substrate; a titre of 1:≥5 was 
regarded as positive in both tests. TG2 antibodies were determined with a 
commercially available ELISA kit (TG2; Celikey, Phadia GmbH, Freiburg, 
Germany). In Study I, values ≥5.0 absorbance units (AU)/mL were considered 
positive, as were values ≥3.0 AU/ml in Study IV. TG3 antibodies were determined 
with a commercially available ELISA kit (TG3; Immunodiagnostik, Bensheim, 
Germany), and values >30 AU/ml were considered positive. 
9.4 Gluten challenge study protocol (IV) 
The inclusion criteria were a diagnosis of DH based on the typical clinical picture, 
the presence of granular IgA deposits in the papillary dermis with direct IF 
examination, adherence to a GFD for at least five years, and the absence of skin 
symptoms for at least three years. Exclusion criteria were an age >80 years, severe 
cardiovascular disease, previous cancer, immunosuppressive or anti-coagulation 
medication other than acetylsalicylic acid, and the use of dapsone during the past 
three years.  
Of the 19 DH study patients, a small bowel biopsy result at diagnosis was 
available for 14 subjects: 12 (86%) had villous atrophy and two (14%) had normal 
villous architecture. Before the gluten challenge, the patients had been on a GFD for 
a mean of 23 (range 5–40) years. Sixteen patients had adhered to the diet strictly and 
three reported having 1–5 dietary lapses per month. HLA DQ2 and DQ8 genotypes 
were determined using the Olerup SSP DQB1 low-resolution kit (Olerup AB, 
Saltsjöbaden, Sweden/Qiagen Vetriebs GmbH, Vienna, Austria). 
A detailed flowchart of the study protocol is shown in Figure 4. The gluten 
challenge was initiated by giving the patients 200 g of commercially available wheat 
bread to be consumed daily for three days (Anderson et al., 2000). The first follow-
up visit was conducted at day 6, after which the patients started to adhere to a normal 
gluten-containing diet. The minimum daily amount of gluten was set at 1 gram, 
which was verified with a follow-up telephone call after the first three weeks and 
thereafter with a three-day dietary diary that was filled by the patients before every 
follow-up visit. Follow-up visits were conducted every three months until the final 
examination at 12 months. The patients had been informed to contact the 
researchers when the DH rash or severe gastrointestinal symptoms appeared. The 
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researchers then decided if the challenge had to be discontinued. In addition, the 
challenge was discontinued if the serum EmA and TG2 antibodies were positive. 
 
Figure 4.  Flowchart of the gluten challenge study protocol including 19 gluten-free diet-treated 
dermatitis herpetiformis (DH) patients. 
Abbreviations: GFD = gluten free diet, GSRS = Gastrointestinal Symptom Rating Scale, DLQI = Dermatology Life Quality Index, 
EmA = endomysium antibodies, TG = transglutaminase, Vh/CrD = villous height, crypt depth ratio, IEL = intraepithelial 
lymphocytes 
1 An age over 80 years, severe cardiovascular disease, previous malignancies, and the use of dapsone, immunosuppressive or 
anti-coagulation medication other than acetylsalicylic acid  
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Questionnaires (III, IV) 
The disease-specific study questionnaires for the DH patients and coeliac disease 
controls were designed for study purposes (Studies I and III) and are available online 
as supplementary material for the publication of Study III (www.mdpi.com/2072-
6643/10/5/641). The questionnaires included questions about the presence and 
duration of DH and coeliac disease-related symptoms before and after the diagnosis, 
the occurrence of malignancies and fractures, strictness of the GFD, smoking and 
other lifestyle characteristics, and the family history of coeliac disease or DH. 
Compliance with a GFD was reported as a strict diet without dietary lapses, dietary 
lapses once per month, dietary lapses one to five times per month, or dietary lapses 
once per week. In addition, the questionnaire included questions about the presence 
of coeliac disease complications and associated diseases, malignancies, other long-
term illnesses, and regularly used medications.  
The Psychological General Well-Being (PGWB) questionnaire used in Study III 
is a validated 22-item questionnaire that evaluates self-perceived health-related well-
being and distress, and it includes six dimensions: anxiety, depressed mood, positive 
well-being, self-control, vitality, and general health (Dimenäs et al., 1996). The total 
score ranges from 22 to 132, with a higher score indicating better quality of life.  
The Gastrointestinal Symptom Rating Scale (GSRS) questionnaire was used in 
Studies III and IV. The GSRS includes 15 items and assesses the severity and 
existence of gastrointestinal symptoms in five categories: diarrhoea, indigestion, 
constipation, abdominal pain, and reflux (Svedlund et al., 1988). It uses a seven-point 
Likert scale for each question: one indicates an absence of symptoms and seven 
indicates severe symptoms.  
The Dermatology Life Quality Index (DLQI) (Studies III and IV) is a 10-item 
dermatology-specific quality of life instrument (Finlay and Khan, 1994). The 
questionnaire includes six different sections: symptoms and feelings, daily activities, 
leisure, work and school, personal relationships, and treatment unit. The scores for 
all ten questions are calculated together, and the total score varies from a minimum 
of 0 to a maximum of 30, with a higher score indicating a more impaired life quality. 
9.5 Statistical analysis  
For the descriptive statistics and further analysis, patients in Studies I and II were 
divided into three groups according to the year of DH diagnosis: 1970−1984, 
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1985−1999, and 2000−2014. In Study III, DH patients were divided into two groups 
according to presence or absence of villous atrophy at diagnosis.  
In all studies, categorical variables are expressed as percentages and numbers. 
Numeric data are described as the means with ranges or the 95% confidence interval 
(CI), or as the medians with ranges or lower and upper quartiles (Q1−Q3), as 
appropriate.  
In Studies I, II, and III, the two-sided χ2 test, Fisher’s exact test, and/or Kruskal–
Wallis test were used as appropriate. In Study I, binary logistic regression analysis 
was used when identifying factors associated with delayed diagnosis. Univariate 
analysis was used initially for each associating factor, and then multivariable analysis 
was used for detecting the independence of delay-associated parameters found in the 
univariate analysis. In Study II, the linearity of small-bowel histology findings across 
the three 15-year periods was tested by using the Cochran–Armitage test, and the 
analysis of variance. Differences in TG2 IgA antibody levels between patients with 
PVA or SVA and normal villous architecture were determined using the Kruskall-
Wallis test followed by pairwise multiple comparisons with the Dunn test. In Study 
III, logistic regression analysis was used to adjust the study groups according to age 
at the time of the study, and sex, age at diagnosis, calendar period of diagnosis, 
severity of rash, presence of gastrointestinal symptoms, and small bowel biopsy 
findings at diagnosis were all taken into account in the multivariable analysis. In 
Study IV, the statistical comparisons within-subjects were performed by a 
permutation test or Wilcoxon matched-pairs signed-rank test with exact p-values, 
and correlations were assessed by Spearman’s correlation coefficient method. The 
normality of the variables was tested by using the Shapiro–Wilk W-test.  
In all studies, statistical significance was set at a p-value below 0.05. Analyses were 
performed using IBM SPSS Statistics for Windows (Version 23.0., IBM Corp., 
Armonk, NY, USA) or the Stata 15.0 (StataCorp LP; College Station, Texas USA) 
statistical package. 
9.6 Ethical aspects  
The Declaration of Helsinki (1975) was followed in each study. The study protocol 
and usage of the register-based data was approved by the Regional Ethics Committee 
of Tampere University Hospital. Informed consent was obtained from each patient 
participating in the questionnaire studies and the gluten challenge study. 
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10 RESULTS 
10.1 Diagnostic delay in dermatitis herpetiformis (I) 
Of the 446 DH patients diagnosed between 1970 and 2014 with an available small 
bowel biopsy result, 151 were diagnosed between 1970 and 1984, 161 between 1985 
and 1999, and 134 between 2000 and 2014. The median duration of the rash before 
DH diagnosis was 10 months, and the mean was 3.1 years for the entire study period. 
In the three 15-year periods, the median duration decreased significantly, from 12.0 
to 11.0 months and then to 8.0 months (p = 0.002). Statistical significance was 
found when the first and third period were compared.  
In 378 patients with available data, the rash was considered mild in 72 (19%), 
moderate in 193 (51%), and severe in 113 (30%) at the time of diagnosis. In the 
follow-up questionnaire, 41% reported having suffered from gastrointestinal 
symptoms at diagnosis. There was no significant change in the prevalence of severe 
rash or the presence of gastrointestinal symptoms between the three study periods.  
Of the study patients, 389 (87%) had sufficient information for the analysis of 
the factors associated with delayed diagnosis, i.e. the presence of the rash before 
diagnosis for two years or more. Altogether, 142 (37%) patients had a delayed 
diagnosis. The frequency of delayed diagnosis decreased significantly from 47% to 
38% and then to 25% from the first to the third study period. The diagnosis of DH 
between 1970 and 1984 was significantly associated with delayed diagnosis in both 
the univariate (p=0.001) and multivariable (p=0.017) analyses. Similarly, a 
significant association was detected between villous atrophy (SVA or PVA) at 
diagnosis and delayed diagnosis in both the univariate (p = 0.001) and multivariable 
(p = 0.003) analyses. Female sex at diagnosis associated significantly with delayed 
diagnosis in the univariate analysis (p=0.043; Table 2 in the publication for Study 
I). In the 250 DH patients with available data, ARA and/or EmA positivity 
associated significantly with diagnostic delay in the univariate analysis (p = 0.001). 
DH patients with a delayed diagnosis did not report more bone fractures or 
malignancies in the follow-up questionnaires compared to those with a non-delayed 
diagnosis. 
 55 
10.2 The prevalence of villous atrophy and serum TG2 antibody 
levels in dermatitis herpetiformis (II) 
Of the 393 DH patients in Study II, DH was diagnosed in 144 patients between 
1970 and 1984, in 144 patients between 1985 and 1999, and in 105 patients between 
2000 and 2014. Out of all the patients, small bowel mucosa was considered normal 
in 108 (28%), while 145 (37%) had PVA and 140 (36%) had SVA in the small bowel 
mucosa at diagnosis. In the three 15-year periods, a significant decrease (p = 0.032) 
occurred in the prevalence of SVA, from 42% to 35% and then to 29%. At the same 
time, an 8% increase from 33% to 37% and then to 41% occurred in the prevalence 
of PVA (p = 0.22), albeit statistically insignificantly, and there was a 5% increase in 
normal villous architecture (from 25% to 28% and then to 30%, p = 0.34).  
Serum TG2 IgA antibody levels were collected from DH patients in the last 15-
year period. In 28 patients with normal villous architecture, median TG2 levels were 
significantly lower compared to the 28 patients with SVA (2.8 vs 41.5 AU/ml, 
p<0.001) and 40 patients with PVA (2.8 vs 16.5 AU/ml, p = 0.046). Normal TG2 
antibody levels were detected in 15 (54%) patients with normal villous architecture, 
12 (30%) with PVA, and 3 (11%) patients with SVA.  
10.3 Prognosis of dermatitis herpetiformis patients with and 
without villous atrophy (III) 
Of the 352 DH patients analysed in Study III, 98 (28%) had normal small bowel 
villous architecture and 254 (72%) had villous atrophy (PVA or SVA) at diagnosis. 
Parallel to the results in Study II, 28 patients with normal villous architecture in 
Study III had ARA, EmA or TG2 antibodies significantly less often compared to 
the 139 patients with villous atrophy (39% vs 73%, p<0.001; Table 1 in the 
publication for Study III). The median age at diagnosis was significantly higher in 
the DH patients with normal villous architecture compared to the DH patients with 
villous atrophy (52 vs 37 years, p<0.001). After the DH diagnosis, 80% of the DH 
patients started dapsone treatment. The median duration of dapsone treatment was 
slightly – but not significantly – longer in DH patients with normal villous 
architecture compared to patients with villous atrophy at diagnosis (36 vs 24 months, 
p = 0.097). The severity of the rash and haemoglobin levels at diagnosis did not differ 
significantly between the DH groups. 
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Follow-up data collected with the study questionnaires was available for 181 DH 
patients, of whom 39 (22%) had normal villous architecture and 142 (78%) had 
villous atrophy at diagnosis. The median follow-up time of all DH patients was 22 
years. At the follow-up, DH patients with normal villous architecture were 
significantly older compared to the DH patients with villous atrophy (68 vs 61 years, 
p<0.001). After age adjustment at the follow-up, no significant differences between 
the DH study groups were detected in the presence of coronary heart disease, 
hypertension, type 1 or 2 diabetes, thyroid diseases, cerebrovascular diseases, 
osteopenia/osteoporosis, or malignancies (Figure 1 in the publication for Study III). 
Correspondingly, no significant differences were detected in the use of physician-
prescribed regular medications between the DH study groups after age adjustment. 
Only the usage of vitamin D was more frequent among DH patients with villous 
atrophy compared to those without villous atrophy (40% vs 23%, p = 0.050).  
The long-term QoL and severity of gastrointestinal symptoms measured with the 
PGWB, DLQI, and GSRS questionnaires did not differ between the DH groups. 
Likewise, no differences were detected between the DH groups in the strictness of 
the GFD, BMI, smoking habits, or physical activity. 
Compared to the DH patients, the coeliac disease controls were more often 
female (47% vs 81%, p<0.001). The strictness of the GFD at the time of the study 
did not differ between the DH patients and coeliac disease controls. As the DH 
patients with normal villous architecture were slightly younger (61 vs 65 years) 
compared to the coeliac disease controls, adjustment for current age was made in all 
analyses between the study groups. The total number of long-term illnesses was 
significantly lower (median 1 vs 2, p<0.001) in DH patients compared to the coeliac 
disease controls. The DH patients also had significantly less thyroid disease (p = 
0.019) and osteopenia/osteoporosis (p = 0.012) compared to the coeliac disease 
controls. However, the presence of bone fractures did not differ significantly 
between the DH patients and the coeliac disease controls even though an increased 
trend towards more bone fractures was seen in the coeliac disease controls. The DH 
patients reported significantly fewer malignancies compared to the coeliac disease 
controls (7% vs 19%, p = 0.016). When the DH patients were compared to the 
coeliac disease controls, it was shown that the DH patients used significantly less 
calcium (p = 0.011) and vitamin D (p<0.001) medication than the controls did. 
Moreover, the DH patients with normal villous architecture used significantly more 
statin medication compared to the coeliac disease controls (p = 0.010). 
The coeliac disease controls were shown to have significantly lower PGWB 
general health scores compared to the DH patients with villous atrophy (p = 0.022), 
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but otherwise QoL did not differ between the DH patients and the controls when 
measured with the PGWB. According to the GSRS questionnaire, the coeliac disease 
controls had significantly higher scores in total symptoms, gastrointestinal pain, and 
diarrhoea compared to the DH patients (Table 3 in the publication for Study III). 
10.4 Gluten challenge in dermatitis herpetiformis patients on a 
gluten-free diet (IV) 
By definition, none of the 19 GFD-treated patients participating in the gluten 
challenge study had the rash at pre-challenge, but three (16%) had skin IgA and TG3 
deposits and two had slightly elevated serum TG3 antibody levels. Serum TG2 
antibodies and EmA were negative in all patients. Small bowel histology was normal 
in all 19 patients but 11 (58%) had increased densities of CD3+ IELS and 17 (89%) 
had increased densities of γδ+ IELs (Table 4). Sixteen patients carried the HLA-
DQ2 haplotype and three carried the HLA-DQ8 haplotype.  
Gluten challenge caused a relapse of the rash and/or small bowel villous atrophy 
in 18 (95%) DH patients after a mean of six months. The first relapse occurred after 
one month and the last was discovered when a small bowel biopsy was performed 
at the final examination after 12 months of the gluten challenge (Figure 5). Fifteen 
(79%) patients relapsed with the rash (Figure 6) and altogether 15 (79%) developed 
small bowel villous atrophy (Table 1 in the publication for Study IV). Twelve (63%) 
patients had elevated levels of serum TG2 antibodies post-challenge. Two patients 
without the rash developed high levels of serum TG2 antibodies (100 and 54 
AU/ml), resulting in the challenge being discontinued; a small bowel biopsy showed 
villous atrophy in both patients. In addition, one patient did not show any rash or 
gastrointestinal symptoms and the serum EmA and TG2 antibodies were negative, 
but a small bowel biopsy at 12 months evinced villous atrophy (Figure 6). 
 58
 
Figure 5.  The Kaplan-Meier estimator measuring the relapse % in time (months) after the initiation 
of the gluten challenge in the 19 patients with dermatitis herpetiformis. 
During the gluten challenge, skin IgA became positive in ten DH patients, and all 
ten also experienced the rash (Figure 6). In double stainings, TG3 co-localized with 
IgA in all skin biopsy specimens. Two patients relapsing with typical but mild DH 
rash remained negative for skin IgA and TG3 deposits. In both patients, the rash 
had appeared less than two weeks before the skin biopsy was taken. Both patients 
had markedly elevated levels of serum TG3 antibodies and also villous atrophy. 
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Figure 6.  Skin immunofluorescence (IF) biopsy results in 19 dermatitis herpetiformis patients at the 
pre-challenge □ and post-challenge ■ visit. The symbol     depicts a situation when IF 
result remained unchanged. The skin IF-IgA result was graded negative (-), positive (+) or 
strong positive (++). The presence or absence of a rash at the post-challenge is shown 
with + or -. The symbol      marks the one patient who did not relapse during the study. 
The duration of the GFD before the challenge correlated significantly with the 
relapse time (r = 0.62, CI: 0.24–0.84; Figure 2 in the publication for Study IV). One 
patient did not relapse during the 12-month gluten challenge. At the final 
examination, he was asymptomatic, his skin IgA and TG3 deposits and serum TG2 
and TG3 antibodies were negative, and the small bowel mucosa was normal. The 
dietary diary showed that the patient’s gluten consumption had been at least eight 
grams of gluten per day. After a two-year follow-up on a gluten-containing diet, the 
patient was still asymptomatic and the skin IgA and serum TG2 and TG3 antibodies 
were negative. 
When the pre-challenge data were compared to the post-challenge data, a 
significant increase was seen in the median levels of serum TG3 and TG2 antibodies 
and EmA (Table 4). In the small bowel specimens, the mean Vh/CrD decreased 
significantly and the mean densities of CD3+ and γδ+ IELs increased significantly. 
The GSRS score showed a mild but not significant increase. However, the mean 
DLQI score increased significantly (Table 4). 
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Table 4.  Pre- and post-challenge data comparisons in 19 gluten-challenged patients with dermatitis 
herpetiformis. 
 
 Pre-challenge Post-challenge p-value 
Skin IgA positive, n (%) 3 (16) 13 (68) 0.003 
Skin TG3 positive, n (%) 3 (16) 13 (68) 0.003 
TG3-ab, median (range) 4 (0–41) 89 (5–89) <0.001 
TG2-ab, median (range) 0 (0–0) 12 (0–100) <0.001 
EmA, median (range) 0 (0–0) 200 (0–4000) <0.001 
Vh/CrD, mean (SD) 2.8 (0.59) 1.2 (0.87) <0.001 
CD3+IELs, mean (SD) 40 (15) 74 (29) <0.001 
γδ+IELs, mean (SD) 10.8 (8.0) 16.5 (11.3) 0.018 
TG2-specific IgA deposits in the small bowel 
mucosa, n (%) 
0 (0) 17 (100) 0.002 
GSRS total, mean 1.66 (0.55) 1.86 (0.73) 0.22 
DLQI mean 0.11 (0.32) 1.58 (2.04) <0.001 
Abbreviations: IgA = immunoglobulin A, TG = transglutaminase, ab = antibodies, EmA = endomysium antibodies, Vh/CrD = villous 
height, crypt depth ratio, SD = standard deviation, IELs = intraepithelial lymphocytes, GSRS = Gastrointestinal Symptom Rating 
Scale, DLQI = Dermatology Life Quality Index 
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11 DISCUSSION 
11.1 Delayed diagnosis in dermatitis herpetiformis 
The present study examining DH patients diagnosed in 1970–2014 disclosed that 
the median duration of the rash before the diagnosis has decreased over the period 
from 12 months to 8 months. However, considering the troublesome and severely 
itchy skin symptoms, which reduces the patient’s QoL (Pasternack et al., 2017), the 
time from the onset of the rash to the diagnosis of DH is still far too long. 
Importantly, in the last 15 years, as many as one quarter of the DH patients 
experienced the rash for two years or more before being diagnosed, i.e. they had a 
delayed diagnosis. Females and patients with small bowel villous atrophy were shown 
to be especially at risk for a delayed diagnosis.  
Compared to the median duration, the mean duration was longer, at 3.1 years 
from the onset of the rash to the diagnosis in this study. This is in line with earlier 
DH studies with far smaller numbers of patients; a study from Ireland (Egan et al., 
1997) reported a somewhat shorter (1.6 years) duration of the rash to diagnosis, while 
a study from Germany (Rose et al., 2010) reported a similar (3.2 years) duration. By 
contrast, the duration from the onset of gastro-intestinal symptoms to the diagnosis 
has been notably longer in coeliac disease studies. In hospital cohorts and 
questionnaire studies, the duration of symptoms before diagnosis has ranged from 
three to 11 years (Green et al., 2001, Häuser et al., 2006, Rampertab et al., 2006, 
Ukkola et al., 2011). Moreover, in a recent Finnish study 32% of coeliac disease 
patients reported their symptoms presenting for over 10 years before the diagnosis 
(Fuchs et al., 2018). 
In the present study, DH patients with villous atrophy at diagnosis were shown 
to have a delayed diagnosis more often compared to those with normal villous 
architecture. It is probable that the higher prevalence of villous atrophy is the result 
rather than the cause of the delayed diagnosis. In line with this, the DH patients 
evincing normal villous architecture and only coeliac-type inflammation in the small 
bowel seem to be at an early stage of gluten-induced autoimmune activity. Moreover, 
a higher frequency of positive ARA/EmA antibodies in DH patients with a delayed 
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diagnosis is likely a reflection of the progression of small bowel mucosal changes 
towards villous atrophy.  
In Finland, the decrease in diagnostic delay may be a result of better awareness 
of DH due to nationwide guidelines for the diagnosis and treatment of coeliac 
disease (Coeliac disease, Current Care Guidelines, 2018). Physicians can access these 
guidelines online, which also include DH with clinical pictures of the rash and 
recommendations on how and where to diagnose patients. The present study 
showed that diagnosis before the year 2000 was significantly associated with a longer 
diagnostic delay and this result can be partially explained by these guidelines, which 
became available from 1997 onwards. The diagnostic delay in coeliac disease likewise 
became shorter in Finland after the publication of these guidelines (Fuchs et al., 
2014). 
In this study, the female gender was associated with a delayed DH diagnosis. 
Fuchs et al. (2014) have also reported a similar finding in Finnish coeliac disease 
patients. Furthermore, parallel results have been detected in other coeliac disease 
studies (Rampertab et al., 2006, Vavricka et al., 2016). We did not seek to determine 
whether the diagnostic delays in the present study were due to the inability of doctors 
to recognise DH or due to the patients. However, it could be expected that the 
females with an obvious rash and intense itch would seek help from a doctor just as 
rapidly as males would. In a recent coeliac disease study, the diagnostic delay was 
caused especially by doctors, and it was even more pronounced in female patients 
(Vavricka et al., 2016). Nevertheless, the fundamental reasons why female patients 
seem to have a longer diagnostic delay in DH and coeliac disease remain obscure. 
11.2 Villous atrophy in dermatitis herpetiformis 
11.2.1 Prevalence of severe villous atrophy is decreasing 
During the present DH study covering a period of 45 years, a significant decrease 
occurred in the prevalence of SVA, and there was a concomitant – albeit not 
significant – increase in PVA and normal villous architecture. This tendency towards 
milder small bowel villous findings in DH patients is in line with coeliac disease 
studies, where the small bowel mucosal damage has become milder over time (Volta 
et al., 2014; Brar et al., 2007). At present, active risk-group screening detects many 
new cases of coeliac disease (Husby et al., 2014; Leffler et al., 2010). Therefore, 
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patients with asymptomatic coeliac disease are also diagnosed earlier (Volta et al., 
2014). The improved coeliac disease diagnostics obviously lead to a smaller cohort 
of undiagnosed coeliac disease patients continuing to consume gluten and 
developing severe villous damage and DH. It seems, however, that a rather long 
period of time is needed for the phenotype change from classical coeliac disease to 
DH (Gawkrodger et al., 1993, Salmi et al., 2015). Patients with normal small bowel 
mucosal histology but positive EmA or TG2 IgA antibodies could especially be at 
risk for developing DH when gluten exposure continues. Supporting this, one 
quarter of the newly diagnosed DH patients in the present study showed normal 
villous architecture, and half of them had serum TG2 IgA antibodies. 
In the last 15-year period of this DH study, serum TG2 IgA antibody levels were 
shown to associate significantly with SVA and PVA. This finding agrees well with 
previous DH and coeliac disease studies (Dahlbom et al., 2010, Leffler and 
Schuppan, 2010, Singh et al., 2015). However, some of the DH patients with villous 
atrophy had normal TG2 antibody levels, and a few patients with normal villous 
architecture had increased antibody levels. This shows that the sensitivity of the TG2 
antibody test for detecting villous atrophy is not 100% in DH, but overall, a positive 
TG2 antibody test is a relatively good predictor of the presence of villous atrophy in 
child and adult patients with DH (Dahlbom et al., 2010).  
It is important to acknowledge, however, that a negative TG2 antibody test does 
not exclude DH. In this study, as much as 30% of the patients had a negative TG2 
antibody test at DH diagnosis, whereas in earlier studies the percentage was 20 
(Kumar et al. 2001, Rose et al. 2009). As fewer DH patients currently evince villous 
atrophy at DH diagnosis, the negative TG2 antibody result is even more probable. 
In the present study, 54% of the patients with normal villous architecture were 
seronegative. 
11.2.2 Similar prognosis in patients with and without villous atrophy 
The current study established that the prognosis of DH patients with and without 
villous atrophy at diagnosis does not differ in regard to GFD treatment response, 
nor in the long-term development of chronic illnesses and coeliac disease-associated 
complications or QoL. 
After the DH diagnosis, 80% of DH patients in this study started dapsone 
medication. The duration of dapsone treatment was considered the active disease 
time period, which lasted until the patients were symptom-free with a GFD alone. 
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The median duration of dapsone treatment (30 months) was in line with earlier GFD 
treatment studies (Fry et al., 1982, Gawkrodger et al., 1984). Importantly, even 
though in the present study the DH patients with normal small bowel mucosa used 
dapsone slightly longer compared to those with villous atrophy, the difference was 
not statistically significant. Therefore, the responsiveness of the DH rash to a GFD 
does not seem to depend on the absence or presence of small bowel mucosal damage 
at diagnosis. In addition, this study also showed that after long-term adherence to a 
GFD, the presence of chronic illnesses, complications, and QoL are equal in DH 
patients with and without villous atrophy at diagnosis. Moreover, an earlier DH study 
from our group showed that the mortality of DH patients with villous atrophy at 
diagnosis does not differ from that of DH patients with normal villous architecture 
at diagnosis (Hervonen et al., 2012). Therefore, it is obvious that GFD-treated DH 
patients have a similar short- and long-term prognosis that is independent of the 
presence or absence of villous atrophy at diagnosis. Due to this, routine gastroscopy 
with small bowel biopsies for DH patients is no longer recommended in the Finnish 
Coeliac Disease Guidelines (2018). However, the need for small bowel biopsy is 
obvious when the patient has obscure gastrointestinal symptoms or a suspicion of 
malignancy, as recommended earlier in an Italian DH guideline (Caproni et al., 2009).  
In this study, the median age at DH diagnosis was significantly higher in patients 
without villous atrophy compared to those with villous atrophy (52 vs 37 years), but 
the diagnostic time period did not differ between the study groups. Therefore, the 
earlier reported finding by our group (Salmi et al., 2011) that age at diagnosis in DH 
has increased continuously from 1970 does not explain the difference between the 
two study groups. However, it is possible that elderly people might have a less 
prominent immune response resulting in milder small bowel mucosal alterations. In 
line with this, older patients with coeliac disease have shown to be more commonly 
seronegative, and a trend towards less severe histopathology has also been observed 
with increasing age (Salmi et al., 2006, Vivas et al., 2008).  
In agreement with a previous study showing a slightly higher frequency of 
autoimmune diseases in patients with coeliac disease compared to patients with DH 
(Reunala and Collin, 1997), thyroid disease associated more often with coeliac 
disease than with DH in this study. Compared to the DH patients, the GFD-treated 
coeliac disease controls in the present study had significantly more malignancies and 
long-term illnesses, and osteopenia or osteoporosis were more common in 
particular. Earlier studies have shown that even in GFD-treated coeliac disease 
patients, the risk of osteoporotic fractures, malignancies, and mortality is increased 
(Asklinget al., 2002, Kamycheva et al., 2017, West et al., 2004). Additionally, the 
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GFD-treated coeliac disease controls in the present study reported poorer general 
health and gastrointestinal pain and diarrhoea more often compared to the DH 
patients. These results are in line with a recent long-term study by our group, which 
showed DH patients on a GFD had a better QoL and fewer gastrointestinal 
symptoms when compared to coeliac disease patients (Pasternack et al., 2015). 
11.3 Gluten challenge causes relapse in long-term gluten-free 
diet treated dermatitis herpetiformis patients 
In this study, 18 (95%) of the GFD treated DH patients participating in the 12-
month gluten challenge study showed disease relapse in the skin and/or in the small 
bowel mucosa. In 15 patients, the challenge induced a DH rash and 80% of these 
patients also showed a progression towards small bowel mucosal villous atrophy. 
Interestingly, however, three relapsed patients did not develop the rash or skin IgA 
and TG3 deposits but evinced the development of villous atrophy. One challenged 
patient did not develop any signs of DH or coeliac disease during a two-year follow-
up on a normal gluten-containing diet. 
IgA and TG3 deposits are considered pathognomonic for untreated DH 
(Donaldson et al., 2007, Sárdyet al., 2002). At pre-challenge, three patients in this 
study had IgA and TG3 deposits in the skin, but 16 were negative. This fits well with 
their long (mean 23 years) adherence to a GFD. During the GFD treatment, these 
deposits are known to disappear, but they can persist for many years after the rash 
and small bowel villous atrophy have healed (Hietikko et al., 2018a). In the present 
study, we observed a rather fast (mean 6.2 months, range 3–12 months) re-
appearance both IgA and TG3 in 10 challenged patients, which is an unreported 
finding. Surprisingly, two patients with a mild DH rash and markedly elevated serum 
TG3 antibody levels remained negative for skin IgA and TG3 deposits. As their skin 
biopsies were taken correctly from the perilesional skin area (Donaldson et al., 2007, 
Zoneet al., 1996), one possibility could be that IgA and TG3 were not yet detectable 
by the conventional IF technology used in the study. The results of this study suggest 
that if a patient has adhered to a GFD for several years and skin IgA is negative, at 
least three-month gluten challenge is necessary before reappearance of IgA can be 
expected and skin biopsy should be taken. However, if the duration of GFD is 
shorter, weeks to months, there is no need to discontinue GFD before the diagnostic 
skin biopsy, since IgA deposits persist in the skin for a long time after patient has 
initiated GFD (Garioch et al., 1994, Reunala et al., 2015b). 
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It is possible that the three relapsed patients with no rash or skin IgA or TG3 
deposits had a phenotype change to coeliac disease. A change of phenotype from 
coeliac disease to DH has been reported earlier mostly in patients not adhering 
strictly to a GFD (Gawkrodger et al., 1993, Salmi et al., 2015). However, it is also 
possible that these DH patients without the rash at the relapse could have developed 
skin symptoms later if gluten consumption had continued. Importantly, most DH 
patients relapsing with the rash also had villous atrophy, strongly indicating that the 
small bowel mucosa is the primary target of the gluten-induced autoimmune reaction 
in DH (Collinet al., 2017, Sárdy et al., 2002).  
In this study, the duration of the GFD before the gluten challenge correlated with 
the relapse time, and a similar result was documented previously by Leonard et al. 
(1983a). In their gluten challenge study of 12 DH patients, 92% relapsed with a rash, 
and 64% of these also developed small bowel villous atrophy. Later, Bardella et al. 
(2003) reported a lower relapse rate of 82% in 38 challenged patients. However, all 
seven non-relapsed patients were children, and their compliance with a GFD was 
only moderate or poor before the challenge. Due to this, the authors suggested that 
diagnosis in childhood and dietary lapses could induce the redevelopment of a 
tolerance to gluten. On the contrary, another well performed study showed that all 
gluten-challenged DH children relapsed (Kosnai et al., 1986, Table 5). In the current 
study, none of the patients had been diagnosed in childhood, but three patients 
reported dietary lapses when adhering to a GFD. One of these was the non-relapsed 
patient who had adhered for 36 years to a GFD. This may be one reason for the 
non-relapse, and a follow-up longer than two years on a normal gluten-containing 
diet is required before a persistent tolerance to gluten can be confirmed. However, 
until further knowledge becomes available, life-long adherence to a GFD is justified 
in all DH patients. 
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Table 5.  Gluten challenge and remission studies in dermatitis herpetiformis. 
 
Challenge 
studies 
Patients 
 
GFD duration 
before 
challenge, 
mean years 
(range) 
Non-relapsed 
patients on 
gluten 
challenge  
Challenge 
duration,  
mean months 
(range) 
Comment 
Mansikka et al., 
2019  
Finland 
19 adults 23 (5–40) 1 1 (5%) 6 (1–12) Duration of GFD before 
challenge correlated with the 
relapse time. Ten skin IgA-
negative patients tested 
positive after the challenge. 
Bardella et al., 
2003 
Italy 
38 adults and 
children 
7.3 7 2 (18%)  2 (1–6) 4 
 
All 7 patients in remission 
were children who did not 
follow a strict GFD before the 
challenge. At pre-challenge, 
all had lost skin IgA deposits 
and had normal small bowel 
mucosa. 
Kosnai et al., 
1986  
Hungary and 
Finland 
16 children 1.5 (0.9–3.7) 0 5 (3–29) All children had the rash and 
villous atrophy after the 
challenge. 
Leonard et al., 
1983  
England 
12 adults 7.6 (2.6–11.7) 13 (8%)  3 (0.5–9) Duration of GFD before the 
challenge associated with the 
relapse time. Three skin IgA-
negative patients tested 
positive after the challenge.  
Remission 
studies 
Patients Study years Patients in 
remission  
  
Paek et al., 2011 
USA 
86 
34 adhered to a 
GFD 
1972–2010 10 (12%)  - No skin IgA or small bowel 
data during remission. 
Garioch et al., 
1994 
UK 
133 on a GFD 
77 on a normal 
diet 
1967–1992 2 (5%) 
8 (10%) 
- All except one patient in 
remission had IgA deposits in 
the skin. No small bowel data 
during remission. 
Gawkrodger et 
al., 1984 
Scotland 
51 on a GFD 
25 on a normal 
diet 
1972–1983 0 
2 (8%)  
-  
1 Two-year follow-up time on a gluten-containing diet; 2 median follow-up time 12 (range 3–21) years on a gluten-containing diet; 3 
one-year follow-up time on a gluten-containing diet; 4 in relapsed patients; GFD = gluten free diet  
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11.4 Strengths and limitations of the study 
The main strength in Studies I–III is the large patient cohort collected from 1970 
onwards at a special DH out-patient clinic at Tampere University Hospital 
(Hervonen et al., 2012). The diagnosis was invariably based on the presence of 
granular IgA deposits in the papillary dermis (Zone et al., 1996). Two experienced 
dermatologists examined and treated almost all the present patients with DH. In 
addition, small bowel biopsy results were available for the majority of the patients, 
since endoscopy with small bowel biopsy has been performed routinely for most 
newly diagnosed patients with DH. Moreover, a GFD has been recommended to all 
DH patients. Most of them have started GFD treatment and have had excellent 
dietary adherence rates (Hervonen et al., 2012). In Study I, data on the duration of 
the rash before the diagnosis was retrieved primarily from the medical records, which 
is more reliable than questionnaire-based data obtained several years or even decades 
after the diagnosis. The major strengths of Study IV are the well-defined long-term 
GFD-treated study group and the thoroughly conducted gluten challenge with 
regular follow-up visits and clinical, serological, and small bowel mucosal biopsy 
endpoints. At the relapse, we could also examine the re-appearance of IgA and TG3 
deposits in the skin and TG2 deposits in the small bowel mucosa, which are rather 
new research findings that have not been previously examined during a gluten 
challenge (Donaldson et al., 2007, Salmi et al., 2014, Sárdy et al., 2002). 
The main limitation in Studies I–III is the retrospective study design. In addition, 
the definition of delayed diagnosis in Study I, i.e. two years or more, was based only 
on personal clinical experience. The definition was adapted from a previous study in 
which the median duration of rash before diagnosis was 9 months in patients with 
refractory DH and 12 months in control DH patients (Hervonen et al., 2016). 
Furthermore, as the follow-up data for Studies I and III were collected from 
questionnaires, selection and recall bias is possible. The disease-specific 
questionnaires were designed for this study and have not been validated. In addition, 
even though widely used in coeliac disease studies, the GSRS and PGWB 
questionnaires have not been validated specifically for coeliac disease. Additionally, 
in Study II and III, there was no opportunity for the more accurate examination of 
mucosal samples other than the routine histological evaluation performed by the 
pathologists. A limitation of Study IV is the relatively small number of patients, as is 
the rather short follow-up time of the non-relapsed DH patient. 
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12 CONCLUSIONS AND CLINICAL IMPLICATIONS  
DH is the best known extraintestinal manifestation of coeliac disease, and Finland 
has the highest prevalence of this autoimmune skin disease. Diagnosis is based on 
pathognomonic granular IgA deposits in the papillary dermis. The mainstay of 
treatment is a life-long GFD. The mean age at diagnosis is increasing in Finland and 
mortality in GFD-treated DH patients is lower than that in the general population. 
However, there has been a lack of insight on the diagnostic delay and prognostic 
value of small bowel histological changes. Finally, earlier studies have suggested that 
some GFD-treated DH patients may go into remission by re-developing gluten 
tolerance. 
The principal conclusions of the present study are as follows: 
 
1. The time from the onset of rash to diagnosis in DH has decreased over the 
past 45 years. Even at present, one quarter of DH patients have a delayed 
diagnosis, i.e. they have the rash for two years or more before diagnosis. 
Delayed diagnosis is more common in female patients and those with villous 
atrophy. 
2. Small bowel histology in DH has altered over the past 45 years towards 
milder small bowel damage. Serum TG2 IgA antibody levels are more 
reliable in detecting DH patients with villous atrophy than those without 
atrophy.  
3. DH patients with or without small bowel villous atrophy at diagnosis have a 
similar and excellent long-term prognosis on GFD treatment.  
4. A gluten challenge of up to one year induces DH rash and/or villous atrophy 
in the vast majority of long-term GFD-treated DH patients. DH rash relapse 
results in the rather rapid appearance of skin IgA and TG3 deposits in       
most – but not all – patients. 
As is the case with coeliac disease, it is important to increase the awareness of DH, 
and both are treatable with a GFD. At present, the duration of the rash before 
diagnosis in DH is still excessively long in Finland, and, similarly to coeliac disease, 
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there is an unexplained diagnostic delay particularly in female patients. The 
awareness of DH and coeliac disease among general practitioners in Finland seems 
to have improved, which is probably the result of the online available Current Care 
Guidelines (2018). A trend towards milder small bowel mucosal findings was 
observed in the present study, and importantly, the DH patients with and without 
villous atrophy had a similar short- and long-term prognosis on a GFD treatment. 
These results revealed that there is no need to perform routine gastroscopies at DH 
diagnosis to obtain small bowel biopsies. This has now been updated in the Finnish 
Coeliac Disease Guidelines (2018). Furthermore, the present DH study showed that 
elevated serum TG2 antibodies indicate rather well the presence of villous atrophy 
in DH. As the TG2 IgA antibody ELISA test is widely available, it can be easily used 
to detect the majority of DH patients with villous atrophy, but it does not detect all 
individuals with villous atrophy. In clinical work however, it is imperative to 
recognize that a negative serum TG2 antibody result does not exclude DH, and if 
the clinical picture is compatible with DH, further investigations with skin IF biopsy 
are necessary.  
The present gluten challenge study showed that even after long-term GFD 
treatment, all except one DH patient relapsed. The reason for the non-relapse could 
be the rather short follow-up time on the gluten-containing diet. Therefore, a strict 
life-long GFD still seems necessary for all adult DH patients. Whether the 
redevelopment of a tolerance to gluten may be achieved in some DH children not 
adhering strictly to a GFD remains a possibility, although it was not examined in the 
present dissertation. The results of the present gluten challenge study showed a 
relapse in both the skin and the small bowel mucosa. In addition, a few patients 
without any skin symptoms evinced small bowel villous damage in the relapse, 
indicating that the primary target in gluten intolerance is in small bowel mucosa also 
in DH. In the present DH study, both the small bowel mucosal TG2 deposits and 
skin IgA and TG3 deposits were shown to reappear at the relapse. However, the 
exact immune reaction initiating from the small bowel mucosal TG2-targeted IgA 
deposits and leading to skin IgA/TG3 deposits and the rash requires is not known. 
Further studies to investigate this would be of value. 
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Dermatitis herpetiformis (DH) is an extra-intestinal 
manifestation of coeliac disease. The highest currently 
reported prevalence of DH is in Finland, but knowledge 
of diagnostic delay is limited. This study investigated 
the duration of rash prior to diagnosis in 446 patients 
with DH, analysing the results in 3 periods of 15 years. 
The diagnosis was considered delayed when the dura-
tion of rash before diagnosis was 2 years or longer. 
Factors associated with delayed diagnosis were analy-
sed. Within the 45 years, the median duration of rash 
EHIRUHGLDJQRVLVGHFUHDVHGVLJQL¿FDQWO\IURPWR
PRQWKVp DQGWKHRFFXUUHQFHRIDGHOD\-
ed diagnosis decreased from 47% to 25% (p 
Female sex, the presence of villous atrophy, and a di-
DJQRVLVRI'+EHIRUHWKH\HDUZHUHVLJQL¿FDQWO\
associated with delayed diagnosis. In conclusion, the 
present study showed that one-quarter of patients 
currently have a diagnostic delay of 2 years or more, 
which is far from ideal. 
Key words: dermatitis herpetiformis; coeliac disease; diag-
nostic delay; gluten-free diet; dapsone.
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Dermatitis herpetiformis (DH) is a cutaneous mani-festation of coeliac disease presenting as an itchy 
polymorphic blistering rash on the elbows, knees, buttocks 
and scalp (1). Diagnosis of DH is based on the presence 
of typical skin symptoms and the demonstration of IgA 
LQWKHSDSLOODU\GHUPLVGXULQJGLUHFWLPPXQRÀXRUHVFHQFH
examination (2). Although 75% of patients with DH have 
small bowel mucosal villous atrophy at diagnosis, only a 
minority have marked gastro intestinal symptoms (3, 4). 
The treatment of DH is a lifelong gluten-free diet (GFD), 
similar to treatment of coeliac disease (4, 5). A GFD results 
in healing of the enteropathy and the rash, but the rash 
alleviates slowly and additional treatment with dapsone 
(4,4’-diaminodiphenylsulfone) is frequently needed at the 
start of dietary treatment (6, 7).
DH is considered relatively uncommon, having the 
highest reported prevalence of 75.3 per 100,000 people in 
Finland and a lower prevalence in UK and the USA (8–10). 
In contrast to the established increase in the incidence of 
coeliac disease, the incidence of DH decreased in both 
Finland and UK during the 1990s (8, 9). DH constitutes 
a diagnostic challenge to general practitioners and other 
non-dermatologists, and can easily be misdiagnosed as 
other itchy or blistering skin diseases (11, 12). Early 
diagnosis is warranted in DH, since ongoing symptoms 
reduce quality of life, and undiagnosed DH predisposes to 
complications, such as lymphoma and low bone mineral 
density (13–15).
For coeliac disease, the median time from onset of 
gastro intestinal symptoms to diagnosis in Finland is 
currently 3 years (16). Fortunately, diagnostic delay has 
decreased over the past decades in Finland, other European 
countries, and the USA (17–20). However, up-to-date 
knowledge about diagnostic delay in DH is lacking. The 
aim of this study was to investigate the changes in the 
diagnostic delay in DH and to analyse possible factors 
associated with delayed diagnosis. Our prospectively 
collected large DH cohort enabled us to perform delay 
analyses for 3 periods of 15 years. 
PATIENTS AND METHODS
All patients suspected of having DH in the Tampere region, 
Finland, are referred by private dermatologists and general 
practitioners working in healthcare centres to the Department of 
'HUPDWRORJ\7DPSHUH8QLYHUVLW\+RVSLWDOIRUFRQ¿UPDWLRQRI
DH diagnosis. Clinical suspicion of DH is an adequate reason for 
referral regardless of coeliac autoantibody result, and the referral 
policy for DH has remained the same for the years of the present 
study. In Tampere University Hospital, diagnosis of DH is based 
on the detection of typical clinical symptoms and the presence 
of granular IgA deposits in the papillary dermis (2), and this 
diagnostic procedure has remained unchanged during the study 
period. All patients are treated at a special DH clinic, where they 
are advised to adhere to a lifelong GFD. 
Our DH cohort consists of 512 patients who had been diagnosed 
and treated at the DH clinic between 1970 and 2014. A total of 
446 patients were included for further analysis. Of the 66 patients 
excluded, 10 did not have IgA deposits in the skin, 21 had died 
over 20 years previously and their data was not available, and 35 
had a previous diagnosis of coeliac disease. Data on the duration 
of the rash before diagnosis were collected from medical records 
held at Tampere University Hospital. The diagnosis was conside-
red delayed when the duration of the rash before diagnosis was 
\HDUVRUPRUH7KHGH¿QLWLRQIRUGHOD\HGGLDJQRVLVZDVEDVHG
on a previous study performed in our hospital district (21) and 
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clinical experience. In December 2015, a special questionnaire 
that included questions about the duration of the rash, presence 
of gastrointestinal symptoms before the diagnosis and the occur-
rence of malignancies and fractures was sent to all 413 surviving 
patients with DH. A total of 237 (56%) patients responded, and 
217 were included in the analysis of gastrointestinal symptoms. 
Self-reported bone fractures and malignancies were recorded from 
questionnaires. Excessive-trauma fractures (the trauma causing 
WKH IUDFWXUH FRQVLGHUHG VXI¿FLHQW WR FDXVH D ERQH IUDFWXUH IRU
any person) and stress fractures were excluded from further bone 
fracture analyses, and non-melanoma skin cancers were excluded 
from further malignancy analyses.
The severity of the rash at DH diagnosis was collected from 
medical records and scored as mild, moderate, or severe accor-
ding to the presence of a few, several, or many blisters; macular 
eruptions; and erosions on the knees, elbows, buttocks, scalp, or 
elsewhere on the body. Small bowel biopsy results at diagnosis 
collected from medical records were graded by experienced pa-
thologists as subtotal villous atrophy (SVA), partial villous atrophy 
(PVA), or normal mucosa (22).
The results of reticulin and/or endomysium autoantibodies at 
diagnosis were collected from medical records and categorized 
as positive or negative.
The study protocol was approved by the Ethics Committee of 
Pirkanmaa Hospital District (R15143). Informed consent was ob-
tained from each study participant responding to the questionnaire.
For the descriptive statistics and further analysis, the patients 
were grouped into three 15-year periods according to the year of 
WKHLU'+GLDJQRVLV í í DQG í
Diagnostic delay was expressed as the median with lower and 
upper quartiles (Q1í43), and also as mean, in order to be able WRFRPSDUHLWZLWKSUHYLRXVVWXGLHV7KHVLGHGȤ2 test, Fisher’s 
exact test, and the Kruskal–Wallis test were used for verifying the 
relationship between the year of diagnosis of DH, diagnostic delay, 
VHYHULW\RIUDVKDQGJDVWURLQWHVWLQDOV\PSWRPV7KHVLJQL¿FDQFH
OHYHOZDVVHWDW
To identify factors associated with delayed diagnosis, binary 
logistic regression analysis was used. Univariate analysis was used 
DW¿UVWIRUHDFKDVVRFLDWLQJIDFWRUWKHQPXOWLYDULDEOHDQDO\VLVZDV
used for detecting the independence of delay-associated parameters 
found in the univariate analysis. In the multivariable analysis, 
sex, age at diagnosis, calendar period of diagnosis, severity of 
rash, presence of gastrointestinal symptoms, and small bowel 
ELRSV\¿QGLQJV DW GLDJQRVLVZHUH DOO WDNHQ LQWR FRQVLGHUDWLRQ
Associations are expressed in terms of odds ratios (OR) with 
FRQ¿GHQFHLQWHUYDOV7RGHWHUPLQHZKHWKHUWKHSDWLHQWVZLWK
delayed diagnosis developed more bone fractures or malignancies, 
3HDUVRQȤ2 test and Fisher’s 2-sided exact test were used. A p-value 
ZDVFRQVLGHUHGVWDWLVWLFDOO\VLJQL¿FDQW6WDWLVWLFDODQDO\VLV
was performed using IBM SPSS Statistics for Windows (Version 
23.0. Armonk, NY: IBM Corp.).
RESULTS
Patients, duration of rash before diagnosis, and small 
ERZHOELRSV\¿QGLQJV
Of the 446 patients with DH, 229 (51%) were males. Mean 
age at diagnosis was 43 (range 3–83) years. The number 
of patients with DH diagnosed within the three 15-year 
SHULRGVZDVLQíLQíDQG
LQíTable I). As already reported in our 
previous study (8), the median age at diagnosis increased 
VLJQL¿FDQWO\p IURP\HDUVLQWKH¿UVWVWXG\
period to 54 years in the third study period. 
During the entire study period, the median duration of 
the rash before diagnosis was 10 months and the mean 
was 3.1 years. The median duration of the rash decreased 
VLJQL¿FDQWO\ IURP WRDQG WKHQ WRPRQWKV
(p = 0.002) during the three 15-year periods, respectively 
(Fig. 1VWDWLVWLFDOVLJQL¿FDQFHZDVIRXQGZKHQWKH¿UVW
and third period were compared (Table I). The correspon-
ding mean values were 37 (range 0.1–240), 43 (0.1–528), 
and 34 (1–480) months, respectively.
The rash was severe at diagnosis in 112 (29%) of the 
386 patients, and 89 out of 217 (41%) reported having had 
gastrointestinal symptoms at diagnosis. There was no dif-
ference in the occurrence of severe rash or gastrointestinal 
symptoms at diagnosis during the 3 study periods (Table 
I). The small bowel biopsy result was available for 347 
(78%) patients, of whom 131 (38%) had SVA, 116 (33%) 
PVA, and 100 (29%) normal mucosal morphology (Table 
,2YHUDOOWKHUHZDVQRVWDWLVWLFDOO\VLJQL¿FDQWFKDQJHLQ
the three 15-year periods; however, a decreasing trend was 
seen in the occurrence of SVA and there was a concomitant 
increasing trend in normal villous architecture.
Factors associated with delayed diagnosis 
2IWKHSDWLHQWVLQWKHVWXG\KDGVXI¿FLHQW
information for the analysis of factors associated with 
the delayed diagnosis (Table II). Altogether, 142 (37%) 
patients had a delayed diagnosis, i.e. time from onset of 
rash to diagnosis was 2 years or more. The percentages 
in the 3 study periods were 47%, 38% and 25%, respec-
tively (Table I).
7DEOH,'HPRJUDSK\GXUDWLRQRIUDVKGHOD\HGGLDJQRVLVDQGVPDOOERZHOELRSV\¿QGLQJVLQWKHWKUHH\HDUSHULRGVLQSDWLHQWV
with dermatitis herpetiformis (DH)
Number of patients with DH 
1970–1984
n = 151
1985–1999
n = 161
2000–2014
n = 134 p-value
Males, n (%) 74 (49) 83 (52) 72 (54) 0.727
Age at diagnosis; median (Q1–Q3) 33 (23–47) 42 (30–54) 54 (35–65) < 0.001
Duration of rash before diagnosis, months, median (Q1–Q3) 12.0 (7–48) 11.0 (6–36) 8.0 (4–24) 0.002
a
Delayed diagnosisb, n (%) 55 (47) 56 (38) 31 (25) 0.002
Severe rash at diagnosis, n (%) 36 (32) 33 (24) 43 (35) 0.134
Presence of gastrointestinal symptoms at diagnosis, n (%) 43 (48) 56 (49) 56 (48) 0.990
Small bowel histology at diagnosis, n (%)
  Subtotal villous atrophy
  Partial villous atrophy
  Normal mucosa
51 (46)
35 (31)
26 (23)
48 (37)
45 (34)
38 (29)
32 (30)
36 (35)
36 (35)
0.214c
a7KLUGSHULRGFRPSDUHGZLWKWKH¿UVWSHULRGbDuration of 2 years or more. cAll biopsy results analysed together.
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)HPDOHVH[25ZDVVLJQL¿FDQWO\p = 0.043) as-
sociated with delayed diagnosis in the univariate analysis, 
but not in multivariable analysis (p = 0.061, Table II). 
Age at diagnosis was not associated with the delay. DH 
GLDJQRVLV SHUIRUPHGGXULQJ WKH¿UVW VWXG\ SHULRGZDV
VLJQL¿FDQWO\DVVRFLDWHGZLWKGHOD\HGGLDJQRVLVERWKLQ
the univariate (OR 2.62, p = 0.001) and multivariable (OR 
2.32, p = 0.017) analyses (Table II). The severity of rash 
or presence of gastrointestinal symptoms at diagnosis 
was not connected with delayed diagnosis. By contrast, 
villous atrophy (subtotal or partial) at diagnosis was sig-
QL¿FDQWO\ DVVRFLDWHGZLWKGLDJQRVWLFGHOD\ ERWK LQ WKH
univariate (OR 2.70, p = 0.001) and multivariable (OR 
2.52, p = 0.003) analyses. Furthermore, the positivity of 
coeliac autoantibodies (reticulin and/or endomysium) 
ZDVVLJQL¿FDQWO\DVVRFLDWHGZLWKGLDJQRVWLFGHOD\LQWKH
univariate analysis (OR 2.63, p = 0.001) in the 250 patients 
with available autoantibody results.
The patients with delayed diagnosis did not develop 
more bone fractures (17.6%) than those without long 
delay in diagnosis (14.3%) (p = 0.523), nor did they de-
velop more malignancies (7.4% vs. 6.0% respectively; 
p = 0.765).
DISCUSSION
This long-term study of DH patients diagnosed between 
1970 and 2014 analysed time tendencies from the onset of 
the rash to diagnosis. In the three 15-year study periods, 
the median durations of rash before diagnosis were 12, 11 
and 8 months, respectively. Importantly, the rash duration 
LQWKHWKLUGDQGODWHVWSHULRGZDVVLJQL¿FDQWO\VKRUWHUWKDQ
LQWKH¿UVWSHULRG2QHUHDVRQIRUWKLVVHHPVWREHEHWWHU
awareness of the disease due to nationwide guidelines for 
the diagnosis and treatment of coeliac disease in Finland, 
which were published in 1997 and are updated regularly 
(23). General practitioners and other physicians can access 
these guidelines online, and they also include DH, with 
clinical pictures of the rash and recommendations on how 
and where to diagnose patients. 
Similarly to DH, the diagnostic delay for coeliac disease 
became shorter in Finland after the publication of the 
Current Care Guidelines (17). However, it is noteworthy 
that the diagnostic delay in coeliac disease is still much 
longer than in DH; in approximately one-third of Finnish 
patients with coeliac disease (17) and DH, there are delays 
of over 10 and 2 years, respectively. 
The present DH cohort of 446 patients showed that the 
PHDQWLPHIURPWKH¿UVWV\PSWRPVRIUDVKWRGLDJQRVLV
was 3.1 years. Two previous DH studies with a smaller 
number of patients, one from Ireland (24) and another from 
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Fig. 1. Duration of rash before diagnosis in patients with dermatitis 
herpetiformis (DH) in the three 15-year diagnostic periods. The 
ORZHUDQGXSSHUOLPLWVRIWKHER[HVLQGLFDWHWKHDQGFRQ¿GHQFH
intervals and the black bars indicate median values. The whiskers extend 
to 1.5 times the height of the box and the circles are outliers that exceeded 
the interquartile range ± 1.5 times, The asterisk is an extreme outlier that 
exceeded the interquartile range +3 times.
Table II. Associations between clinical characteristics, time of diagnosis, and delayed diagnosisa in 389 patients with dermatitis herpetiformis
n
Delayed diagnosis 
%
Univariate Multivariablec
OR (95% CI) p-value OR (95% CI) p-value
Sex
  Male 199 32 1 1
  Female 190 42 1.5 (1.02–2.33) 0.043 1.64 (0.98–2.74) 0.061
Age at diagnosis
  > 50 years 146 30 1 1
  30–50 years 141 40 1.68 (0.99–2.85) 0.056 1.15 (0.80–2.74) 0.214
  < 30 years 102 41 1.63 (0.996–2.65) 0.052 0.88 (0.60–2.50) 0.581
Calendar period of diagnosis
  2000 to 2014 124 47 1 1
  1985 to 1999 147 38 1.85 (1.09–3.12) 0.022 1.55 (0.81–2.97) 0.184
  1970 to 1984 118 25 2.62 (1.52–4.51) 0.001 2.32 (1.17–4.62) 0.017
Severity of rash at diagnosis 
  Severe 104 33 1 1
  Moderate 181 39 1.30 (0.63–2.31) 0.573 1.64 (0.39–1.90) 0.858
  Mild 65 37 1.21 (0.78–2.16) 0.313 1.30 (0.63–2.66) 0.184
6PDOOERZHOELRSV\¿QGLQJDWGLDJQRVLV
  Normal 87 23 1 1
  Villous atrophyb 222 45 2.70 (1.53–4.75) 0.001 2.52 (1.36–4.68) 0.003
a5DVKODVWLQJ\HDUVEHIRUHGLDJQRVLVRIGHUPDWLWLVKHUSHWLIRUPLVbPartial or subtotal villous atrophy. c280 patients in this analysis. 
&,FRQ¿GHQFHLQWHUYDO25RGGVUDWLR
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
E. Mansikka et al.198
www.medicaljournals.se/acta
Germany (25), documented a shorter (1.6 years) or similar 
(3.2 years) duration to diagnosis, respectively (Table III). 
By comparison, a recent Swiss study showed that, in bul-
ORXVSHPSKLJRLGWKHPHDQWLPHIURPWKH¿UVWV\PSWRPV
to diagnosis was much shorter (6.1 months) (26). It is clear 
that the blistering rash with accompanying intense itch 
in DH means that there is usually little delay before the 
patient contacts a physician. When DH is suspected, the 
SDWLHQWLVVHQWGLUHFWO\WRRXU8QLYHUVLW\+RVSLWDOIRUD¿QDO
diagnosis. It is, however, noteworthy that the time needed 
for diagnosis can vary greatly among patients with DH. In 
the present study, the range was from 0.1 to 44 years, and 
in the 2 previous DH studies, the longest durations were 
4 and 20 years, respectively (24, 25). 
In contrast to DH, the delay in diagnosis of coeliac 
disease has received much attention in recent years. The 
diagnostic delay for coeliac disease in hospital cohorts 
and questionnaire studies has been reported to be very 
long, from 3 to 11 years (Table III) (16, 19, 20, 27–29). 
Consuming a gluten-containing diet for such a long time 
may increase the risk of developing DH, which is the most 
common extra-intestinal manifestation of coeliac disease 
(1, 30). An important issue is how long the patients with 
DH have had preceding undiagnosed coeliac disease in the 
small bowel. The time period can be very long (up to 30 
years), as shown by studies reporting a phenotype change 
from partially GFD-treated coeliac disease to DH (31, 32). 
Moreover, coeliac-type dental enamel defects observed in 
adults with DH suggest that undiagnosed coeliac disease 
had been present in childhood in many of the patients (33).
Small bowel mucosal damage in patients with DH 
ranges from severe, to partial villous atrophy, to normal 
YLOORXVVWUXFWXUHZLWKFRHOLDFW\SHLQÀDPPDWRU\FKDQJHV
(22). The present study analysed whether the small bowel 
damage could be linked to the delay in diagnosis of DH. 
,WZDVIRXQGWKDWWKHSDWLHQWVZLWKYLOORXVDWURSK\VLJQL¿-
cantly more often had a long diagnostic delay than those 
with normal villous mucosa. Villous atrophy can be a result 
rather than a cause of delayed diagnosis; after initial onset 
of gluten intolerance, it can take a long time before villous 
atrophy develops in coeliac disease (34, 35). Therefore, pa-
tients with DH who have undamaged villous morphology 
could be in the early stages of this process. Similarly, we 
found that the patients with positive coeliac autoantibodies 
VLJQL¿FDQWO\PRUHRIWHQKDGDGHOD\HGGLDJQRVLVWKDQWKRVH
ZLWK QHJDWLYH DXWRDQWLERGLHVZKLFK SUREDEO\ UHÀHFWV
the same thing; since the diagnosis becomes delayed the 
autoantibody response has time to progress. 
Several studies of coeliac disease have shown that 
females have a longer diagnostic delay than males (17, 
20, 29). Similarly, in the univariate statistical analysis of 
WKHSUHVHQW'+VWXG\ IHPDOHVVLJQL¿FDQWO\PRUHRIWHQ
had a delayed diagnosis than did males. Irritable bowel 
syndrome is common in females, and may mask the di-
agnosis of coeliac disease (20). Patients with DH rarely 
have obvious gastrointestinal symptoms, and the rash 
with intense itch is the reason for seeking medical advice. 
Therefore, the reasons why females seem to have delayed 
diagnosis in both coeliac disease and DH compared with 
males remain unknown.
Untreated DH has shown to decrease patients’ quality 
of life, which improves along with GFD treatment after 
diagnosis (13). The current study did not detect association 
with delayed diagnosis and development of bone fractures 
or malignancies, but the burden and complications related 
to delayed diagnosis of DH are yet to be fully elucidated.
The main strengths of the present study were the large 
patient cohort, collected from 1970 onwards at the single 
DH clinic. The diagnosis was invariably based on the 
presence of granular IgA deposits in the papillary dermis 
(2). Two experienced dermatologists have treated almost 
all of the present patients with DH, making notes on the 
presence of the rash at the time of diagnosis. In addition, 
small bowel biopsy results were available for the majority 
of patients, since endoscopy with small bowel biopsy 
has been performed routinely for all newly diagnosed 
patients with DH (22). The main limitations were the 
retrospective study design and a rather low response rate 
to the questionnaire. However, the data on the duration 
of the rash before the diagnosis was retrieved primarily 
from the patients’ medical records, and only the data on 
the presence of gastrointestinal symptoms was derived 
from the questionnaires. A further limitation is that the 
threshold of 2 years or more for delayed diagnosis is 
Table III. Time from the onset of symptoms to diagnosis in dermatitis herpetiformis (DH) and coeliac disease (CD) in the present and 
previous studies
Studies
Patients, n, (M/F ratio) 
Years diagnosed
Age at diagnosis, 
years, mean 
(range) 
Duration of symptoms 
before diagnosis, years, 
mean (range) Comment on diagnostic delay
DH studies
Present study, 2017, Finland 446 (1.1)a, 1970–2014 43.0 (3–83) 3.1 (0.1–44) Decreased over time. Longer in females
Rose et al. 2010, Germany 32 (1.5)a, 1996–2008 43.0 (10–84) 3.2 (0.1–20)
Egan et al. 1997, Ireland 54 (1.8)a, 1984–1993 42.0 (18–79) 1.6 (0.25–4)
CD studies
Vavricka et al. 2016, Switzerland 1,689 (0.29)b, not given 31.1 (0–83) 7.3 (0–65) Decreased from 1990 to 2010. Longer in females
Ukkola et al. 2011, Finland 490 (0.30)b, 2007–2008 49.0 (16–84)c 3.0 (0–59)c
Hurley et al. 2012, Wales 347 (0.50)a, 1996–2005 49.9 (16–88) 6.1 (0.1–15)
Rampertab et al. 2006, USA 590 (0.47)a, 1952–2004 43.4 (16–83) 4.6 (0–60) Decreased over time. Longer in females
Häuser et al. 2006, Germany 446 (0.41)b, not given 37.3 (0–85) 4.4 (0–62)
Green et al. 2001, USA 1,138 (0.34)b, not given 45.2 (18–88) 11.0 (0–70)
aHospital cohort. bQuestionnaire study to Coeliac Disease Society members. cMedian.
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somewhat arbitrary; however, it is partially based on our 
previous study in which the median duration of rash before 
diagnosis was 9 months in patients with refractory DH and 
12 months in control patients with DH (21). In addition, 
from a clinical point of view, we consider a diagnostic 
delay of 2 years or more with itchy rash to be far too long.
In conclusion, the present long-term study showed that 
one-third of patients had a diagnostic delay of at least 2 
years. Female sex, villous atrophy at diagnosis, and a DH 
GLDJQRVLVEHIRUHWKH\HDUZHUHVLJQL¿FDQWO\DVVR-
ciated with delayed diagnosis. Even though the situation 
has improved over the past 45 years, the diagnostic delay 
is still unacceptably high for a country with such a high 
prevalence of the disorder.
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The Decreasing Prevalence of Severe Villous Atrophy in
Dermatitis Herpetiformis
A 45-Year Experience in 393 Patients
Eriika Mansikka, MD,* Kaisa Hervonen, MD, PhD,*w Teea T. Salmi, MD, PhD,*w
Hannu Kautiainen, MSc,zy8 Katri Kaukinen, MD, PhD,wz
Pekka Collin, MD, PhD,w# and Timo Reunala, MD, PhD*w
Goals: We analyzed from our prospectively collected series of
patients with dermatitis herpetiformis (DH) whether small-bowel
histologic ﬁndings are changing and how serum tissue trans-
glutaminase (TG2) IgA antibodies correlate to mucosal damage.
Background: DH is an extraintestinal manifestation of celiac dis-
ease presenting with itchy blistering rash and pathognomonic IgA
deposits in the skin. Prominent gastrointestinal symptoms are rare,
and small-bowel ﬁndings range from severe villous atrophy (SVA)
and partial villous atrophy (PVA) to normal mucosa with inﬂam-
matory changes.
Methods: The cohort included 393 patients (214 male and 179
female) with DH having small-bowel biopsies performed at Tam-
pere University Hospital since 1970. The small-bowel ﬁndings were
calculated in the three 15-year periods, and in the last period they
were correlated with serum IgA class TG2 antibody levels meas-
ured by enzyme-linked immunosorbent assay.
Results: The prevalence of SVA decreased signiﬁcantly (P=0.032),
from 42% in the ﬁrst study period to 29% in the last study period.
A concomitant increase was seen in PVA, from 33% to 41%, and
normal villous architecture, from 25% to 30%. The patients with
SVA (P<0.001) and PVA (P=0.046) had signiﬁcantly higher
TG2 antibody levels than those with normal villous architecture.
Conclusions: This long-term study in patients with DH disclosed a
signiﬁcant decrease in the occurrence of SVA. Serum IgA TG2
antibody levels correlated to damage in the small bowel. The trend
toward milder small-bowel histology in DH suggests that a similar
pattern could occur in the pool of undiagnosed celiac disease from
which DH develops.
Key Words: dermatitis herpetiformis, celiac disease, small-bowel
histology, severe villous atrophy, transglutaminase antibodies
(J Clin Gastroenterol 2017;51:235–239)
Dermatitis herpetiformis (DH) is an extraintestinalmanifestation of celiac disease presenting with itchy,
blistering rash mainly on the elbows, knees, and but-
tocks.1–3 Diagnosis is conﬁrmed by direct immuno-
ﬂuorescence examination of uninvolved skin showing
granular IgA deposits in the upper dermis.4 Small-bowel
biopsies performed on patients with DH in the 1960s
detected celiac enteropathy.5,6 Thereafter, the rash was
also shown to respond to a strict gluten-free diet (GFD)
and relapse on gluten challenge.7–9 Further evidence that
DH is an extraintestinal manifestation of celiac disease
came from immunogenetic and family studies. The
patients of both diseases had the same strong association
with HLA DQ2.10 Moreover, DH and celiac disease were
shown to cluster in the same families, and monozygotic
twins, one with DH and the other with celiac disease, were
also reported.11
Gender diﬀerences are obvious between adults with
DH and celiac disease; male patients dominate in DH and
female patients dominate in celiac disease.2 Moreover, only
a minority of patients with DH present with prominent
gastrointestinal symptoms or signs of malabsorption, and,
interestingly, about one fourth of the patients have no vil-
lous atrophy in the small bowel.8,12 Nevertheless, these
patients with DH also have mucosal inﬂammation com-
patible with early developing celiac disease,13,14 and their
rash responds to a GFD treatment similarly to the patients
with villous atrophy.8
The diagnostic capability of celiac disease has
increased within the past decades, resulting in the
detection of numerous new cases.15,16 In our area in
Finland, the ratio of diagnosed celiac disease to DH was 1
to 1 in the early 1980s, whereas at present it is 8 to 1, and
0.7% of the adult population has the disorder.17,18 In
contrast to celiac disease, the incidence of DH is now
decreasing both in Finland and the United Kingdom.19,20
This ﬁts to the hypothesis that DH develops on the basis
of undiagnosed celiac disease by formation of IgA-class
epidermal transglutaminase antibodies, which are depos-
ited into the skin.21,22 Whether the increased detection of
celiac disease could have an impact on the severity of
enteropathy in DH is of interest. The aim of the present
study covering the years from 1970 to 2014 was to analyze
whether any changes have occurred in the degree of small-
bowel mucosal damage. A further aim was to compare
small-bowel ﬁndings and serum IgA TG2 antibodies
to elucidate whether the antibody levels also in patients
with DH correlate to the damage in the small-bowel
mucosa.
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PATIENTS AND METHODS
The study group comprised all adult patients with DH
(214 male and 179 female) who were admitted and diag-
nosed at the Department of Dermatology in 1970 to 2014.
Thereafter, a small-bowel biopsy was performed at the
Department of Gastroenterology and Alimentary Tract
Surgery or previously at the Department of Internal Med-
icine in Tampere University Hospital. The diagnosis of DH
was based on the blistering, itchy rash mainly on the
elbows, knees, and buttocks, and the demonstration of
granular IgA deposits in the papillary dermis by direct
immunoﬂuorescence examination.4
Small-bowel biopsy was oﬀered to all patients before
starting a GFD treatment, and 75% of all 524 patients
accepted the examination. In the 70s, biopsies were
obtained with Crosby capsule under x-ray control and
thereafter upon upper gastrointestinal endoscopy. Small-
bowel mucosal samples were stained by hematoxylin-eosin
and scored morphologically as severe villous atrophy (SVA;
ie, subtotal or total villous atrophy compatible with Marsh-
Oberhuber types III-b and III-c), partial villous atrophy
(PVA, type III-a), or normal villous architecture.15 Path-
ologists with a special knowledge of intestinal pathology
made the interpretations.
Serum samples taken from 96 patients with DH
diagnosed in 2000 to 2014 were examined for TG2 anti-
bodies with IgA anti-TG2 enzyme-linked immunosorbent
assay (ELISA) kits (Celikey; Phadia, GmbH, Freiburg,
Germany), as previously described.23 Levels below 5
absorbance units (AU)/mL were considered negative, and
the highest measured level was 120AU/mL.
The linearity of small-bowel histology ﬁndings across
the three 15-year periods was tested by using Cochran-
Armitage test and analysis of variance. Diﬀerences in TG2
IgA antibody levels between patients with SVA or PVA and
normal villous architecture were determined using the
Kruskall-Wallis test followed by pairwise multiple com-
parisons with the Dunn test.
RESULTS
Patients in the Three 15-Year Periods
The number of the patients with DH was 144 in 1970
to 1984, 144 in 1985 to 1999, and 105 in 2000 to 2014
(Table 1). Male patients (n=214) outnumbered female
patients (n=179), and no signiﬁcant change occurred in
the three 15-year periods (Table 1). The mean age of the
patients at diagnosis increased signiﬁcantly (P<0.001),
from 37.7 to 52.1 years, during the study, and this occurred
both in male and female patients (Table 1).
Small-Bowel Histology in the Three 15-Year
Periods
Of all the 393 patients with DH, 140 (35.6%) showed
SVA, 145 (36.9%) showed PVA, and 108 (27.5%) showed
normal villous architecture in small-bowel histology. In the
three 15-year periods, prevalence of SVA decreased from
42% to 35% and then to 29% (P=0.032, Table 1
and Fig. 1). A concomitant increase, although not sig-
niﬁcant (P=0.22 and 0.34), occurred in the prevalence of
PVA, from 33% to 41%, and normal villous architecture,
from 25% to 30% (Table 1 and Fig. 1).
TG2 IgA Antibodies and Small-Bowel Histology
in the Last 15-Year Period
Serum TG2 IgA antibody levels in DH patients with
SVA, PVA, and normal villous architecture diagnosed in
2000 to 2014 are shown in Figure 2. These were signiﬁcantly
elevated in the 28 patients with SVA (median, 41.5AU/mL;
P<0.001) and in the 40 patients with PVA (median,
16.5AU/mL; P=0.046) compared with the levels in 28
patients with normal villous architecture (median, 2.75AU/
mL). Three (11%) patients with SVA, 12 (30%) with PVA,
and 15 (54%) with normal villous architecture had normal
TG2 IgA antibody levels.
DISCUSSION
The main ﬁnding in the present study in 393 patients
with DH was that the occurrence of SVA has become less
common within the observation period of 45 years. The
prevalence of SVA decreased from 42% to 35% and then to
29% in the 3 study periods, and a concomitant increase,
although not signiﬁcant, occurred in the percentage of PVA
and normal villous architecture. At the same time with
these changes the mean age at diagnosis increased sig-
niﬁcantly, from 38 to 52 years, which agrees with our pre-
vious report including also small-bowel nonbiopsied
patients with DH.19 In our previous register study, we
found no basic diﬀerences in the mean ages of adult
patients with DH and celiac disease; the mean age in DH
was 39 years and that of celiac disease was 44 years.17 The
age at the diagnosis of celiac disease is highly dependent of
the diagnostic accuracy, because the symptoms of patients
are often vague. By contrast, we believe that in DH the
intensive itching brings the patient to the physician very
soon. We do not see any alteration or ﬂaws in the diag-
nostic procedure in DH over the past decades. Thus, the
explanation for the increased age at diagnosis in DH may
be improved diagnostic accuracy resulting in markedly
increased incidence of celiac disease in our country.17,18
High index of suspicion and screening in at-risk groups
TABLE 1. Sex, Mean Age, and Small-Bowel Histology at Diagnosis in 393 Patients With Dermatitis Herpetiformis
1970-1984 (N=144) 1985-1999 (N=144) 2000-2014 (N=105) P*
No. male patients (%) 77 (53) 76 (53) 61 (68) 0.50
Mean age (range) 37.7 (18-69) 43.7 (20-84) 52.1 (19-75) <0.001w
Small-bowel biopsy [n (%)]
Severe villous atrophy 60 (42) 50 (35) 30 (29) 0.032
Partial villous atrophy 48 (33) 54 (37) 43 (41) 0.22
Normal villous architecture 36 (25) 40 (28) 32 (30) 0.34
The cohort was prospectively collected from 1970, and the results are expressed in three 15-year periods.
*For linearity.
wSimilar increase in male and female patients.
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reveal many new cases of celiac disease.16,24 Patients par-
ticularly with asymptomatic celiac disease will be diagnosed
earlier,25 and also these patients are placed on a GFD.
Because of this, a smaller potential cohort of undetected
celiac disease will nowadays continue on gluten-containing
diet and have time to develop SVA and skin
manifestation—that is, DH. The long time period needed
for phenotype change from celiac disease to DH supports
this ﬁnding.26,27
Serologic screening of celiac disease by measuring TG2
IgA antibodies in ELISA test has become a widely accepted
practice.16,24 The sensitivity and speciﬁcity for TG2 IgA
antibody ELISA tests have been shown to be high, over 90%
in various study populations.28 This test has been used also
in DH, and diagnostic sensitivities lower than those in celiac
disease have been found.23,29–31 In the present study, we
correlated TG2 IgA antibody levels to small-bowel ﬁndings
in a much larger patient population than in previous studies
in adults with DH.30–32 As expected from celiac disease
studies,24,33,34 the levels were signiﬁcantly elevated and
highest in the patients with SVA and lower but still sig-
niﬁcantly elevated in the patients with PVA. These results
agree with a large study of children with DH in which high
IgA TG2 antibody levels were associated with the degree of
mucosal villous atrophy.35 Importantly, 11% of the present
patients with SVA and 30% with PVA had normal TG2 IgA
antibody levels, obviously indicating that normal antibody
levels cannot exclude that the patient with DH has damaged
mucosa in the small bowel. Although TG2 IgA antibody
ELISA test does not detect all DH patients with small-bowel
villous atrophy, a need for small-bowel biopsy is obvious
only when the patient has prominent gastrointestinal symp-
toms or a suspicion of malignancy. We agree with this
opinion presented in an Italian guideline36 when we now
know that the DH patients with and without small-bowel
villous atrophy have similar excellent prognosis after
adherence to a strict GFD.37
Strengths of the present study were the long-term
prospective survey in a specialized center covering the same
catchment area and using the best diagnostic criterion for
DH—that is, demonstration of granular IgA deposits in the
uninvolved skin.2,4 Moreover, we have had a close coop-
eration with dermatologists and gastroenterologist oﬀering
routinely small-bowel biopsies to every of our newly diag-
nosed patients with DH. Three-fourths of these—that is,
393 patients—had a successful biopsy, whereas the number
of patients and percentage of biopsies have been
much lower in earlier studies in adults with DH.32,38,39
FIGURE 1. Severe villous atrophy (SVA), partial villous atrophy
(PVA), and normal small-bowel villous architecture in 393
patients with dermatitis herpetiformis in three 15-year periods:
I = 1970 to 1984, II = 1985 to 1999, III = 2000 to 2014. SVA shows
a significant linear decrease (P=0.032), whereas the increases in
PVA and normal villous architecture are nonsignificant (P=0.22
and 0.34).
FIGURE 2. Serum tissue transglutaminase (TG2) IgA antibody
levels (median with interquartile range whiskers showing 5 and
95 percentiles) measured at diagnosis by ELISA test in 96 patients
with dermatitis herpetiformis. Patients with severe villous atrophy
(SVA; P<0.001) and partial villous atrophy (PVA; P=0.046) have
significantly higher TG2 antibody levels than the patients with
normal villous architecture.
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We excluded children with DH from the present study—the
percentage of whom has been only 4% of all of our
patients40 but markedly higher in Hungarian and Italian
series.35,41 The mean age of our 18 children with DH was 10
years at diagnosis, and a half of them had SVA.40 Limi-
tations in the present study were diﬀerent methods (capsule,
endoscopy) to obtain small-bowel biopsy samples and no
opportunity to more accurately examine the mucosal sam-
ples than routine histologic evaluation. However, we have
previously shown that also the DH patients with normal
mucosal histology have inﬂammatory changes such as
increased numbers of gamma/delta T cells.13,14 Moreover,
the rash in DH patients with normal small-bowel villous
architecture responds to a GFD similarly to the patients
with villous atrophy,8 conﬁrming that also these patients
belong to the same pool of skin manifestation of celiac
disease.3 In accordance, several celiac disease studies have
focused attention to the patients presenting with normal
mucosal histology together with endomysium or TG2 IgA
antibodies, and they have shown that on a gluten-con-
taining diet many of them later develop villous atro-
phy.42–44 This condition has been termed as early devel-
oping43 or potential celiac disease.45 It is of interest that
DH seems to be able also to arise from this condition, as
one fourth of the present patients had normal villous
architecture and a half of them presented with TG2 IgA
antibodies. The trend toward milder small-bowel histology
in DH suggests that a similar pattern could occur in the
pool of undiagnosed celiac disease from which DH devel-
ops possibly as an autoimmune reaction against epidermal
transglutaminase.21,22 In agreement with this, recent studies
in celiac disease have shown that the severity of symptoms
and small-bowel mucosal damage have become milder.25,46
Brar et al46 examined 499 patients with adult celiac disease
in 1981 to 2004 and could show that there was a signiﬁcant
trend over time for a greater proportion of patients pre-
senting as atypical/silent celiac disease and having PVA.
Whether environmental factors such as changes in gluten
consumption,47 intestinal microbiota,48 and smoking49
might have had an eﬀect on the decreased severity of small
bowel villous atrophy in celiac disease and DH needs to be
addressed in future studies.
In conclusion, the present long-term prospective study
in DH showed that severe enteropathy has signiﬁcantly
decreased in this common extraintestinal manifestation of
celiac disease. TG2 IgA antibody levels in ELISA were
highest in patients with SVA, but negative test results
occurred as well. The trend toward milder small-bowel
histologic damage in DH suggests that a similar pattern
could occur in the pool of undiagnosed celiac disease from
which DH develops.
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Abstract: Dermatitis herpetiformis (DH) is a cutaneous manifestation of coeliac disease. At diagnosis,
the majority of patients have villous atrophy in the small bowel mucosa. The objective of this
study was to investigate whether the presence or absence of villous atrophy at diagnosis affects the
long-term prognosis of DH. Data were gathered from the patient records of 352 DH and 248 coeliac
disease patients, and follow-up data via questionnaires from 181 DH and 128 coeliac disease patients
on a gluten-free diet (GFD). Of the DH patients, 72% had villous atrophy when DH was diagnosed,
and these patients were signiﬁcantly younger at diagnosis compared to those with normal small
bowel mucosa (37 vs. 54 years, p < 0.001). Clinical recovery on a GFD did not differ signiﬁcantly
between the DH groups, nor did current adherence to a GFD, the presence of long-term illnesses,
coeliac disease-related complications or gastrointestinal symptoms, or quality of life. By contrast,
the coeliac disease controls had more often osteopenia/osteoporosis, thyroid diseases, malignancies
and current gastrointestinal symptoms compared to the DH patients. In conclusion, villous atrophy
at the time of DH diagnosis does not have an impact on the clinical recovery or long-term general
health of DH patients.
Keywords: dermatitis herpetiformis; coeliac disease; gluten-free diet; small bowel; villous
atrophy; prognosis
1. Introduction
Dermatitis herpetiformis (DH) is an extraintestinal manifestation of coeliac disease currently
affecting approximately 13% of coeliac disease patients [1,2]. DH induces intense pruritus and a
symmetrical papulovesicular rash typically on the elbows, knees, and buttocks [3]. Coeliac disease and
DH are genetically predisposed by the human leukocyte antigen (HLA) DQ2 or DQ8 haplotypes, and
exogenous gluten causes an immune response and small bowel mucosal injury in both [4,5]. Furthermore,
autoantibodies against endogenous enzyme tissue transglutaminase (TG2) are characteristically present
in the serum and the intestine in both conditions [6–9].
Diagnosis of DH is veriﬁed with the detection of pathognomonic granular immunoglobulin A
(IgA) deposits in the uninvolved skin by direct immunoﬂuorescence (IF) examination [10]. This IgA is
known to target epidermal transglutaminase (TG3) [11], which is considered the autoantigen in DH,
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while in coeliac disease it is TG2 [6]. In addition to the skin, TG3 antibody response is often present in
the sera of DH patients, although TG3 antibodies are occasionally also found in the serum of some
coeliac disease patients without DH [12–14].
At the time of the DH diagnosis, some degree of small bowel mucosal villous atrophy is known to
exist in approximately 75% of patients, but the remainder have normal villous architecture with only
coeliac-type inﬂammation [15,16]. Regardless of the small bowel mucosal alterations, DH patients only
rarely present with obvious gastrointestinal symptoms [17,18].
A strict life-long gluten-free diet (GFD) is the mainstay of treatment in both DH and coeliac
disease. However, resolution of DH rash can take months or even longer on the dietary treatment, and
therefore, DH patients with severe skin symptoms are additionally treated with dapsone medication
to control the rash more quickly [3,19]. Coeliac disease and DH both carry an increased risk of
concomitant autoimmune conditions such as thyroid diseases and type 1-diabetes; furthermore,
the risk of developing non-Hodgkin lymphoma is increased [20–22]. Mortality in coeliac disease,
but not in DH, has shown to be increased [23]. A GFD is known to have a preventive effect against
the development of lymphoma in DH [24], but other than that, previous research about the factors
inﬂuencing the prognosis of DH is lacking. Currently, it is not known whether DH patients with small
bowel villous atrophy at diagnosis have a worse outcome compared to those with normal small bowel
mucosa, and furthermore, whether the prognosis of DH patients with villous atrophy is corresponding
to that of classical coeliac disease patients. This issue is of importance when necessary investigations,
at the time of DH diagnosis, are assessed.
The aim of the current study was to assess whether the presence of villous atrophy at DH diagnosis
would affect clinical recovery on a GFD or the long-term prognosis of DH. In addition, DH patients
were compared to classical coeliac disease controls with abdominal symptoms at diagnosis and a
histologically conﬁrmed diagnosis. The hypothesis of this study was that the presence or absence of
villous atrophy at diagnosis would not be an inﬂuential factor in the prognosis of DH.
2. Materials and Methods
Between 1970 and 2014, a total of 526 DH patients were diagnosed at the Department of
Dermatology, Tampere University Hospital. During the study period, all patients with DH living
in a defined area around Tampere were diagnosed at this dermatology unit since IF biopsies required
for the diagnosis were not performed elsewhere. Each DH patient’s diagnosis was based on the typical
clinical picture and the demonstration of granular IgA deposits in skin biopsies [10]. In addition,
all diagnosed patients were routinely suggested to undergo gastroscopy and small bowel biopsy
obtainment at the time of the diagnosis while on a gluten-containing diet. After diagnosis, a strict
GFD was advised to all patients and dapsone was instituted in those with severe skin symptoms.
According to routine treatment policies, all patients were followed up at a DH outpatient clinic
until the rash had cleared and the dapsone medication could be discontinued. In this study, all DH
patients without prior coeliac disease diagnosis (made ≥2 years earlier) diagnosed between 1970 and
2014 and having an available small bowel biopsy result and commencing on a GFD after diagnosis,
were included as study patients. Altogether, 352 DH patients fulﬁlled the inclusion criteria and
were included as DH study patients. Further, 248 classical coeliac disease patients with abdominal
symptoms at diagnosis and a histologically conﬁrmed diagnosis at Tampere University Hospital
during the same time period served as controls.
Data on demographic characteristics, the severity of clinical symptoms and small bowel mucosal
histology, and the results of coeliac autoantibodies and hemoglobin values at the time of DH or coeliac
disease diagnosis were gathered from the patient records of Tampere University Hospital between
March and October 2016. The small bowel biopsy results were graded as subtotal villous atrophy (SVA),
partial villous atrophy (PVA), or normal mucosa according to the analysis of the routine pathologist
as previously described [16]. In DH patients, the skin symptoms at the time of the diagnosis were
graded as mild, moderate, or severe according to the presence of a few, several or many blisters,
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macular eruptions and erosions. The grading was performed by one dermatologist. In addition,
the commencement and duration of dapsone medication after diagnosis was recorded.
Follow-up data were collected using questionnaires (see below for more detail) mailed to all
294 living DH patients fulfilling the inclusion criteria of this study (on December 2015) and the 222 living
coeliac disease controls (on May 2016). The final response rate was 62% for the DH patients and 58% for
the coeliac disease patients; hence, the follow-up study included 181 DH and 128 coeliac disease patients.
The study protocol and usage of the register-based data were approved by the Regional Ethics
Committee of Tampere University Hospital (R15143), and furthermore, informed consent was obtained
from each patient participating in the follow-up study.
2.1. Questionnaires
The disease-speciﬁc questionnaire designed for this study, the Psychological General Well-Being
(PGWB) [25] and Gastrointestinal Symptom Rating Scale (GSRS) [26] questionnaires were mailed to the
DH and coeliac disease study patients. PGWB and GSRS questionnaires are validated questionnaires,
which have been widely applied in previous coeliac disease studies [27–31]. In addition, the DH
patients received the Dermatology Life Quality Index (DLQI) questionnaire [32].
The disease-speciﬁc questionnaire included both open and multiple-choice questions. The patients
were asked about the presence and duration of DH and coeliac disease-related symptoms before and
after the diagnosis, the strictness of the GFD, smoking and other lifestyle characteristics, the number of
children born, the family history of coeliac disease or DH, and the patient’s current height and weight.
Compliance with a GFD was reported as strict diet without dietary lapses, dietary lapses once per
month, dietary lapses one to ﬁve times per month, or dietary lapses once per week. In addition, the
questionnaire included questions about the presence of coeliac disease complications and associated
diseases, malignancies, other long-term illnesses, and the regular usage of physician-prescribed
medications and over-the-counter (OTC) medications. In the malignancy analysis, non-melanoma skin
cancers were excluded, as were excessive trauma fractures in bone fracture analyses.
As previously described, the validated 22-item PGWB questionnaire evaluates self-perceived
health-related well-being and distress and includes six dimensions: Anxiety, depressed mood, positive
well-being, self-control, vitality, and general health [25]. The total score ranges from 22 to 132,
with a higher score indicating better quality of life. The 15-item GSRS questionnaire assesses
the severity and existence of gastrointestinal symptoms in ﬁve categories: Diarrhea, indigestion,
constipation, abdominal pain, and reﬂux [26]. It uses a seven-point Likert scale for each question:
One indicates an absence of symptoms and seven indicates severe symptoms. The DLQI is a 10-item
dermatology-speciﬁc quality of life instrument. The questionnaire includes six different sections:
Symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment
unit. The scores of all ten questions are calculated together, and the total score varies from a minimum
of 0 to a maximum of 30, with a higher score indicating a more impaired life quality [32].
2.2. Statistical Analysis
A Two-sided chi-squared test was used to compare the categorical variables and a Kruskall–Wallis
test was performed to assess differences between the continuous variables. Logistic regression analysis
was used to standardize the study groups according to age at the time of the study. Statistical signiﬁcance
was set at p < 0.05. The analyses were performed using IBM SPSS Statistics for Windows (Version 23.0.,
IBM Corp., Armonk, NY, USA).
3. Results
3.1. DH Patients with Normal Villous Architecture Compared to DH Patients with Villous Atrophy at Diagnosis
Of the 352 DH patients, 98 (28%) had normal villous architecture, and 254 (72%) had small bowel
mucosal villous atrophy (PVA or SVA) at the time of the DH diagnosis (Table 1). GFD was not initiated
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before the diagnosis in study participants. Mean time since the year of DH diagnosis, was 20 years in
the DH patients with normal villous architecture and 23 years in the DH patients with villous atrophy,
and the difference was not statistically signiﬁcant. The median age at diagnosis was signiﬁcantly
higher in the DH patients with normal villous architecture compared to the DH patients with villous
atrophy (p < 0.001, Table 1). At diagnosis, the DH patients with villous atrophy were signiﬁcantly
more often serum coeliac autoantibody-positive compared to the DH patients with normal villous
architecture (73% vs. 39%, p < 0.001, Table 1). The severity of the DH rash at diagnosis did not differ
signiﬁcantly between the DH groups (p = 0.862). Eighty percent of all DH patients used dapsone after
the diagnosis. The duration of dapsone usage was longer in the DH patients with normal villous
architecture compared to the DH patients with villous atrophy at diagnosis (median 36 vs. 24 months),
but the difference was not statistically signiﬁcant (p = 0.097, Table 1).
Table 1. Demographic data and disease-related characteristics of 98 dermatitis herpetiformis (DH)
patients with normal small bowel villous architecture and 254 DH patients with villous atrophy at
diagnosis, and 248 coeliac disease (CD) control patients.
DH Patients CD Controls(n = 248) p-Value *
With Normal
Villous Architecture
(n = 98)
With Villous
Atrophy
(n = 254)
Females; n (%) 50 (51) 125 (49) 193 (78) <0.001
Age at diagnosis; median (range) 52 (3–84) 37 (4–78) 42 (7–75) <0.001 a
Coeliac autoantibodies 1 present in the serum at diagnosis; n (%) 28/72 (39) 139/191 (73) 124/148 (84) <0.001 a
Haemoglobin level at diagnosis 2, g/L; median (Q1–Q3) 3 138 (128–148) 136 (129–146) 130 (121–140) 0.057
Dapsone treatment used; n (%) 75/93 (81) 191/243 (79) - -
Duration of dapsone treatment, months; median (range) 36 (5–324) 24 (2–384) - -
* p-value measured across the three study groups; 1 Transglutaminase 2-, endomysium-, or antireticulin IgA
antibodies; 2 Statistical analysis was further performed for patients ≥16 years of age and for females and males
separately—there were no statistically signiﬁcant differences between the three groups; 3 Interquartile range;
a Statistically signiﬁcant difference (p < 0.001) between DH patients with normal villous architecture and DH
patients with villous atrophy.
Of the 181 DH patients with available follow-up data, 39 (22%) had normal villous architecture,
and 142 (78%) had villous atrophy at the time of DH diagnosis. The median follow-up time was
20 years in patients with normal villous architecture and 23 years in the DH patients with villous
atrophy at diagnosis (Table 2). The presence of gastrointestinal symptoms at diagnosis did not differ
between the DH study groups according to the follow-up study questionnaire (p = 0.170). At the time
of the follow-up study, DH patients with normal villous architecture were signiﬁcantly older compared
to those DH patients who had villous atrophy at diagnosis (Table 2).
The strictness of the GFD and BMI did not differ between the DH study groups at the time of
the study (Table 2). Similarly, no signiﬁcant differences were detected in smoking habits or physical
activity: 3% of DH patients without villous atrophy and 13% of patients with villous atrophy at
diagnosis were current smokers, and 49% and 69% exercised at least three times a week, respectively.
Table 2. Follow-up data of 39 dermatitis herpetiformis (DH) patients with normal villous architecture
and 142 DH patients with small bowel mucosal villous atrophy at diagnosis, and 128 coeliac disease
(CD) control patients.
DH Patients CD Controls(n = 128) p-Value *
With Normal
Villous Architecture
(n = 39)
With Villous
Atrophy
(n = 142)
Females; n (%) 18 (46) 67 (47) 104 (81) <0.001
Follow-up time, years; median (range) 20 (1–44) 23 (1–42) 18 (6–43) 0.003
Age; median (range) 68 (52–85) 61 (18–96) 65 (34–85) <0.001 a
BMI, kg/m2; median (range) 25 (19–37) 25 (16–38) 26 (15–46) 0.772
Strict adherence to GFD, no dietary lapses; n (%) 30 (77) 101 (71) 107 (84) 0.170 b
Number of long-term illnesses; median (range) 1 (0–7) 1 (0–14) 2 (0–9) <0.001
Number of prescription medications used; median (range) 2 (0–11) 1 (0–18) 3 (0–16) 0.078
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Table 2. Cont.
DH Patients CD Controls(n = 128) p-Value *
With Normal
Villous Architecture
(n = 39)
With Villous
Atrophy
(n = 142)
Uses statin medication; n (%) 14 (36) 21 (15) 15 (12) 0.001 c
Uses antihypertensive medication; n (%) 20 (51) 50 (35) 49 (38) 0.188
Uses proton pump inhibitor medication; n (%) 5 (13) 16 (11) 16 (13) 0.938
Number of over-the-counter medications used; median (range) 0 (0–5) 1 (0–7) 2 (0–7) <0.001
Number of children born; median (range) 2 (0–5) 2 (0–6) 2 (0–5) 0.497
First-degree relatives with DH or CD; n (%) 13 (33) 53 (37) 55 (43) 0.464
BMI: Body mass index; GFD: Gluten-free diet. * p-value measured across the three study groups; a Statistically
signiﬁcant difference (p < 0.001) between DH patients with normal villous architecture and DH patients with villous
atrophy at diagnosis; b p-value was tested for categorical variables including categories: strict diet, dietary lapses
once per month, dietary lapses 1–5 times/month, dietary lapses once per week; c Statistically signiﬁcant difference
(p = 0.003) between DH patients with normal villous architecture and DH patients with villous atrophy at diagnosis.
At the time of the follow-up study, coronary heart disease and hypertension were signiﬁcantly
more common among the DH patients with normal villous architecture compared to the DH patients
with villous atrophy at diagnosis (Figure 1); however, after adjustment for the current age, signiﬁcant
differences disappeared (p = 0.198, OR = 0.482 and p = 0.273, OR = 0.653, respectively). Signiﬁcant
differences were not detected in the presence of type 1- or 2-diabetes, thyroid diseases, cerebrovascular
diseases, osteopenia or osteoporosis, or malignancies between the DH study groups (Figure 1). Patients
with self-reported bone fractures were slightly more numerous among the DH patients with villous
atrophy than among those with normal villous architecture at diagnosis, but the difference was not
statistically signiﬁcant (p = 0.321, Figure 1).
Figure 1. Percentages of dermatitis herpetiformis (DH) patients with normal small bowel mucosal
villous architecture and with villous atrophy at diagnosis, and coeliac disease control patients with
long-term illnesses or complications at the time of the follow-up study. (a) Statistically significant
difference (p < 0.05) between the three study groups; (b) statistically significant difference (p < 0.05)
between DH patients with normal villous architecture and DH patients with villous atrophy at diagnosis.
Statistically signiﬁcant differences were not detected in the use of physician-prescribed regular
medications between the DH study groups; even the signiﬁcant difference in the use of statin
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medication disappeared after adjustment for the current age (OR = 0.479, p = 0.88, Table 2). Furthermore,
the total amount of used OTC medications was similar in the DH groups; only the usage of vitamin D
was more frequent among DH patients with villous atrophy at diagnosis compared to those without
villous atrophy (40% vs. 23%, p = 0.050).
The presence of gastrointestinal symptoms or the quality of life according to the total or the
subscores of the GSRS, PGWB (Table 3) and DLQI questionnaires at the time of the study did not differ
between the DH study groups
Table 3. The Psychological General Well-Being (PGWB) and Gastrointestinal Symptom Rating Scale
(GSRS) questionnaires’ median and interquartile range (Q1–Q3) results for the gluten-free diet-treated
dermatitis herpetiformis (DH) patients with normal villous architecture and with villous atrophy at
diagnosis, and the coeliac disease (CD) controls at the time of the follow-up study.
DH Patients
CD Controls
(n = 128)
p-Value *
With Normal Villous
Architecture (n = 39)
With Villous Atrophy
(n = 142)
PGWB median (Q1–Q3) median (Q1–Q3) median (Q1–Q3)
Total 110 (99–116) 110 (101–117) 106 (96–117) 0.200
Anxiety 26 (23–27) 26 (23–27) 25 (23–28) 0.891
Depression 17 (16–18) 17 (16–18) 17 (15–18) 0.587
Well-being 18 (16–20) 18 (16–20) 18 (16–20) 0.279
Self-control 16 (15–17) 16 (15–17) 16 (14–17) 0.295
General health 13 (12–15) 14 (12–16) 13 (11–15) 0.022
Vitality 20 (17–21) 19 (17–21) 18 (16–20) 0.104
GSRS median (Q1–Q3) median (Q1–Q3) median (Q1–Q3)
Total 1.6 (1.3–2.0) 1.7 (1.3–2.3) 2.1 (1.5–4.2) <0.001
Diarrhoea 1.0 (1.0–1.7) 1.3 (1.0–2.3) 1.7 (1.0–2.7) 0.006
Indigestion 1.8 (1.5–2.5) 2.0 (1.5–2.5) 2.0 (1.5–3.0) 0.227
Constipation 1.7 (1.0–2.3) 1.7 (1.0–2.3) 1.7 (1.0–2.4) 0.482
Pain 1.3 (1.0–1.7) 1.7 (1.0–2.0) 1.7 (1.3–2.3) 0.007
Reﬂux 1.0 (1.0–1.5) 1.0 (1.0–2.0) 1.5 (1.0–2.0) 0.084
* p-value measured across the three study groups.
3.2. Comparisons between the DH Patients and the Classical Coeliac Disease Controls
Compared to the DH patients, the coeliac disease controls were more often female (Tables 1 and 2),
and their median diagnostic age was signiﬁcantly lower compared to DH patients with normal villous
architecture at diagnosis (Table 1).
In the long-term follow-up data, there were no observed differences in current smoking habits
or physical activity between the DH patients and the coeliac disease controls. By contrast, the total
number of long-term illnesses was found to be higher among the coeliac disease controls compared
to the DH patients (Table 2). More speciﬁcally, after adjustment for the current age, thyroid diseases
(OR = 3.443, p = 0.019) and osteopenia or osteoporosis (OR = 14.132, p = 0.012) were more common
among the coeliac disease controls than among the DH patients (Figure 1). However, the presence of
self-reported bone fractures did not differ signiﬁcantly between the DH study groups and the coeliac
disease controls. In the malignancy analysis, the coeliac disease controls outnumbered the DH patients
after adjustment for the current age (OR = 6.527, p = 0.016) (Figure 1).
In the analysis of regularly used physician-prescribed medications and after adjustment for the
current age, the coeliac disease controls were found to use less statin medication compared to the DH
patients with normal villous architecture (OR = 0.319, p = 0.01). In turn, the total number of regularly
used OTCs was higher among the coeliac disease patients compared to the DH patients (p = 0.003,
Table 2), and speciﬁcally the use of calcium (p = 0.011) and vitamin D (p < 0.001) was more common.
Quality of life measured with the PGWB did not differ between the coeliac disease controls and
the DH patients with normal villous architecture at diagnosis, but the coeliac disease controls had
signiﬁcantly lower PGWB general health scores compared to the DH patients with villous atrophy at
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diagnosis (Table 3). In the GSRS questionnaire, the coeliac disease controls had signiﬁcantly higher
total symptoms gastrointestinal pain and diarrhea scores compared to both DH groups.
4. Discussion
This study demonstrated that the disease severity and the clinical response to a GFD does not
differ between DH patients with normal villous architecture and those with villous atrophy at diagnosis.
Furthermore, the long-term general health and well-being of DH patients are not inﬂuenced by the
severity of small bowel mucosal damage at the time of DH diagnosis. The outcomes of the current
study were obtained from a large, prospectively collected series of DH patients, all of whom adhered
to a GFD treatment. Furthermore, in the present study, the proportions of DH patients with villous
atrophy and normal villous architecture were consistent with the ﬁndings in earlier DH studies [15,33].
In our previous study, the presence of villous atrophy at DH diagnosis was found to be associated
with a delayed diagnosis, i.e., the presence of the rash for two years or more before the diagnosis,
suggesting that prolonged diagnosis might enable the small bowel mucosal damage to progress [34].
In the current study, the occurrence of villous atrophy did not associate with the severity of the rash
or with the presence of gastrointestinal symptoms at diagnosis. The duration of dapsone medication
was considered the most reliable method of determining the active period of rash after adherence to
a GFD since the majority of patients used dapsone medication, and the medicine was discontinued
as early as possible without a relapse in skin symptoms. The median duration of dapsone usage in
DH study groups corresponded well with previous GFD treatment studies [35,36], and even though
the duration was longer in DH patients with normal small bowel mucosa than in those with villous
atrophy at diagnosis, the difference was not statistically signiﬁcant. Therefore, presence or absence of
small bowel villous atrophy at diagnosis seems not to inﬂuence the clinical recovery of the DH rash.
The long-term follow-up performed in the present DH patients further demonstrated that small
bowel villous atrophy at diagnosis did not have any impact on the presence of long-term illnesses
and complications, or long-term quality of life or the presence of persistent gastrointestinal symptoms.
Additionally, our previous study showed that the mortality of DH patients with villous atrophy
at diagnosis does not differ from that of DH patients with normal villous architecture, and in fact,
the mortality of DH patients was shown to be lower than in the general population [37]. Therefore,
all these results show that DH patients with and without villous atrophy at diagnosis have a similar
good long-term prognosis when they adhere to a GFD.
In contrast to DH, the mortality rate of the patients with coeliac disease are known to be increased
compared to the general population [23,38]. Moreover, when the GFD-treated coeliac disease patients in
the current study were compared to the DH patient groups, they had signiﬁcantly more malignancies
and long-term illnesses, especially thyroid diseases and osteopenia or osteoporosis. A previous
comparison between DH and coeliac disease also showed a higher frequency of diseases of autoimmune
origin in patients with coeliac disease [39], but then another study demonstrated that autoimmune
diseases were as common among DH patients without classical coeliac disease symptoms than in
those DH patients with preceding coeliac disease diagnosis [40]. In the present study, the coeliac
disease controls were further found to have worse self-reported general health, and they had more
gastrointestinal symptoms at the time of the study compared to the DH patients. These results ﬁt
with our recent study that likewise found a better quality of life and fewer gastrointestinal symptoms
among long-term treated DH patients compared to treated coeliac disease patients [41].
The results of the present study thus suggest that the prognosis of different phenotypes of coeliac
disease diverge and villous atrophy is not the determinative factor in the outcome of DH. Different
adherence rates to GFD or varying lifestyle habits did not explain the outcome differences between
coeliac disease and DH study patients in this study. One explanation for the different prognosis
between coeliac disease and DH might be slightly diverse autoimmune reactions, but this remains to
be elucidated in future studies.
Nutrients 2018, 10, 641 8 of 10
In the current study, the median age at diagnosis in DH patients with normal villous architecture
was signiﬁcantly higher compared to DH patients with villous atrophy. We were aware from our earlier
long-term DH studies that the age at diagnosis had increased signiﬁcantly from 1970 onwards [1], and
further, that there was a signiﬁcant trend towards milder villous atrophy [16]. However, in the present
study, the time period of DH diagnosis did not differ signiﬁcantly between DH study groups. Therefore,
the divergence in diagnostic periods does not explain the difference in the diagnostic age between DH
patients with and without villous atrophy at diagnosis. One explanation might be, however, that older
patients are more prone to develop milder small bowel mucosal alterations, e.g., due to divergent
immune responses. Previous research shows that older coeliac disease patients are more likely to
remain seronegative and further, a trend toward less severe histopathology has been observed with
increasing age at the time of coeliac disease diagnosis [42,43]. Nonetheless, these age-related ﬁndings
detected in coeliac disease and DH should be examined in more detail in further studies.
As a possible limitation of the current study, it must be recognized that the follow-up data were
obtained from questionnaires, which might cause selection bias. Recall bias is always a possibility when
requiring data from several decades ago. The disease-speciﬁc questionnaire used in the study was
designed for this particular study and for comparing the results of the study groups, and it has not been
used in other disease studies, and it has not been validated. GSRS is not optimized for coeliac disease,
but it has been the most commonly used generic questionnaire in coeliac disease studies [28]. PGWB is
not a disease-speciﬁc instrument, and therefore, it is possible that it might not assess all of the issues
that are having an impact on life in DH and coeliac disease patients. GSRS and PGWB questionnaires
have not been validated speciﬁcally for coeliac disease. Furthermore, all study patients were recruited
from the same hospital, and in the future, results from a more comprehensive geographical distribution
would be of value. In turn, the major strengths of the study are: A well-deﬁned, prospectively collected
DH cohort from a high prevalence area with excellent dietary adherence rates, and the long follow-up
time [1]. Moreover, similar large DH studies with knowledge about the diagnostic small bowel mucosal
ﬁndings and long-term follow-up data consisting of GFD adherence rates have not been performed
previously to our knowledge.
5. Conclusions
The major outcome of this study is that skin IgA-IF proven DH patients evincing coeliac-type
small bowel mucosal villous atrophy at diagnosis does not differ from DH patients with non-atrophic
small bowel mucosa with regard to GFD treatment response, long-term quality of life, or the presence
of chronic illnesses or coeliac disease-associated complications.
Author Contributions: E.M., T.S., K.H., T.R., K.K., and P.C. conceived and designed the experiments and wrote
the paper; E.M., T.S., and K.H. performed the experiments; and H.H. analyzed the data.
Acknowledgments: This work was supported by the Academy of Finland; the Sigrid Juselius Foundation;
the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital
under Grants 9U019, 9T018, 9V017, 9T058, and 9U053; the Finnish Cultural Foundation; and the Finnish
Medical Foundation.
Conﬂicts of Interest: The authors report no conﬂicts of interest.
References
1. Salmi, T.; Hervonen, K.; Kautiainen, H.; Collin, P.; Reunala, T. Prevalence and incidence of dermatitis
herpetiformis: A 40-year prospective study from Finland. Br. J. Dermatol. 2011, 165, 354–359. [CrossRef]
[PubMed]
2. West, J.; Fleming, K.M.; Tata, L.J.; Card, T.R.; Crooks, C.J. Incidence and prevalence of celiac disease and
dermatitis herpetiformis in the UK over two decades: Population-based study. Am. J. Gastroenterol. 2014,
109, 757–768. [CrossRef] [PubMed]
3. Bolotin, D.; Petronic-Rosic, V. Dermatitis herpetiformis: Part I. Epidemiology, pathogenesis, and clinical
presentation. J. Am. Acad. Dermatol. 2011, 64, 1017–1024. [CrossRef] [PubMed]
Nutrients 2018, 10, 641 9 of 10
4. Spurkland, A.; Ingvarsson, G.; Falk, E.; Knutsen, I.; Sollid, L.; Thorsby, E. Dermatitis herpetiformis and celiac
disease are both primarily associated with the HLA-DQ (α1* 0501,(β1* 02) or the HLA-DQ (α1* 03,(β1* 0302)
heterodimers. HLA 1997, 49, 29–34. [CrossRef]
5. Collin, P.; Salmi, T.T.; Hervonen, K.; Kaukinen, K.; Reunala, T. Dermatitis herpetiformis: A cutaneous
manifestation of coeliac disease. Ann. Med. 2017, 49, 23–31. [CrossRef] [PubMed]
6. Dieterich, W.; Ehnis, T.; Bauer, M.; Donner, P.; Volta, U.; Riecken, E.O.; Schuppan, D. Identiﬁcation of tissue
transglutaminase as the autoantigen of celiac disease. Nat. Med. 1997, 3, 797–801. [CrossRef] [PubMed]
7. Korponay-Szabó, I.R.; Halttunen, T.; Szalai, Z.; Laurila, K.; Kiraly, R.; Kovacs, J.; Fésüs, L.; Mäki, M. In vivo
targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 2004, 53, 641–648.
[CrossRef] [PubMed]
8. Salmi, T.T.; Hervonen, K.; Laurila, K.; Collin, P.; Mäki, M.; Koskinen, O.; Huhtala, H.; Kaukinen, K.; Reunala, T.
Small bowel transglutaminase 2-speciﬁc IgA deposits in dermatitis herpetiformis. Acta Derm. Veneorol. 2014,
94, 393–397. [CrossRef] [PubMed]
9. Dieterich, W.; Schuppan, D.; Laag, E.; Bruckner-Tuderman, L.; Reunala, T.; Kárpáti, S.; Zágoni, T.;
Riecken, E.O. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis
herpetiformis. J. Investig. Dermatol. 1999, 113, 133–136. [CrossRef] [PubMed]
10. Zone, J.J.; Meyer, L.J.; Petersen, M.J. Deposition of granular IgA relative to clinical lesions in dermatitis
herpetiformis. Arch. Dermatol. 1996, 132, 912–918. [CrossRef] [PubMed]
11. Sárdy, M.; Kárpáti, S.; Merkl, B.; Paulsson, M.; Smyth, N. Epidermal transglutaminase (TGase3) is the
autoantigen of dermatitis herpetiformis. J. Exp. Med. 2002, 195, 747–757. [CrossRef] [PubMed]
12. Marietta, E.V.; Camilleri, M.J.; Castro, L.A.; Krause, P.K.; Pittelkow, M.R.; Murray, J.A. Transglutaminase
autoantibodies in dermatitis herpetiformis and celiac sprue. J. Investig. Dermatol. 2008, 128, 332–335.
[CrossRef] [PubMed]
13. Hull, C.M.; Liddle, M.; Hansen, N.; Meyer, L.; Schmidt, L.; Taylor, T.; Jaskowski, T.; Hill, H.; Zone, J. Elevation
of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis. Br. J. Dermatol. 2008, 159,
120–124. [CrossRef] [PubMed]
14. Salmi, T.T.; Kurppa, K.; Hervonen, K.; Laurila, K.; Collin, P.; Huhtala, H.; Saavalainen, P.; Sievänen, H.;
Reunala, T.; Kaukinen, K. Serum transglutaminase 3 antibodies correlate with age at celiac disease diagnosis.
Dig. Liver Dis. 2016, 48, 632–637. [CrossRef] [PubMed]
15. Marks, J.; Shuster, S.; Watson, A. Small-bowel changes in dermatitis herpetiformis. Lancet 1966, 288,
1280–1282. [CrossRef]
16. Mansikka, E.; Hervonen, K.; Salmi, T.T.; Kautiainen, H.; Kaukinen, K.; Collin, P.; Reunala, T. The decreasing
prevalence of severe villous atrophy in dermatitis herpetiformis: A 45-year experience in 393 patients.
J. Clin. Gastroenterol. 2017, 51, 235–239. [CrossRef] [PubMed]
17. Kárpáti, S. Dermatitis herpetiformis: Close to unravelling a disease. J. Dermatol. Sci. 2004, 34, 83–90.
[CrossRef] [PubMed]
18. Zone, J.J. Skin manifestations of celiac disease. Gastroenterology 2005, 128, S87–S91. [CrossRef] [PubMed]
19. Fry, L.; Riches, D.; Seah, P.; Hoffbrand, A. Clearance of skin lesions in dermatitis herpetiformis after gluten
withdrawal. Lancet 1973, 301, 288–291. [CrossRef]
20. Kaplan, R.P.; Callen, J.P. Dermatitis herpetiformis: Autoimmune disease associations. Clin. Dermatol. 1991, 9,
347–360. [CrossRef]
21. Hervonen, K.; Viljamaa, M.; Collin, P.; Knip, M.; Reunala, T. The occurrence of type 1 diabetes in patients
with dermatitis herpetiformis and their ﬁrst-degree relatives. Br. J. Dermatol. 2004, 150, 136–138. [CrossRef]
[PubMed]
22. Ventura, A.; Magazzù, G.; Greco, L. Duration of exposure to gluten and risk for autoimmune disorders in
patients with celiac disease. Gastroenterology 1999, 117, 297–303. [CrossRef] [PubMed]
23. Viljamaa, M.; Kaukinen, K.; Pukkala, E.; Hervonen, K.; Reunala, T.; Collin, P. Malignancies and mortality in
patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study. Dig. Liver Dis.
2006, 38, 374–380. [CrossRef] [PubMed]
24. Hervonen, K.; Vornanen, M.; Kautiainen, H.; Collin, P.; Reunala, T. Lymphoma in patients with dermatitis
herpetiformis and their ﬁrst-degree relatives. Br. J. Dermatol. 2005, 152, 82–86. [CrossRef] [PubMed]
Nutrients 2018, 10, 641 10 of 10
25. Dimenäs, E.; Carlsson, G.; Glise, H.; Israelsson, B.; Wiklund, I. Relevance of norm values as part of the
documentation of quality of life instruments for use in upper gastrointestinal disease. Scand. J. Gastroenterol.
1996, 31, 8–13. [CrossRef]
26. Svedlund, J.; Sjödin, I.; Dotevall, G. GSRS—A clinical rating scale for gastrointestinal symptoms in patients
with irritable bowel syndrome and peptic ulcer disease. Dig. Dis. Sci. 1988, 33, 129–134. [CrossRef] [PubMed]
27. Ludvigsson, J.F.; Ciacci, C.; Green, P.H.; Kaukinen, K.; Korponay-Szabo, I.R.; Kurppa, K.; Murray, J.A.;
Lundin, K.E.A.; Maki, M.J.; Popp, A. Outcome measures in coeliac disease trials: The Tampere recommendations.
Gut 2018. [CrossRef] [PubMed]
28. Hindryckx, P.; Levesque, B.G.; Holvoet, T.; Durand, S.; Tang, C.-M.; Parker, C.; Khanna, R.; Shackelton, L.M.;
D’haens, G.; Sandborn, W.J. Disease activity indices in coeliac disease: Systematic review and recommendations
for clinical trials. Gut 2016, 67, 61–69. [CrossRef] [PubMed]
29. Roos, S.; Kärner, A.; Hallert, C. Psychological well-being of adult coeliac patients treated for 10 years.
Dig. Liver Dis. 2006, 38, 177–180. [CrossRef] [PubMed]
30. Viljamaa, M.; Collin, P.; Huhtala, H.; Sievänen, H.; Mäki, M.; Kaukinen, K. Is coeliac disease screening
in risk groups justiﬁed? A fourteen-year follow-up with special focus on compliance and quality of life.
Aliment. Pharmacol. Ther. 2005, 22, 317–324. [CrossRef] [PubMed]
31. Hallert, C.; Svensson, M.; Tholstrup, J.; Hultberg, B. Clinical trial: B vitamins improve health in patients with
coeliac disease living on a gluten-free diet. Aliment. Pharmacol. Ther. 2009, 29, 811–816. [CrossRef] [PubMed]
32. Finlay, A.Y.; Khan, G. Dermatology life quality index (DLQI)—A simple practical measure for routine clinical
use. Clin. Exp. Dermatol. 1994, 19, 210–216. [CrossRef] [PubMed]
33. Fry, L.; Keir, P.; McMinn, R.; Cowan, J.; Hoffbrand, A. Small-intestinal structure and function and
haematological changes in dermatitis herpetiformis. Lancet 1967, 290, 729–734. [CrossRef]
34. Mansikka, E.; Salmi, T.; Kaukinen, K.; Collin, P.; Huhtala, H.; Reunala, T.; Hervonen, K. Diagnostic delay
in dermatitis herpetiformis in a high-prevalence area. Acta Derm. Venereol. 2018, 98, 195–199. [CrossRef]
[PubMed]
35. Fry, L.; Leonard, J.; Swain, F.; Tucker, W.; Haffenden, G.; Ring, N.; McMinn, R. Long term follow-up of
dermatitis herpetiformis with and without dietary gluten withdrawal. Br. J. Dermatol. 1982, 107, 631–640.
[CrossRef] [PubMed]
36. Gawkrodger, D.; Blackwell, J.; Gilmour, H.; Rifkind, E.; Heading, R.; Barnetson, R. Dermatitis herpetiformis:
Diagnosis, diet and demography. Gut 1984, 25, 151–157. [CrossRef] [PubMed]
37. Hervonen, K.; Alakoski, A.; Salmi, T.; Helakorpi, S.; Kautiainen, H.; Kaukinen, K.; Pukkala, E.; Collin, P.;
Reunala, T. Reduced mortality in dermatitis herpetiformis: A population-based study of 476 patients.
Br. J. Dermatol. 2012, 167, 1331–1337. [CrossRef] [PubMed]
38. Tio, M.; Cox, M.; Eslick, G. Meta-analysis: Coeliac disease and the risk of all-cause mortality, any malignancy
and lymphoid malignancy. Aliment. Pharmacol. Ther. 2012, 35, 540–551. [CrossRef] [PubMed]
39. Reunala, T.; Collin, P. Diseases associated with dermatitis herpetiformis. Br. J. Dermatol. 1997, 136, 315–318.
[CrossRef] [PubMed]
40. Krishnareddy, S.; Lewis, S.K.; Green, P.H. Dermatitis herpetiformis: Clinical presentations are independent
of manifestations of celiac disease. Am. J. Clin. Dermatol. 2014, 15, 51–56. [CrossRef] [PubMed]
41. Pasternack, C.; Kaukinen, K.; Kurppa, K.; Mäki, M.; Collin, P.; Reunala, T.; Huhtala, H.; Salmi, T. Quality of
life and gastrointestinal symptoms in long-term treated dermatitis herpetiformis patients: A cross-sectional
study in Finland. Am. J. Clin. Dermatol. 2015, 16, 545–552. [CrossRef] [PubMed]
42. Salmi, T.T.; Collin, P.; Korponay-Szabo, I.R.; Laurila, K.; Partanen, J.; Huhtala, H.; Kiraly, R.; Lorand, L.;
Reunala, T.; Mäki, M. Endomysial antibody-negative coeliac disease: Clinical characteristics and intestinal
autoantibody deposits. Gut 2006, 55, 1746–1753. [CrossRef] [PubMed]
43. Vivas, S.; De Morales, J.M.R.; Fernandez, M.; Hernando, M.; Herrero, B.; Casqueiro, J.; Gutierrez, S.
Age-related clinical, serological, and histopathological features of celiac disease. Am. J. Gastroenterol.
2008, 103, 2360. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
 4 
PUBLICATION 
IV 
Gluten challenge induces skin and small bowel relapse in long-term 
gluten-free diet treated dermatitis herpetiformis  
Mansikka E, Hervonen K, Kaukinen K, Ilus T, Oksanen P, Lindfors K, Laurila K, 
Hietikko M, Taavela J, Jernman J, Saavalainen P, Reunala T and 
Salmi T. 
J Invest Dermatol 2019 (Epub ahead of print) 
doi: 10.1016/j.jid.2019.03.1150 
Publication reprinted with the permission of the copyright holders 

Gluten Challenge Induces Skin and Small
Bowel Relapse in Long-Term Gluten-Free
DieteTreated Dermatitis Herpetiformis
Eriika Mansikka1,2, Kaisa Hervonen1,2, Katri Kaukinen2,3, Tuire Ilus4, Pia Oksanen4,5, Katri Lindfors2,
Kaija Laurila2, Minna Hietikko2, Juha Taavela2,6, Juha Jernman7, Pa¨ivi Saavalainen8,9, Timo Reunala1,2
and Teea Salmi1,2
Dermatitis herpetiformis (DH) is an extraintestinal manifestation of celiac disease causing an itchy, blistering
rash. Granular IgA deposits in the skin are pathognomonic for DH, and the treatment of choice is a lifelong
gluten-free diet (GFD). Preliminary evidence suggests that there are patients with DH who redevelop gluten
tolerance after adherence to a GFD treatment. To evaluate this, we performed a 12-month gluten challenge
with skin and small-bowel mucosal biopsy samples in 19 patients with DH who had adhered to a GFD for a
mean of 23 years. Prechallenge biopsy was negative for skin IgA and transglutaminase 3 deposits in 16 patients
(84%) and indicated normal villous height-to-crypt depth ratios in the small bowel mucosa in all 19 patients.
The gluten challenge caused a relapse of the rash in 15 patients (79%) in a mean of 5.6 months; of these 15
patients, 13 had skin IgA and transglutaminase 3 deposits, and 12 had small-bowel villous atrophy. In addition,
three patients without rash or immune deposits in the skin developed villous atrophy, whereas one patient
persisted without any signs of relapse. In conclusion, 95% of the patients with DH were unable to tolerate
gluten even after long-term adherence to a GFD. Therefore, lifelong GFD treatment remains justiﬁed in all
patients with DH.
Journal of Investigative Dermatology (2019) -, -e-; doi:10.1016/j.jid.2019.03.1150
INTRODUCTION
Dermatitis herpetiformis (DH) is an extraintestinal manifesta-
tion of celiac disease presenting with an itchy and blistering
rash, mainly on the elbows, knees, and buttocks (Bolotin and
Petronic-Rosic, 2011; Collin et al., 2017). The diagnosis of DH
is conﬁrmed with direct immunoﬂuorescence examination
showing granular IgA deposits in the papillary dermis of per-
ilesional skin (Zone et al., 1996). Marked gastrointestinal
symptoms are rare in DH, although approximately 75% of
patients develop villous atrophy in the small bowel mucosa
(Mansikka et al., 2017). Even in patients without obvious
changes in the villous structures, intestinal celiac-type
inﬂammation with increased densities of intraepithelial lym-
phocytes (IELs)—in particular gdþ IELs (Savilahti et al.,
1992)—is evident. Parallel to celiac disease, trans-
glutaminase 2 (TG2)etargeted autoantibodies are frequently
observed in the serum and small-bowel mucosa in untreated
DH and are known to respond to a gluten-free diet (GFD)
(Dieterich et al., 1999; Salmi et al., 2014). However, in DH,
the antigen for deposited cutaneous IgA is epidermal trans-
glutaminase (e.g., transglutaminase 3 [TG3]), another member
of the transglutaminase family along with TG2, and IgA-class
TG3 antibodies (Abs) are often observed in the serum of pa-
tients with DH (Hull et al., 2008; Sa´rdy et al., 2002).
In DH, the treatment of choice is a GFD, which treats both
the rash and small-bowel villous atrophy (Fry et al., 1973).
However, adherence to the diet must be strict; and it has been
observed that the rash typically disappears after a mean
duration of 2 years (Garioch et al., 1994; Reunala et al.,
1977), but IgA and TG3 deposits in the skin are known to
persist much longer (Hietikko et al., 2018). It is generally
accepted that in DH and celiac disease, adherence to GFD
treatment should be lifelong (Caproni et al., 2009;
Ludvigsson et al., 2014). There are, however, a few studies
that show that up to 18% of patients with DH seem to acquire
a tolerance to gluten during the GFD and do not relapse upon
the reintroduction of gluten (Bardella et al., 2003; Garioch
et al., 1994; Leonard et al., 1983; Paek et al., 2011). Like-
wise, there are sporadic reports demonstrating the develop-
ment of gluten tolerance during a GFD in patients with celiac
disease (Hopman et al., 2008; Matysiak-Budnik et al., 2007).
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The aim of this study was to investigate in detail whether
gluten tolerance may exist in patients with DH after long-
term adherence to a GFD. The study speciﬁcally focused on
examining the skin TG3 and IgA immune response during
gluten reintroduction in treated subjects with DH. To address
these issues, a gluten challenge of up to 12 months was
performed in volunteering patients with DH in remission, and
the reappearance of the rash, skin IgA and TG3 deposits,
serum TG2- and TG3-targeted Abs, and small bowel mucosal
deterioration were examined.
RESULTS
Of the 19 patients with DH who volunteered for this study, 13
were male and 6 were female, and their mean age was 58
years (see Table 1). At the prechallenge examination, none of
the 19 patients with DH exhibited a rash, and 16 patients
(84%) did not have IgA or TG3 deposits in the skin. Serum
TG2-targeted Abs (TG2 and endomysial Abs [EmAs])
were negative in all patients, and two had slightly elevated
TG3 Ab levels (40 and 41 AU/ml). The small-bowel villous
height-to-crypt depth ratio was normal in all 19 patients (see
Figure 1), and none had TG2-speciﬁc IgA deposits in the
small bowel mucosa. Sixteen patients carried HLA-DQ2
(three homozygous) haplotypes, and three carried HLA-
DQ8 haplotypes.
The gluten challenge led to the reappearance of the DH
rash in 15 patients (79%) in a mean of 5.6 (range, 1e12)
months (see Table 1). At postchallenge, 12 of these patients
evinced small-bowel mucosal villous atrophy, and 10 pa-
tients with a rash had elevated levels of serum TG2-targeted
Abs. However, one patient (patient 12, see Table 1) present-
ing with a rash but a normal villous height-to-crypt depth
ratio at relapse showed a marked increase in the densities of
CD3þ (from 31 cells/mm at prechallenge to 91 cells/mm at
postchallenge) and gdþ (from 10.5 cells/mm at prechallenge
to 38.3 cells/mm at postchallenge) IELs. Two patients who did
not develop a rash during the challenge (patients 16 and 17,
see Table 1) developed high levels of serum IgA-class TG2-
targeted Abs (TG2 Ab levels 100 and 54 AU/ml, EmA titers
1:1000 and 1:500, respectively), because of which the
challenge was discontinued at 4 months. The small bowel
biopsy showed villous atrophy in both patients. In addition,
one patient (patient 18, see Table 1) had no rash or serum
TG2-targeted Abs, but the small bowel biopsy performed at
Table 1. Gluten Challenge Outcome in 19 Patients with Dermatitis Herpetiformis
Patient/Sex/Age
Duration of GFD Before
Challenge, Y
Challenge Outcome
Challenge
Duration, Mo
Skin IgA and TG3
Deposits Pre/
Postchallenge
Serum TG3
Abs7 Pre/
PostchallengeRash
Villous
Atrophy2
Serum
TG2-Targeted
Abs4
1/M/49 5 þ þ e 1 þ/þ6 e/e
2/M/61 5 þ e e 2 þ/þ6 e/e
3/M/60 24 þ þ3 þ 3 e/þ e/þ
4/M/41 20 þ þ þ 3 e/þ e/þ
5/M/65 24 þ þ3 þ 3 e/þ e/þ
6/F/56 31 þ þ3 þ 3 e/e e/þ
7/M/47 14 þ þ3 þ 3 e/þ e/þ
8/M/72 15 þ þ3 þ 4 e/þ þ/þ6
9/M/51 8 þ þ3 þ 4 e/e e/þ
10/F/55 40 þ þ e 6 e/þ e/þ
11/F/68 33 þ þ3 þ 9 e/þ e/þ
12/F/59 34 þ e3 þ 9 e/þ e/e
13/M/58 18 þ þ þ 10 e/þ e/þ
14/M/66 34 þ þ e 12 e/þ e/e
15/F/71 341 þ e e 12 þ/þ e/þ
16/M/56 22 e þ3 þ5 4 e/e þ/þ6
17/F/37 9 e þ3 þ5 4 e/e e/e
18/M/68 221 e þ e 12 e/e e/e
19/M/58 361 e e e 12 e/e e/e
Mean Age at
Prechallenge,
Y (Range)
Mean Duration
of GFD, Y (Range)
Rash, n
(%)
Villous
Atrophy,
n (%)
Serum TG2-
Targeted Abs,
Mean Duration
(Range)
Negative to
Positive, n (%)
Negative to
Positive, n (%)
n (%)
58 (37e72) 23 (5e40) 15 (79) 15 (79) 12 (63) 6.1 (1e12) 10 (53) 10 (53)
Abbreviations: Ab, antibody; F, female; GFD, gluten-free diet; M, male; Mo, month; TG, transglutaminase; Y, year.
1Dietary lapses 1e5 times per month.
2Villous height-to-crypt depth ratio < 2.0.
3TG2-speciﬁc IgA deposits in the small bowel mucosa.
4Serum TG2 antibodies  3.0 AU/ml and endomysial antibody titer 1:5.
5Challenge discontinued because of appearance of serum TG2-targeted antibodies.
6At postchallenge, deposits more intense or antibody levels more increased.
7TG3 antibodies > 30 AU/ml.
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12 months according to the study protocol disclosed villous
atrophy. Thus, a relapse was demonstrated in 18 gluten-
challenged patients (95%) with DH after a mean of 5.8
months (see Table 1). The remaining patient (patient 19, see
Table 1) did not exhibit any skin or gastrointestinal symptoms
during the challenge, and at the ﬁnal examination at 12
months, the small-bowel villous structures were normal, as
were the densities of CD3þ and gdþ IELs. According to the
dietary diary, the patient’s gluten consumption had been at
least 8 g of gluten per day. After 2 years on a gluten-
containing diet, the patient was still asymptomatic, and the
skin IgA and serum TG2- and TG3-targeted Abs were
negative.
During the gluten challenge, skin IgA became positive in
10 patients with DH, who also developed a rash (see Table 1).
In addition, two of the three patients with the positive skin
IgA ﬁndings at prechallenge (patients 1 and 2, see Table 1)
showed more intense ﬂuorescence after the challenge. In
double staining, TG3 was found to colocalize with IgA in all
skin biopsy samples. Two patients (patients 6 and 9, see
Table 1) with the reappearance of the typical DH rash
remained negative for skin IgA and TG3 deposits. In both
patients, the rash was mild and had appeared a few days to 2
weeks before the skin biopsy samples were taken. However,
both had markedly elevated levels (189 AU/ml) of serum TG3
Abs at this time.
When the prechallenge data were compared to the post-
challenge data, signiﬁcant increase in the median levels of
serum Abs was noted: TG3 Abs from 4 (range, 0e41) to 89
(range, 5e189) AU/ml; TG2 Abs from 0 to 12 (range, 0e100)
AU/ml; and EmA titers from 0 to 1:200 (range, 0e1:4000) (P
< 0.001, in all analyses). In the small-bowel biopsy samples,
the mean villous height-to-crypt depth ratio (see Figure 1)
decreased signiﬁcantly from 2.8 (standard deviation [SD]
0.59) to 1.2 (SD 0.87) (P < 0.001), whereas the mean den-
sities of CD3þ and gdþ IELs increased signiﬁcantly from 40
(SD 15) to 74 (SD 29) cells/mm (P < 0.001) and from 10.8
(SD 8.0) to 16.5 (SD 11.3) cells/mm (P ¼ 0.018), respectively.
The Dermatology Life Quality Index mean score increased
signiﬁcantly (P < 0.001) from 0.11 (SD 0.32) at prechallenge
to 1.58 (SD 2.04) at postchallenge. The total Gastrointestinal
Symptom Rating Scale score showed no signiﬁcant change
(P ¼ 0.22) with mean scores of 1.66 (SD 0.55) and 1.86 (SD
0.73).
The duration of the GFD before the challenge was shown
to correlate signiﬁcantly with the relapse time (r ¼ 0.62,
conﬁdence interval ¼ 0.24e0.84; see Figure 2), but age at the
time of the DH diagnosis was found not to correlate with the
relapse time (r ¼ e0.23, conﬁdence interval: e0.62 to 0.25).
DISCUSSION
In this study featuring 19 GFD-treated patients with DH in
remission, a gluten challenge was shown to induce relapse in
95% of the patients. The vast majority (15 of 19 patients,
79%) of the relapsed patients experienced a DH rash, and
most also developed small-bowel mucosal villous atrophy. In
addition, three relapsed patients with no rash exhibited pro-
gression to villous atrophy. The remaining patients, however,
did not manifest any signs of DH or celiac disease during 2
years on a normal gluten-containing diet.
Figure 1. Villous height-to-crypt
depth ratios in 19 gluten-challenged
patients with dermatitis herpetiformis
at pre- and at postchallenge. Eighteen
patients experienced relapse during
the challenge (pre- , and
postchallenge -). One patient (pre ▵
and postchallenge:) did not relapse
during the challenge. Values above
the dashed line are considered
normal. The two bars on the right-
hand side show mean villous height-
to-crypt depth ratios with 95% CIs at
pre- and postchallenge depicted with
B and C, respectively. CI,
conﬁdence interval.
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We are aware of two previously conducted gluten chal-
lenge studies in adults with DH. Parallel results to ours were
found in a study by Leonard et al. (1983): 11 out of 12 pa-
tients (92%) with DH relapsed with a rash, and of these, 7
patients (64%) also developed villous atrophy. Bardella et al.
(2003) reported 31 patients with DH in whom the rash
relapsed within 6 months on a gluten challenge. However,
they also observed seven patients (18% of the study group)
who did not manifest any type of relapse in the skin or small
bowel during the prolonged gluten challenge. It must be
noted that these seven patients had been diagnosed in
childhood, and compliance with a GFD in these nonrelapsed
patients with DH had been only moderate or poor before the
challenge. Therefore, the authors suggested that the ingestion
of small doses of gluten from childhood may induce immune
tolerance (Bardella et al., 2003). Supporting this, the devel-
opment of tolerance to gluten has also been reported in pa-
tients with celiac disease, especially when they have been
diagnosed in childhood and continued to eat a normal
gluten-containing diet (Hopman et al., 2008; Matysiak-
Budnik et al., 2007). In this study, none of the patients had
been diagnosed in childhood, and moreover, our previous
study on GFD-treated children with DH did not ﬁnd any
patients achieving tolerance to gluten (Hervonen et al.,
2014). Furthermore, three of the patients with DH from this
series reported dietary lapses when adhering to a GFD, and
two of these patients relapsed. The only patient not relapsing
during the challenge was documented to consume enough
gluten to cause villous atrophy (La¨hdeaho et al., 2011).
However, this patient had been on a GFD for 36 years, which
might cause a delayed DH relapse. Hence, a longer follow-
up than 2 years on a normal gluten-containing diet is
mandatory before a ﬁnal conclusion of redeveloped gluten
tolerance can be drawn.
In this study, 15 of the gluten-challenged patients with DH
developed villous atrophy, and of these, three patients had no
rash or skin IgA or TG3 deposits. It has been previously
shown that the phenotype of celiac disease can change,
especially from the classical disease to DH (Salmi et al.,
2015), but it is also probable that the patients with DH
without the rash at postchallenge would have developed skin
symptoms if gluten exposure had been prolonged. None-
theless, the results of this study suggest that the gut could be
the initial site of the gluten-induced autoimmune reaction,
that is, celiac disease, and it is only thereafter that the skin
become affected, that is, DH develops (Collin et al., 2017;
Sa´rdy et al., 2002). Nevertheless, we also observed that in
three patients with DH who relapsed with the rash, villous
atrophy had not developed. It is widely recognized that in
celiac disease, small-bowel mucosal changes develop grad-
ually, and villous atrophy is only the end stage of the disease
process and not evident in all affected individuals (Kurppa
et al., 2009). For instance, the presence of small-bowel
mucosal TG2-speciﬁc IgA deposits can precede villous at-
rophy in celiac disease (Koskinen et al., 2008), and the de-
posits have been shown to occur also in patients with DH
with normal small bowel mucosa (Salmi et al., 2014). In
agreement with this, one gluten-challenged patient with DH
with no villous atrophy had intestinal TG2-speciﬁc IgA
deposits and increased densities of CD3þ and gdþ IELs. In
addition, this patient further showed signiﬁcant levels of
TG2-targeted Abs in the serum, also suggesting an ongoing
gluten-induced inﬂammatory response in the small bowel
(Katz et al., 2011; Kumar et al., 2001).
At prechallenge, 16 patients were found not to have IgA and
TG3 deposits in the skin. These deposits are considered
pathognomonic for untreated DH (Donaldson et al., 2007;
Sa´rdy et al., 2002) and are known to resolve slowly during
the GFD treatment (Hietikko et al., 2018). In the previous
challenge studies by Leonard et al. (1983) and Bardella et al.
(2003), 24% and 42% of the patients, respectively, were
found not to have IgA deposits in the skin. In these two studies,
the patients had adhered to GFD treatment for a mean of 8
years, whereas in this study, the mean duration was 23 years,
that is, almost three times longer. This shows that the likeli-
hood of testing negative for skin IgA deposits increases parallel
to the duration of the GFD treatment. It is, however, intriguing
why skin IgA and TG3 deposits persist for several years after
the rash and small-bowel villous atrophy have resolved in
patients on a GFD (Hietikko et al., 2018). The explanation
might be that IgA and TG3 are deposited in the papillary
dermis as immune aggregates in which the TG3 enzyme is
active, resulting in covalent cross-linking of the complex to
dermal structures (Taylor et al., 2015). In contrast to the very
slow disappearance from the skin of a patient on a GFD, this
Figure 2. Correlation between the duration of a GFD before the study
(years) and relapse time (months) in 19 gluten-challenged patients with
dermatitis herpetiformis. The 95% CI of the correlation curve is shown in
gray. Patients following a strict GFD before the challenge are marked withB,
and those with a history of dietary lapses are marked withC. One patient not
relapsing during the challenge and with a history of dietary lapses in GFD
before the challenge is marked with:. CI, conﬁdence interval; GFD, gluten-
free diet.
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study documented a rather rapid reappearance (after 3e12
months) of both IgA and TG3 in ten challenged patients, which
is to our knowledge a previously unreported ﬁnding.
This study also examined whether skin IgA and TG3 ag-
gregates reappear simultaneously with the rash. Coincidental
appearance was shown to occur in ten challenged patients.
Unexpectedly, two patients developed the DH rash but
remained skin IgA- and TG3-negative, though they had
markedly elevated TG3 Ab levels in the serum. Skin biopsy
samples were taken from the perilesional skin of both patients
(Donaldson et al., 2007; Zone et al., 1996), making it un-
likely that the results are false negatives. However, there is a
possibility that with a short-term rash, the quantity of IgA and
TG3 in these two patients was so minute that they were not
detectable by the conventional technology that was used.
Skin lesions in DH have been previously produced experi-
mentally by the application of potassium iodide, and these
studies have shown the activation of elastase and urokinase
plasminogen activator enzymes but no alteration in the in-
tensity of IgA deposits (Airola et al., 1997; Reitamo et al.,
1981). Furthermore, Taylor and Zone (2018) showed that
potassium iodine directly activates IgA-bound TG3 in DH
skin and suggested that lesion development is likely depen-
dent on the aberrant activity of the TG3 enzyme.
The major strengths of this study were a well-deﬁned long-
term GFD-treated study group from our prospectively
collected large DH series (Salmi et al., 2011) and the thor-
oughly conducted gluten challenge with regular follow-up
visits and clinical, serological, and small-bowel mucosal bi-
opsy end points. A limitation, however, was the relatively
small number of patients, as was the comparatively short
follow-up time for the nonrelapsed patient with DH.
In conclusion, this 12-month gluten challenge study in
adult patients with DH showed that 95% of the patients had
not achieved tolerance to gluten even after long-term GFD
treatment. The gluten challenge was shown to induce a DH
rash in the majority of the patients, but intriguingly in a few
challenged patients, only small-bowel mucosal deterioration
was documented. Moreover, IgA and TG3 aggregates in the
skin were not disclosed in every patient with a DH rash. At
present, a lifelong adherence to GFD seems justiﬁed in all
patients with DH.
MATERIALS AND METHODS
Patients and gluten challenge
A total of 19 patients with DH on a GFD from our prospectively
collected DH series at Tampere University Hospital participated in
the study (see Table 1) (Salmi et al., 2011).
The inclusion criteria were as follows: a diagnosis of DH based on
the typical clinical picture, the presence of granular IgA deposits in
the papillary dermis with direct immunoﬂuorescence examination,
adherence to a GFD for at least 5 years, and absence of skin
symptoms for at least 3 years. The exclusion criteria were as follows:
age > 80 years, severe cardiovascular disease, previous malig-
nancies, and the use of dapsone or immunosuppressive or anti-
coagulation medication other than acetylsalicylic acid. At the time
of the diagnosis of DH, the mean age of the study participants was
35 (range, 19e57) years, and twelve patients (86%) with available
data had small-bowel villous atrophy, and two (14%) had normal
villous architecture in the small bowel mucosa.
Before the gluten challenge, the patients had been on a GFD for a
mean of 23 (range, 5e40) years. Sixteen patients adhered to the diet
strictly, and three reported having 1e5 dietary lapses per month.
The study protocol was approved by the Regional Ethics Com-
mittee of Tampere University Hospital (R16039), and all study par-
ticipants gave their written informed consent.
After the prechallenge investigations, the gluten challenge was
initiated by giving the patients 200 g of commercially available
wheat bread to be consumed daily for 3 days (Anderson et al., 2000).
A follow-up visit was conducted at day 6, and subsequently, the
patients commenced a normal gluten-containing diet with a mini-
mum of 10 g of wheat (i.e., about 1 g of gluten) per day. A follow-up
telephone call was conducted after 3 weeks, and regular follow-up
visits were made every 3 months until the ﬁnal examination at 12
months. The patients were advised to contact the researchers if they
noticed skin or gastrointestinal symptoms, or if they experienced any
medical problems during the challenge. In such cases, an extra visit
was arranged at the outpatient clinic to consider whether the chal-
lenge should be discontinued.
Clinical and dietary evaluation and questionnaires
At each study visit, patients were examined for the presence of skin,
gastrointestinal, and other celiac diseaseerelated signs. To ensure
the adequate consumption of gluten, a 3-day dietary diary was ﬁlled
out by the study participants before every follow-up visit and
analyzed by a dermatologist experienced in GFD treatment.
Dermatology Life Quality Index and Gastrointestinal Symptom
Rating Scale questionnaires assessing the quality of life and the
presence of gastrointestinal symptoms were ﬁlled out by the patients
during the study visits. The Dermatology Life Quality Index is used in
dermatological diseases, and it includes six sections: symptoms and
feelings, daily activities, leisure, work and school, personal re-
lationships, and treatment unit. Higher scores indicate decreased
quality of life (Finlay and Khan, 1994). The Gastrointestinal Symp-
tom Rating Scale has been widely used in previous celiac disease
studies (Ludvigsson et al., 2018; Viljamaa et al., 2005), and it in-
cludes ﬁve categories: diarrhea, indigestion, constipation, abdom-
inal pain, and reﬂux. Higher scores indicate more severe symptoms
(Svedlund et al., 1988).
Skin and small-bowel biopsy samples
Skin and small-bowel biopsy samples were obtained at prechallenge
and the end of the gluten challenge to detect ﬁndings compatible
with DH and/or celiac disease. The skin biopsy sample was taken
from uninvolved elbow skin or perilesional skin when the rash had
appeared. The samples were ﬁxed in optimal cutting temperature
compound (Tissue-Tek O.C.T. Compound, Sakura Finetek USA,
Torrance, CA), snap-frozen in liquid nitrogen, and stored at e70 C
until examined. To investigate IgA deposits, sections cut from the
samples were stained with TRITC-conjugated goat anti-human IgA
(1:50) (A18786, Life Technologies, Frederick, MD). For the exami-
nation of TG3 deposits, sections were stained with FITC-conjugated
rabbit polyclonal TG3 antibody (1:100) (A030, ZEDIRA GmbH,
Darmstadt, Germany). All sections were further double stained for
IgA and TG3 as previously described (Hietikko et al., 2018).
During gastroscopy, 6e8 forceps biopsy samples were obtained
from the distal part of the duodenum, and at least two samples were
stained with hematoxylin and eosin and investigated with light mi-
croscopy. At least three well-oriented villous crypt units were
measured, and the mean was given as a result. A ratio over 2.0 was
considered normal. The remaining samples were freshly embedded
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in OCT, snap-frozen in liquid nitrogen, and stored at e70 C.
Stainings of CD3þ and gdþ IELs was carried out on 5-mm-thick
frozen sections, and the normal values were <37 cells/mm for CD3þ
and <4.3 cells/mm for gdþ IELs (Ja¨rvinen et al., 2003). Small-bowel
TG2-targeted IgA deposits were studied from unﬁxed, frozen, 5-mm-
thick small-bowel mucosal sections by direct immunoﬂuorescence
as described by Korponay-Szabo´ et al. (2004).
Serological investigations
Serological investigations were performed at each study visit. The
investigated TG2-targeted Abs were TG2 Abs and EmAs (Korponay-
Szabo´ et al., 2003). TG2 Abs were determined with a commercially
available ELISA kit (Celikey, Phadia, GmbH, Freiburg, Germany) as
previously described (Dieterich et al., 1999), and values  3.0 AU/
ml were considered positive. Serum EmA was measured with an
indirect immunoﬂuorescence method with human umbilical cord as
a substrate, and a titer of 1:5 was regarded as positive (Ladinser
et al., 1994). In cases where TG2-targeted Abs were found to
convert to positive, the challenge was discontinued, and post-
challenge investigations were carried out. TG3 Abs were determined
with a commercially available ELISA kit (Immundiagnostik, Ben-
sheim, Germany) as previously described (Reunala et al., 2015), and
values >30 AU/ml were considered positive. Elevation of serum TG3
Abs alone was not considered a reliable marker of DH or celiac
disease relapse and thus was not considered a sufﬁcient reason for
challenge discontinuation. HLA DQ2 and DQ8 genotypes were
determined using the Olerup SSP DQB1 low-resolution kit (Olerup
SSP AB, Saltsjo¨baden, Sweden/Qiagen Vertriebs GmbH, Vienna,
Austria).
Statistical analysis
Statistical comparisons within-subjects were performed by permu-
tation test or Wilcoxon matched-pairs signed rank test with exact
P-values. Correlations were estimated by Spearman correlation co-
efﬁcient method. The normality of the variables was tested by using
the Shapiro-Wilk W test. Stata 15.0 (StataCorp LP, College Station,
TX) statistical package was used for the analysis.
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